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Abstract 
Protein modification is an essential tool in Chemical Biology, allowing a functional 
biomolecule to be equipped with a small molecule tag or label. However, as proteins are 
constructed from a limited palette of around 20 canonical amino acids, achieving selective 
modification can be problematic. Previously reported methods for protein modification will 
be discussed in Chapter 1; these often rely on alteration of the protein sequence to introduce 
a uniquely reactive (often non-canonical) amino acid which may then be covalently modified 
in a bioorthogonal manner. An alternative approach is to identify a uniquely reactive site 
within the native protein sequence, such as the protein N-terminus or the reactive side chain 
of an amino acid with low frequency, and modify this using selective chemistry. 
In this project, modification of a native sequence protein was achieved by targeting a low 
abundance residue, tyrosine (Tyr), in a selective manner. Tyr was identified as the ideal 
candidate as it displays only ~3% frequency in the proteome and, due to its electron-rich aryl 
ring, it can be selectively modified by electrophilic aromatic substitution. Using a diazonium 
salt as the tuned electrophile, modification results in formation of an azobenzene motif which 
may be orthogonally cleaved under mild reducing conditions. The resulting cleavage product 
bears an o-aminophenol modification on the Tyr side chain, which can then be conjugated to 
a fluorescent label using established chemistry. This system has been developed on a solid-
phase platform to give further control over the extent of modification achieved. 
In Chapter 2, the component parts of this method are developed through reactions performed 
in-solution on small molecule substrates. In Chapter 3, this work is then moved onto a solid-
phase resin in order to ‘catch-and-release’ small molecule and peptide substrates. Finally in 
Chapter 4, the resin-based catch-and-release system is optimised for use in protein 
modification, and analysis of the modification site is explored. 
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Lay Abstract 
Proteins are complex functional biomolecules which serve a range of diverse roles in Nature. 
From the perspective of a researcher, the recruitment of these biomolecules to help answer 
research questions is highly desirable, and generally this requires labelling of the protein using 
Chemical or Biological techniques. While proteins are highly diverse in composition and 
structure, they are all constructed from the same pool of around 20 amino acids. Some of these 
amino acids bear a side chain which has a reactive group, allowing modification of this 
building block with a synthetic label such as a fluorescent group. 
The work contained in this thesis describes a new method for protein labelling which targets 
the natural amino acid tyrosine. Tyrosine is an appropriate target as it bears a side chain which 
shows nuanced reactivity, while its relatively low abundance and moderate surface-exposure 
offer the potential for selective labelling when more than one tyrosine is present in the protein. 
Using a solid-phase resin to ‘catch’ the protein via a reactive tyrosine residue, and release it in 
a modified form, a protein substrate has been successfully labelled with a fluorescent group, 
and this type of protein bioconjugate could be used in future as a probe for fluorescence 
microscopy. 
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Chapter 1 Introduction: Chemical Biology 
approaches to protein modification 
1.1 Overview 
Biomolecules and natural products have proven a rich source of inspiration for various sub-
disciplines in Chemistry and Biology, including Medicinal Chemistry, Materials Chemistry 
and Chemical Biology. Through millions of years of evolution, Nature has developed 
functional molecules which display exquisite binding specificity and serve roles including 
catalysis, structural organisation and signalling. These functions are of great interest to the 
modern day chemist, and through careful modification of native substrates, the researcher can 
endow these functional biomolecules with an orthogonal functionality which suits their needs. 
The work presented in this thesis is particularly concerned with bioconjugation, where a 
biomolecule, such as a peptide, protein or nucleic acid, is labelled with a functional group. 
These labels may be synthetic small molecules such as a ligand, drug or reporter group, or 
biological labels such as carbohydrates, nucleic acids or lipids. In addition, macromolecular 
labels may be employed, such as functional proteins or polymers; or bioconjugation chemistry 
may be used for attachment of a biomolecule to an activated surface.1 Depending on the 
application, the choice of biomolecular substrate and functional label will differ, and common 
examples of these will be explored. For the current project fluorescent reporters are the labels 
of interest, and through bioconjugation with a protein substrate, a protein-based fluorescent 
probe is formed. For this reason, nucleic acids as biomolecular substrates or labels will not be 
discussed. 
While various methods have been reported to achieve covalent attachment to a biomolecule, 
achieving chemoselectivity and site-specificity remains challenging. This has given rise to the 
development of a toolbox of protein modification strategies, each of which are best suited to 
specific applications. The most common examples of these toolbox techniques will be 
discussed, incorporating both ‘Chemistry’ and ‘Biology’ approaches. 
1.2 Biomolecular substrates 
The specific choice of biomolecular substrate depends on the application at hand, but these 
biomolecules generally act as the targeting group for the finished bioconjugate. Due to their 
specific binding capabilities, antibodies and their derivatives are often used. Full-length 
antibodies are used for the production of targeted therapies such as antibody‒drug conjugates 
(ADCs), as well as for targeted fluorescent dyes used in microscopy. They exhibit very strong 
and very specific binding to an antigen, and are composed of two heavy chains and two light 
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chains organised in a distinctive ‘Y’ shape with the variable binding region at the tip of each 
arm (Figure 1-1). The majority of the antibody structure consists of highly conserved protein 
sequences (constant regions: CH1, CH2, CH3, CL), and antibody labelling is commonly 
achieved through modification of these regions (often this involves targeting conserved 
disulfide bridges). 
 
Figure 1-1 Biomolecular substrates used for bioconjugation. (a) Antibodies exhibit very 
strong and selective binding, and have therefore been used in the development of ADCs and 
fluorescent probes (V: variable domain; C: constant domain). (b) Nanobodies are the isolated 
VH domain from a heavy chain antibody, and retain strong binding affinity but at roughly one 
tenth of the size of an antibody. (c) Peptides are small in size and easier to synthesise and 
modify than protein substrates, but a labelled peptide may lack the specificity of a protein-
based probe. (PDB ID’s: 1IGY, 3OGO). 
While antibodies are employed in a wide range of applications, they are large proteins at >100 
kDa, which make them difficult to handle and modify. In fact, as the binding interaction occurs 
at a distal region of the protein, the majority of the antibody bulk is not involved in binding. 
A more compact and atom-efficient alternative to antibodies is found in their nanobody 
counterpart. These antibody derivatives may be obtained from camelid or shark species, which 
naturally produce antibodies containing only a heavy chain. The variable binding region, VH, 
may be isolated by enzymatic digestion of the intact antibody.2 The nanobody is around one 
tenth of the size of an antibody at 10‒15 kDa, yet retains a strong antigen-specific binding 
affinity, and is therefore an appealing biomolecular substrate for the production of protein 
based-probes. 
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Among the benefits of using peptides as biomolecular substrates is the fact that many potent 
peptide species are small enough to be synthetically achievable, allowing the production of 
relatively large quantities without relying on protein expression and purification. In addition, 
smaller peptides are likely to tolerate harsh labelling conditions, as they do not exhibit the 
higher order structure of a protein. If a substrate is synthesised using conventional solid-phase 
peptide synthesis, this would also provide excellent regulation over labelling, as the sequence 
is assembled one amino acid at a time, providing temporal control over site-specificity, while 
there is also orthogonal protection of potentially competitive reactive groups. The 
biomolecular labelling methods reviewed in this Introduction will focus on protein-compatible 
strategies, however a recent review by Baran et al. describes a wider range of methods that are 
applicable to peptide substrates.3 
1.3 Functional labels 
In conjunction with the choice of biomolecular substrate, the appropriate functional label is 
selected based on the application of the final bioconjugate. Many functional labels are 
described in the literature, which may equip a biomolecular substrate with a range of 
functionalities (Figure 1-2). 
In Medicinal Chemistry, the bioconjugation of antibodies with cytotoxic drug compounds via 
either a cleavable or non-cleavable linker has been used in the production of ADCs. This 
allows targeted delivery and release of the cytotoxic payload to the desired site, and to date, 
four ADCs have received approval from the Federal Drug Administration (FDA) for clinical 
use, while many more are currently in development.4 Another application of bioconjugation 
in Medicinal Chemistry involves the attachment of hydrophilic polymers [most often 
composed of polyethylene glycol (PEG)] to a therapeutic peptide or protein, which has been 
shown in certain cases to increase blood circulation time, increase solubility and decrease 
immunogenicity.5 
In Materials Chemistry, covalent attachment of a protein to a solid support has been used for 
biophysical assays including Surface Plasmon Resonance (SPR), and in the development of 
separation materials such as (strept)avidin resins, which can be used for the specific 
enrichment of biotin-labelled molecules of interest.6 
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Figure 1-2 Selected functional labels used for bioconjugation. Depending on the application, 
the biomolecular substrate may be equipped with a variety of functional labels, ranging from 
cytotoxic compounds to reporter molecules to affinity labels such as biotin. Alternatively, 
protein labelling chemistry may be used to immobilise the biomolecule on a solid-phase for 
use in a biophysical assay such as surface plasmon resonance (SPR). 
Finally, in Chemical Biology, protein modification has allowed the study of native systems 
using proteins and peptides which have been equipped with reporter molecules, including 
fluorescent groups, spin labels and NMR contrast agents. Alternatively, attachment of a biotin 
label allows enrichment of a protein sample, or detection with fluorophore-labelled 
(strept)avidin. 
The methods to produce these bioconjugates are numerous and varied, but can generally be 
classed as methods which alter the protein sequence, or methods which selectively target a site 
in the native sequence protein. 
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1.4 Methods for protein modification 
1.4.1 Alteration of the protein sequence 
A genetically engineered or ‘Biological’ approach to protein modification involves the 
alteration of a protein’s native sequence to introduce a fused functional protein, a peptide 
recognition sequence or an orthogonally reactive natural or non-natural amino acid. These 
methods are useful for in vivo protein labelling, as the modified species are expressed in cells. 
However, the design and execution of these techniques require bespoke biochemical methods 
and optimisation for each protein substrate of interest, and their use is therefore limited to 
laboratories with specialist biochemical equipment. 
Fusion proteins 
The labelling of a biomolecular substrate with a functional label via the production of a 
chimeric fusion protein represents a useful one-step approach to protein labelling. Following 
the successful cloning and expression of green fluorescent protein (GFP), production of fusion 
proteins in which the GFP sequence was appended to the native sequence of a protein substrate 
became an attractive route to the development of protein-based fluorescent probes (Figure 
1-3). 
 
Figure 1-3 The Ubiquitin-GFP fusion protein. The GFP label (green) is appended to the N-
terminus of the ubiquitin native sequence (grey). The two amino acid linker region is shown 
in the protein sequence in black, the GFP chromophore is shown as spheres. (PDB ID: 3AI5).7 
In recent years, the range of genetically encoded fluorescent proteins has expanded to allow 
multi-colour labelling, which is useful for optical imaging experiments,8 however the 
performance of fluorescent proteins in terms of quantum yield and photostability are generally 
poorer than their synthetic fluorophore counterparts.9, 10 The benefit of the fusion protein 
approach is strict control over the stoichiometry and site-specificity of labelling, however the 
range of labels is limited to those which can be expressed using the protein production 
machinery. As well as the limited functionality of expressed protein labels, the large size of 
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these groups compared with small molecule reporters is more likely to perturb the native 
function of the biomolecular substrate.11 
In order to expand the range of tolerated labels in the fusion protein approach, self-labelling 
enzyme technologies have been developed, which functionalise the biomolecular substrate in 
a two-step procedure. The required fusion protein is first generated, with a self-labelling 
enzyme encoded at the N- or C-terminal end of the substrate, before selective labelling using 
the specific substrate recognised by the fused enzyme. The most common examples of this 
approach involve the use of Halo-tag, SNAP-tag or CLIP-tag (Figure 1-4).12 
 
Figure 1-4 Selected self-labelling enzymes used for the production of self-labelling fusion 
proteins. Halo-tag is modified by reaction with a halo-alkane substrate, to give the labelled 
product via ester formation with Asp106 in the Halo-tag sequence.13 SNAP-tag and CLIP-
tag are derived from the same enzyme, but accept different substrates. They are both 
modified at the active site Cys145 to give a thioether linkage to the label.12, 14 
Using self-labelling enzyme incorporation, protein substrates have successfully been labelled 
with synthetic fluorophores and biotin labels, and this technology has also been used for the 
immobilisation of a biomolecular substrate onto a solid support.13, 15, 16 These methods have 
therefore expanded the range of labels tolerated by a fusion protein approach, while 
maintaining the site-specificity and stoichiometry. However, the addition of a large (20‒40 
kDa) biomolecule to the substrate sequence is still required, which may be detrimental to the 
function and stability of the substrate. Furthermore, genetic manipulation of each target protein 
is required, which potentially limits the application of these techniques. 
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Peptide handles 
In order to avoid the difficulties associated with the incorporation of a large protein label, 
peptide handles have been developed which can facilitate protein labelling in a two-step 
strategy, through enzymatic recognition of a short amino acid sequence. The first example of 
this approach was reported by Cronan, who found that incorporation of a 75 amino acid 
sequence into a target protein resulted in the substrate becoming biotinylated in vivo, which in 
turn allowed its purification from cell lysates.17 Beckett et al. later refined this approach by 
reducing the size of the required recognition peptide to a 14‒15 amino acid sequence, which 
was selectively biotinylated by a biotin ligase enzyme (BirA) (Figure 1-5).18  
 
Figure 1-5 Selected peptide handles used for enzymatic protein labelling strategies. The 
tolerated substrates of BirA and TTL enzymes were expanded to include azide and alkyne 
groups, which allowed later functionalisation using click chemistries. FGE results in 
formation of a reactive aldehyde, which may be functionalised through oxime- or hydrazone-
forming reactions. The peptide recognition sequences for BirA and FGE may be incorporated 
at either the N- or C- termini, however the TTL-specific sequence requires incorporation at 
the C-terminal.19 
As well as its use in affinity purification, this technology has since been used to achieve the 
site-specific immobilisation of an antibody fragment onto a solid support.20 Biotin is of course 
a useful label to attach to a biomolecule, however the BirA labelling technology was further 
developed by an expanded scope of carboxylic acid substrates which the enzyme could tolerate 
and transfer onto the peptide Lys residue, including azide and alkyne-bearing derivatives of 
biotin.21 Labelling of a peptide handle with a click-functionalised biotin analogue then allows 
a third step of selective click conjugation which could incorporate a range of functional labels. 
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Aside from the biotinylating enzyme BirA, a range of enzymes have been used for similar 
peptide recognition-labelling strategies. 
The formylglycine-generating enzyme (FGE) has been employed to recognise a 6 amino acid 
receptor peptide, and convert a Cys side chain within it to a reactive aldehyde. This approach 
allows modification of the target protein with a synthetic hydrazine or hydroxylamine-bearing 
reagent to give a hydrazone or oxime functionalised bioconjugate.  
The final peptide handle highlighted is the 14 amino acid sequence which is recognised and 
modified by tubulin tyrosine ligase (TTL). This peptide sequence (Tub-tag) is labelled by 
addition of a Tyr-derived residue at the C-terminus, and work by Hackenberger et al. 
highlighted a rather broad substrate tolerance in this system.22 Incorporation of a reactive 
azide, iodide and aldehyde via the TTL-dependant system provided a route to later covalent 
labelling with synthetic groups, and ultimately, this system was used to label a functional 
nanobody with fluorophores, a PEG group and a biotin handle.23 
Alongside the highlighted peptide handles, commonly used labels include LAP-tag (22 or 13 
amino acid sequence, labelled by lipoic acid ligase), LPXTG-tag (5 amino acid sequence, 
labelled by Sortase A) and ybbr- or S6-tag (11 or 12 amino acid sequence, labelled by 
phosphopentathienyl transferase).19 
Peptide tags which do not require enzymatic recognition such as the His-tag (H6 or H10) or 
tetracysteine tag (CCXXCC), are also commonly used in biochemistry, as they imbue the 
target protein with selective reactivity. Specifically, His-tagged proteins are routinely purified 
by affinity chromatography, as they bind reversibly to Ni2+ ions. Meanwhile, the tetracysteine 
tag has been used to attach turn-on fluorescent probes, due to their specific affinity for a range 
of biarsenical reagents.24  
Taking the idea of a small peptide tag to its smallest iteration, incorporation of a single reactive 
residue to the N- or C- terminus of a target protein sequence, or point-mutation to incorporate 
a reactive residue elsewhere in the protein chain, has also been reported, e.g. for the 
introduction of a Cys residue.25 These small sequence modifications can offer selective 
modification without the significant burden of a full protein label, and thus are expected to 
show less impact on the function and stability of the target protein. The incorporation of non-
canonical amino acids into the target protein has been shown to offer bioorthogonal reactivity, 
and can be achieved in several ways. 
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Non-canonical amino acid incorporation 
The incorporation of an unnatural amino acid (UAA) into the sequence of a target protein 
allows two-step labelling of the target biomolecule, through expression of the modified 
substrate and then labelling via a bioorthogonal handle on the UAA. The incorporation of a 
range of amino acid derivatives can be achieved in either a residue-specific or site-specific 
manner, using auxotrophic cell lines or genetic code expansion technologies.26 In the first 
example, there is no requirement for genetic modification of the target protein, however the 
expression system used will be depleted in one or more amino acid substrates. Incorporation 
of a non-canonical amino acid in place of the native equivalent then relies upon its acceptance 
by the appropriate tRNA/tRNA synthetase pair, and results in incorporation of the UAA in 
place of the depleted residue.27 This technology has been used to incorporate a range of UAAs 
bearing click handles in place of native methionine residues (Figure 1-6), and the UAAs 
highlighted were found to be accepted by the native Met-tRNA synthetase and incorporated 
into the native protein sequence in place of the Met residue, albeit at a slower rate than the 
native substrate.27 
 
Figure 1-6 Selected non-canonical amino acids used in the auxotrophic cell line and genetic 
code expansion approaches.(a) Met-analogues bearing click handles are shown, these are all 
tolerated by the native Met-tRNA synthetase in the auxotrophic cell line approach. (b) Selected 
UAAs bearing click handles are shown. Lysine (Lys) and phenylalanine (Phe) are common 
native scaffolds to use for the design of UAAs, which are used in the genetic code expansion 
approach.27 
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In the genetic code expansion approach, a blank codon such as the amber stop codon is 
reassigned as a signal to incorporate the UAA, and this involves the recruitment of a modified 
tRNA/tRNA synthetase pair which are specific for the synthetic residue.28 In this way, the site-
specific incorporation of a UAA is achieved, and its position in the protein sequence can be 
modified by introducing the formerly blank codon at different positions on the gene of 
interest.28  
Both the auxotrophic cell line and genetic code expansion methods have proved extremely 
effective at producing functionalised proteins which bear bioorthogonal handles with a high 
degree of selectivity. However, these approaches require genetic manipulation of the target 
protein or its assembly components, and can therefore require time-consuming optimisation 
for each protein substrate of interest. An alternative strategy is to address the issue from a 
purely ‘Chemical’ perspective, and develop selective modification strategies which target 
reactive sites in the native protein target, thus avoiding any alteration of the expressed protein 
sequence. 
1.4.2 Targeting a native site 
In a native polypeptide, there is no shortage of potentially reactive sites which could be 
covalently modified in a protein labelling experiment. In addition to the α-NH2 of the N-
terminus and the terminal CO2H of the C-terminus, many amino acid side chains bear reactive 
groups which offer potential as endogenous targets. In contemplating these options, several 
variables should be considered which may impact the ability to achieve controlled and 
selective modification, which is preferred for the majority of bioconjugate applications. 
The primary consideration when selecting an endogenous target is its reactivity under 
conditions which will be tolerated by the biomolecular substrate as a whole without causing 
denaturation. While the compatible conditions of a given substrate will vary depending on its 
intrinsic stability and solubility, this generally equates to near-neutral pH, a temperature at or 
below 37 °C, and a low substrate concentration in the micromolar range. Reactive amino acid 
side chains which are commonly targeted in protein modification experiments are highlighted 
in Figure 1-7, while the pKa of labile protons are given to indicate the conditions required for 
modification. 
Chapter 1: Introduction: Chemical Biology approaches to protein modification 
 11 
 
 
Figure 1-7 The structures of commonly targeted amino acids are shown, organised by the 
functional groups present. The pKa’s of labile protons are given, as this dictates the reaction 
conditions required for side chain modification (the pKa of the His imidazolium group lies 
close to pH 7 and therefore requires slightly basic conditions to favour the imidazole form).1 
Through consideration of the pKa of the targeted group, the conditions required for efficient 
modification are selected. For example, efficient modification of a Cys residue with an 
electrophile is likely to occur in basic conditions at ~pH 9, where the thiol side chain is largely 
deprotonated to the more nucleophilic thiolate anion. In cases where there is the potential for 
cross-reactivity, such as competition between the nucleophilic N-terminal α-NH2 and the Lys 
ε-NH2, careful control of pH may provide selectivity for a single site. In this instance, at ~pH 
8.5, the N-terminus is mostly uncharged and nucleophilic, while the Lys amine is more likely 
to be protonated and therefore not nearly as good a nucleophile. This being said, the local 
environment of a given residue in a protein sequence will exert some influence over its pKa 
and therefore reactivity, hence the pKa values in Figure 1-7 are given as a range. 
The frequency with which the targeted residue appears in a protein sequence should also be 
considered when selecting a native target, and the frequency of occurrence of each canonical 
amino acid in the UniProt/EMBL database is given in Figure 1-8. It is commonplace in protein 
labelling experiments to use a large excess of reagent due to the high dilution of the substrate 
and relatively low accessibility of many target residues. For this reason, a strategy which aims 
to label a highly abundant residue is more likely to result in multiple, non-specific labelling 
events, giving a stochastic mixture of labelled substrates. 
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Figure 1-8 The frequency of each canonical amino acid in the UniProt/EMBL database is 
shown. The relevant functional group on each amino acid side chain is given in the key, while 
commonly targeted residues are highlighted with an asterisk (*). (>80 million sequence 
entries, accessed 26/9/2017).29 
For this reason, selective protein modification strategies often target Cys residues, which show 
the lowest abundance in the gathered data. The scarcity of reactive Cys residues is 
compounded by their propensity to form intramolecular disulphide bridges, which play a 
crucial role in preservation of the higher order structure of a protein. Cleavage of disulphides 
to the corresponding free thiols is possible under reducing conditions, and these may then be 
re-bridged using a bifunctional linker as a strategy to incorporate a functional label. However, 
disturbance of the native disulphide bridges may destabilise the protein conformation, while, 
due to their hydrophobic nature, Cys residues are not generally readily surface accessible, 
which makes them difficult to address. 
Surface-accessibility of a target residue is therefore another variable which should be 
considered carefully, as it relates to the effective abundance of the targeted group. While there 
are various examples in Medicinal Chemistry of small molecule ligands binding in deep, 
cavernous sites within a targeted protein, effective covalent labelling of a protein substrate 
generally relies upon high surface-exposure of the reactive group, while deeply buried residues 
are considered ‘off limits’. It is well understood that the amino acid composition of the protein 
interior differs from the surface, with more hydrophobic groups found in the interior where 
they are shielded from solvent. The reverse is also true, as amino acids with hydrophilic groups 
on their side chains comprise a larger proportion of the protein surface, where they aid 
solubility and reduce protein aggregation. This effect is amplified as the size of the protein 
increases, as the ratio of interior volume to surface area increases in correlation.30 This is 
perhaps the reason that the four most abundant amino acids in Figure 1-8 bear hydrophobic 
side chains. 
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The hydrophobicity of an amino acid may be assessed in several ways, and various scales of 
amino acid hydrophobicity exist in the literature. A normalised consensus hydrophobicity 
scale was published by Eisenberg et al.,31 which combined the findings from empirical and 
computational assessments of amino acid hydrophobicity, and this is used to rank the 20 
canonical amino acids in Figure 1-9 from most hydrophobic to most hydrophilic. This was 
combined with data published by Chothia et al., who determined the amino acid composition 
of 37 proteins, and from the related crystal structures, separately calculated the amino acid 
composition of each protein interior and protein surface.32 By normalising the protein interior 
and surface data to the amino acid composition of the whole data-set, the up- or down- 
regulation of each residue at each site could be established and this has been plotted against 
each amino acid residue ordered by increasing hydrophilicity in Figure 1-9. 
 
Figure 1-9 Using data gathered from 37 proteins,32 the amino acid composition of the protein 
interior and protein surface was normalised against the total amino acid composition of the 
dataset. The resulting values are plotted against their respective residues, ordered from most 
hydrophobic to most hydrophilic following the Eisenberg hydrophobicity scale.31 These data 
support the assertion that there is a higher proportion of hydrophobic residues in the protein 
interior than at the protein surface, and a higher proportion of hydrophilic residues on the 
protein surface than in the protein interior. 
From the general trend in Figure 1-9, it can be seen that as the hydrophilicity of an amino acid 
increases, the amino acid represents a higher than average proportion of the protein surface 
and vice versa. It is therefore concluded that amino acids with a hydrophilic side chain will 
generally exhibit high surface accessibility, and therefore should be easy to address with 
labelling reagents. 
To realise a chemoselective and site-specific labelling method, the reactivity and 
discrimination potential of the target residue must be balanced. Reactivity relies on the pKa of 
the reactive group (bearing in mind that this may be affected by the local environment), and 
Chapter 1: Introduction: Chemical Biology approaches to protein modification 
 14 
on the surface exposure of the residue (to allow the reactive site to be addressed with an 
exogenous reagent). To limit the number of labelling events, the reaction conditions should 
favour only reaction with the target residue, and the overall abundance of this residue and 
effective abundance based on surface accessibility should limit the number of viable reactive 
sites. 
Protein labelling through covalent modification of an endogenous target has been achieved by 
targeting many of the amino acids already mentioned, and this research area has been 
exhaustively reviewed by Koniev and Wagner,33 Agrawal and Hackenberger,26 and Algar.1 
The most common targets such as Cys, Lys, the N- and C- termini and Tyr are discussed in 
subsequent sections, and several recent advances will be highlighted. 
Cysteine 
Cysteine is an appealing native target due to its high nucleophilicity, low abundance and 
moderate surface exposure. Thanks to the pKa of the thiol side chain (pKa ~9), Cys is a highly 
reactive nucleophile in basic conditions, where it can form a thiolate anion. However, at neutral 
pH, the protonated thiol group is also reactive, whereas many competitive nucleophiles are not 
(e.g. Lys bears a positive charge at pH 7). The tendency of Cys residues to form structurally 
important disulphide bridges further lowers the abundance of reactive targets, to the extent 
that a suitable free Cys is not always present in a native protein structure. In order to address 
this, point mutation to introduce a reactive Cys, or reduction of an existing disulphide bridge 
may be a prior requirement to application of the Cys-labelling chemistries which will now be 
discussed. 
In contrast to the hard nucleophilic character of the thiolate anion, the thiol group is a soft 
nucleophile capable of Michael addition to an electron-poor alkene. The most prominent 
example of this kind of Cys modification is in the use of maleimide-functionalised labels 
(Figure 1-10). The maleimide group allows covalent functionalisation of a Cys residue at near-
neutral pH to give, in the first instance, a thiosuccinimide-labeled residue. However, the initial 
Michael addition of the sulfhydryl group to the maleimide is reversible via a retro-Michael 
mechanism, resulting in thiol exchange or elimination of the unmodified Cys.34 By addition of 
a basic group adjacent to the maleimide in the Cys-targeting label, or by performing the 
reaction in basic conditions, hydrolytic ring-opening of the thiosuccinimide is favoured, which 
forms a more stable covalent linkage.35, 36 Maleimide Cys labelling has played an important 
role in the development of ADCs, where conserved Cys residues in the antibody brentuximab 
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were labelled with the maleimide-functionalised antimitotic peptide derivative monomethyl 
auristatin E, to give brentuximab vedotin, one of the first ADCs to receive FDA approval.34 
 
Figure 1-10 Selected methods for the modification of a Cys residue in a protein substrate. 
Contemporary use of iodoacetamide is commonly confined to the capping of Cys residues 
which have been generated by disulphide reduction for MS studies.37 However, historically 
the α-halocarbonyls have provided an alternative Cys-targeting strategy to maleimides. While 
these reagents are generally less reactive to the Cys thiol group, this has allowed the reported 
selective labelling of Cys residues which have a lower pKa due to their existence in a basic 
local environment.38 The use of α-halocarbonyls has largely been superseded by the advent of 
maleimide chemistry and the variations of this group that may be used. 
Thiol-ene and thiol-yne reactions are interesting examples for protein labelling as they employ 
radical mechanisms which require initiation with a radical-generating catalyst and irradiation 
with UV light. While thiols and alkenes/alkynes are well tuned to react with each other, the 
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generation of free radicals in a biological sample is likely to cause off-target modifications. 
Even within the desired labelling reaction, the initial product is a radical species which requires 
quenching or else it is likely to propagate and react with another partner. In the thiol-yne 
example, the quenched product contains an alkene, which may be further modified by thiol-
ene chemistry. In some respects radical-driven processes are well suited to protein labelling 
applications, which are generally performed at high dilution thus limiting the radical cross-
linking of protein substrates. However, there are photoactive proteins such as fluorescent 
proteins, which may be adversely affected by irradiation with low wavelength light.33 
Disulphide exchange is another common Cys modifying approach, and involves the use of a 
disulphide labelling reagent which contains a motif which will make it a good leaving group. 
A good example is the use of Ellman’s reagent, which is a disulphide species bearing electron-
poor aromatic groups on either side of the disulphide bond.39 These groups facilitate thiol 
exchange with the Cys thiol group to form a new disulphide, which again bears a good leaving 
group on one side. This activates the Cys residue for further disulfide exchange with another 
thiol to give a disulphide labelled substrate.1 The obvious drawback of this approach is the 
lability of the linker which is prone to cleavage by reducing agents, however this may be 
preferred for certain applications, where the reversible labelling and restoration of the native 
protein can be achieved.33, 39 
The final approach which has been highlighted involves the conversion of a native Cys residue 
to dehydroalanine (Dha), which allows subsequent labelling with a thiol reagent via Michael 
addition. Several reagents have been reported which convert Cys to Dha, however the 
highlighted example is the use of o-mesitylenesulfonylhydroxylamine (MSH), which works 
by successive amination of the Cys thiol group, before oxidative elimination to give the Dha 
product and a S(NH2)2 by-product.40 Davies et al. have developed this chemistry, and used the 
Michael addition of thiols to the generated Dha to mimic phosphorylation and glycosylation 
PTMs which occur in nature.41 MSH is known to exhibit some cross reactivity with Met 
residues, however this is reversible and so reaction at the Cys side chain is preferred. It should 
be noted that in conversion of the Cys side chain to an alkene and subsequent Michael addition, 
the stereochemistry at the α-carbon is scrambled.26 
Lysine 
As well as showing moderate abundance, Lys bears a hydrophilic side chain, as the ε-NH2 is 
predominantly protonated at physiological pH. In fact, Lys is the second most hydrophilic 
amino acid, behind Arg, and therefore the majority of Lys residues in a protein sequence are 
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likely to be found on the surface. With this in mind, it should be considered that some Lys 
modification strategies result in a loss of charge (e.g. by conversion of the Lys amine to an 
amide) which may be detrimental to the solubility of the protein. Lys is a commonly targeted 
residue for protein modification, although often in a stochastic labelling approach due to the 
abundance and accessibility of the reactive group. This being said, a number of recent reports 
have addressed Lys labelling in a selective manner, and these will be discussed alongside some 
less selective approaches. 
Due to the nucleophilic character of the Lys side chain, the residue is most commonly targeted 
with an electrophilic reagent. With a ε-NH2 pKa of between 9.3-9.5, successful Lys 
conjugation is usually performed in basic conditions, to increase the proportion of the 
uncharged and nucleophilic amine. Selecting chemoselective reaction conditions is 
complicated however by the presence of competitive nucleophiles in the protein chain. In 
particular, the nucleophilic Cys side chain presents a competitive reactive site for many Lys 
labelling reagents, especially at near-neutral pH where the Cys residue is generally more 
reactive than Lys.26 
A commonly used amine-labelling electrophile is found in the isothiocyanate group (Figure 
1-11), which can be prepared from the reaction of the corresponding aniline with either 
thiophosgene, or the significantly less hazardous 1,1’-thiocarbonyldiimidazole (TCDI).42, 43 
The most prominent example of an isothiocyanate labelling reagent is fluorescein 
isothiocyanate (FITC), which is most often used as a fluorescent labelling reagent in a 
stochastic labelling approach. FITC is known to show cross-reactivity with thiols and alcohols, 
however the resulting products are less stable than the thiourea formed by reaction with an 
amine.35 In addition to the issue of cross-reactivity, FITC is often sold as a mixture of two 
regioisomers which are difficult to separate. While these do not differ in their photophysical 
attributes, the heterogeneity of the reagent further underlines its use only as a non-specific 
labelling reagent. 
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Figure 1-11 Common methods for the modification of Lys residues in a protein substrate. 
A similarly popular family of reagents used for Lys labelling is that of the activated esters, 
with N-hydroxysuccinimide (NHS) ester perhaps the most commonly used variant. NHS acts 
as a good leaving group, and its solubility may be increased by addition of a sulphonate group 
to the succinimidyl ring (Figure 1-11). Some cross-reactivity with alcohol-bearing amino acid 
side chains has been reported when using NHS-esters, however the esters produced by this 
reaction are prone to hydrolysis and therefore less stable than the desired Lys labelled 
product.33 While the amide bond formed with the Lys ε-NH2 is extremely stable, the same 
cannot be said for the NHS-ester reagent, which will hydrolyse in aqueous basic conditions.1 
In a recent report, application of substoichiometric amounts of an NHS-reagent and careful 
choice of protein substrates have allowed residue-specific labelling of native sequence 
proteins.44 Weil et al. have demonstrated this kinetically controlled labelling approach to the 
biotinylation of a protein by addition of 0.5 equivalents of the labelling reagent in 100 small 
volume portions.44, 45 This work resulted in specific labelling of a single Lys residue in each 
protein explored, however, with an excess of protein substrate, the labelled product had to be 
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isolated by affinity chromatography before any future use. The explanation given for site-
selectivity was preferential reaction at the most exposed Lys residue, therefore the specificity 
of the reaction depends on surface accessibility (this will be discussed further in Chapter 4).44, 
45 
Reductive amination is a synthetic strategy which is commonly used in Organic Chemistry for 
the production of secondary amines. Using a mild reducing agent such as NaCNBH3 or 
Na(OAc)3BH, the imine formed by condensation of a primary amine with an aldehyde is 
reduced to the corresponding secondary amine product. For use in protein-labelling, this 
reaction has primarily been applied to the labelling of proteins with carbohydrates, however 
dehydrating conditions are preferred to favour the initial condensation step and generally this 
approach has required long reaction times.33 An additional drawback is the fact that some 
protein targets may contain imino groups which could undergo reduction with the borohydride 
reagent, such as in the porphyrin ring in haeme-containing proteins, or the chromophore 
structure formed within the GFP interior. However, Francis et al. have described the use of a 
water-tolerant iridium-based catalyst, which could be used to selectively reduce an imine 
formed by amine-aldehyde condensation, avoiding the use of the borohydride reagents.46 
Using a PEG-aldehyde, this system was found to label the target protein lysozyme with one or 
two PEG chains via reductive amination (lysozyme has six Lys residues in total).46 
A final example of Lys modification comes in the form of sulphonyl halides, most frequently 
this involves the use of sulphonyl fluorides and sulphonyl chlorides. While the desired Lys-
labelled product is a stable sulphonamide, sulphonyl halides also exhibit significant cross-
reactivity with other nucleophilic residues. The reagent itself is also known to hydrolyse 
readily in basic conditions and therefore requires application in high excess compared to the 
substrate.33 This being said, the compact nature of the –SO2X warhead has allowed genetic 
incorporation of a sulphonyl fluoride-functionalised UAA based on Tyr into the sequence of 
a target protein.47 Applying this technology, Wang et al. observed covalent bridging within 
the modified protein, as well as cross-linking of interacting proteins in vivo, by covalent 
modification of native nucleophilic residues, including Lys.47 
N- or C- terminal modification 
The benefit of targeting the N- or C- terminus of a polypeptide is the potential for high site-
selectivity. Unlike the various amino acid side chains, within a protein monomer there will 
exist only one N-terminus and one C-terminus. Of course, in proteins which exhibit quaternary 
structure, such as the cross-linked light and heavy chains in antibodies, there will be N-/C- 
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termini for every monomeric chain, however this is still a reduction in the number of reactive 
sites when compared with many amino acid targets. Due to their position at the beginning and 
end of the polypeptide chain it is also rare to find these reactive sites playing a role in the 
active site of a functional biomolecule, while accessibility is generally high.48 
In terms of chemoselectivity, the N-terminus offers potential due to its low pKa (7.6-8) when 
compared with the Lys ε-NH2 (pKa: 9.3-9.5), and this arises due to the proximity to the 
electron-withdrawing α-amide. In order to exploit this reactivity, many of the Lys-targeting 
chemistries which have been discussed previously may be applied to labelling of the N-
terminus, with the adaptation that they are performed at neutral or weakly acidic pH where 
there will be a greater proportion of the uncharged, nucleophilic N-terminal α-NH2 than there 
will of the Lys side chain. This being said, it should be noted that the pKa of the N-terminus 
will vary depending on the electron donating/withdrawing properties of the N-terminal amino 
acid side chain.26 In addition it should be considered that as many as 57% of proteins in yeast 
and 84% of proteins in humans have been shown to exhibit at least partial acetylation of the 
N-terminal α-NH2 in vivo, so in these cases targeting the N-terminus may not be possible.49 
 
Scheme 1-1 An example of an N-terminal-specific protein modification strategy. Using 
pyridoxal-5-phosphate (PLP) or a structurally related aldehyde-bearing pyridine, the α-NH2 
of an N-terminal residue may be converted to an aldehyde or ketone by transamination. This 
is converted to a hydrazone or an oxime through reaction with a labelled hydrazine or 
hydroxylamine. 
An interesting example of N-terminus labelling is highlighted above, where Francis et al. have 
used the natural cofactor pyridoxal-5-phosphate (PLP) to selectively convert the N-terminal 
α-NH2 to a ketone or aldehyde by transamination (Scheme 1-1).50 This process works by 
condensation of the amine with the aldehyde present in PLP, followed by imine-hydrolysis to 
yield the aldehyde (if the N-terminal amino acid is Gly) or ketone. Due to its proximity to the 
electron-withdrawing amide of the peptide backbone, the generated carbonyl species is prone 
to nucleophilic attack with a hydrazine or hydroxylamine to give the corresponding hydrazone 
or oxime. Using this system, Francis et al. have shown that it was possible to label proteins 
bearing Gly, Val, Lys and Met as the N-terminal amino acid, however there was poor 
conversion of substrates with His, Trp, Pro, Ser or Cys at this position.50 Rather than relying 
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on a two-step labelling protocol, a PLP-related reagent which was based on a 2-
pyridinecarboxaldehyde (2PCA) structure was developed by the same group which allowed 
labelling of the substrate with the label-bearing 2PCA reagent.51 This reagent initially forms 
an imine with the N-terminal α-NH2 as before, however it does not undergo imine hydrolysis 
and instead promotes cyclisation with the α-NH of the second amino acid in the chain. The 
resulting imidazolidinone structure was found to be reasonably stable, and this system was 
used to introduce labels such as fluorophores, biotin and PEG chains to a native sequence 
protein.51 
Compared to the published works describing N-terminal functionalisation, there is a 
comparative dearth of methods which selectively label the C-terminal α-CO2H. This may 
hinge on the fact that there are few methods to distinguish between the reactivity of the C-
terminus and the carboxylic acids contained on the side chains of Asp and Glu. However, just 
such a distinction was recognised by MacMillan et al., who took advantage of the difference 
in oxidation potential of these sites, to selectively label the C-terminus in a photo-initiated 
decarboxylative alkylation reaction (Scheme 1-2).52 
 
Scheme 1-2 The C-terminal targeting photo-initiated decarboxylative alkylation reaction. 
Using an iridium or flavin-based photocatalyst, the C-terminus undergoes single electron 
oxidation, causing decarboxylation and generating the α-amino radical. Addition of a Michael 
acceptor results in conjugate addition of the radical species to the soft-electrophile, and the 
resulting radical species is reduced by single electron transfer from the photocatalyst.52 
Using an iridium or flavin-based photocatalyst under irradiation with blue LEDs, single 
electron oxidation of the C-terminus was achieved, followed by decarboxylation to give a 
reactive α-amino radical. Conjugate addition of the resultant radical to a Michael acceptor, and 
subsequent single electron reduction from the photocatalyst then gave the stable conjugate 
which had essentially been alkylated at the decarboxylated α-position of the C-terminal amino 
acid.52 
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While not explicitly a protein labelling method, native chemical ligation (NCL) is a technique 
used to covalently attach two peptide sequences in the synthesis of proteins, and represents a 
method which combines N- and C-terminal modification (Scheme 1-3). 
 
Scheme 1-3 An example of native chemical ligation (NCL), which allows peptide fragments to 
be stitched together for the synthesis of full length proteins. The C-terminal α-CO2H is first 
activated as a thioester which generally bears an electron-withdrawing group (EWG) to make 
a good leaving group. A peptide with an N-terminal cysteine residue is introduced and 
reversible thioester exchange may occur. Through S- to N- acyl shift, the ligated product is 
then formed irreversibly. 
This approach requires a thioester-activated C-terminus and a Cys residue at the N-terminus, 
which undergo reversible thioester exchange to link the two peptide sequences. The thioester 
linkage may then undergo irreversible S to N acyl shift to give the native amide link between 
the peptides, with the preservation of the Cys stereocentre. In order to mask the point of 
ligation, many variants of NCL have been described, which include post-ligation 
desulphurisation to give an alanine residue, or the traceless Staudinger ligation, which does 
not require a Cys residue at the N-terminal.53 
Tyrosine 
Tyrosine is the target of choice for the work contained in this thesis, and it is an appealing 
target not only for its low abundance (~3% in the UniProt/EMBL database), but also due to its 
central position on the Eisenberg hydrophobicity scale.29, 31 With its polar headgroup and 
aromatic ring, Tyr is considered amphiphilic and therefore can be found on the protein surface 
or in the protein interior. For this reason, it was considered an apt target for selective labelling, 
as in instances where there were multiple Tyr residues in a target protein, discrimination could 
be achieved based on surface accessibility. 
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Figure 1-12 Common methods for the modification of a Tyr residue in a target protein. 
Aside from the benefit of a low abundance and varied distribution in the protein structure, the 
Tyr side chain also offers nuanced reactivity through nucleophilic and radical-induced 
mechanisms (Figure 1-12). While there are several methods to modify Tyr residues reported 
in the literature, it has not proven as popular a target as Lys and Cys residues, however some 
key examples are highlighted below. 
The first example relies upon nitration of Tyr using the nitrating agent tetranitromethane 
(TNM). In this approach, the Tyr phenol side chain is nitrated at the ortho position to give 3-
nitrotyrosine, which is selectively reduced using a mild reducing agent such as sodium 
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dithionite. This reduction step results in formation of an o-aminophenol group, which may be 
modified by an NHS-ester at acidic pH.54 Due to the low pKa of the aromatic amine (pKa ~5 
for the ammonium form), it should be possible to selectively label the o-amino phenol at pH 
5-7, where the Lys side chain and N-terminus are likely to be protonated and not 
nucleophilic.33 However, in the work describing this method, competitive nucleophiles were 
acetyl-capped prior to reduction of the nitro group, suggesting selective modification of the 
modified Tyr was not easily achieved.54 In addition, the reported cross-reactivity of the 
nitrating reagent TNM with residues including His, Trp and Met, suggest that this method is 
not well suited to use in selective protein labelling applications.55 
Due to the electron-rich aromatic ring on the Tyr side chain, it is capable of single electron 
oxidation to the tyrosyl radical, which may undergo cross linking with a nearby aromatic or 
nucleophilic residue.56 While this modification strategy has not been reported for protein 
labelling applications, it has been used as a means of affinity cross-linking, in which an 
associating protein is cross-linked to its target through radical-initiated cross-linking of Tyr 
residues.56 In addition to Tyr-Tyr cross-linking, cross-reactivity with Cys, His and Trp have 
also been reported.57 
In a more conventional protein-labelling approach, Francis et al. have described a three-
component Mannich-type reaction, which was shown to label a Tyr residue at the electron-
rich ortho position.58 This approach relies upon in situ formation of an imine by an amine-
bearing label and an aldehyde such as formaldehyde. This soft electrophile is subject to 
nucleophilic attack from the ortho position of the Tyr phenol ring, which is guided by a H-
bonding interaction between the alcohol group and the nitrogen of the imine.58 The resulting 
secondary amine is relatively stable, and this method was used to prepare a range of 
fluorescently labelled proteins, although in the example of protein substrate chymotrypsin, this 
resulted in labelling of two out of three native Tyr residues. Some cross-reactivity was 
highlighted with Trp residues and free Cys residues, but otherwise, this approach seems to 
provide good chemoselectivity for a Tyr target.59 
Triazolinedione reagents are perhaps the most popular range of Tyr-labelling groups in current 
use. The disclosure of 4-phenyl-3H-1,2,4-triazoline-3,5(4H)-dione (PTAD) by Barbas et al. 
showed the modification of the phenol ring of the Tyr side chain via an ene-type reaction, 
which resulted in conjugation at the ortho position.60 While some cross-reactivity with Lys 
and Trp residues was identified in single amino acid experiments, only Tyr modification 
resulted from a series of competition experiments.60 Further expansion of the PTAD-reagent 
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scope resulted in the attachment of fluorophores, PEG groups and click handles to a range of 
Tyr-containing peptides and proteins with such high chemoselectivity that the bioconjugation 
reaction was referred to as the ‘tyrosine click reaction’.61 In aqueous conditions, the PTAD-
derived reagents are prone to hydrolysis and for this reason, they are generally formed in situ 
by oxidation using N-bromosuccinimide and pyridine.61, 62 
The final example given is the modification of Tyr residues by electrophilic aromatic 
substitution (SEAr) using diazonium reagents. As with the PTAD example, this labelling 
reaction proceeds through the nucleophilic behaviour of the ortho position of the Tyr phenol 
ring. This approach has been used by Francis et al., Barbas et al. and Haddleton et al. to 
selectively label Tyr residues in peptides and proteins.63-65 The Francis and Barbas groups used 
diazonium reagents to install reactive ketone and aldehyde groups to biomolecular substrates 
through reaction with a Tyr residue.63, 64 These tags were then used to attach functional labels 
through oxime-forming chemistry, resulting in selectively labelled biomolecules bearing 
fluorescent groups, biotin and PEG labels. In terms of selectivity, minor modification of His 
and Trp residues was observed in competition experiments with Tyr, however at much lower 
levels than the intended residue. Little or no cross-reactivity was observed with Cys, Ser or 
Lys.64 A major benefit of this labelling approach is the production of an azobenzene group, 
which is labile to reductive cleavage.66 This allows reversible coupling and uncoupling of a 
label to the Tyr target, while the amino acid, once cleaved, bears an o-aminophenol as evidence 
of modification. A drawback of using this chemistry in solution is the requirement to prepare 
diazonium salts in acidic conditions prior to application, as they tend not to be bench-stable 
reagents. 
1.5 Conclusion 
In this Introduction, a range of biomolecular substrates, labels and methods for protein 
modification have been explored. The array of available protein labelling methods is 
colloquially referred to as a ‘toolbox’, and within this set there remains a space for the 
development of an alternative strategy for the selective modification of a native sequence 
substrate. Given the low abundance, moderate surface-accessibility and nuanced reactivity of 
the Tyr side chain, this residue has been selected as the ideal candidate for the current work. 
The goal of this project is to provide a useful method for future protein labelling experiments, 
and in this way it is hoped that this work may expand the scope of the protein labelling toolbox. 
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1.6 Aims for this project 
Following the assessment of the previously discussed strategies to achieve selective 
modification of a native sequence protein, the current work aims to develop a novel 
bioconjugation method which targets an existing Tyr residue in the protein substrate. 
Employing SEAr chemistry, this work will also involve incorporation of a solid-phase support 
to provide superior selectivity for highly exposed Tyr residues over those which are buried in 
the protein interior. The successful development of this chemistry will allow the ‘catch’ and 
‘release’ of a protein substrate from a solid-phase support, with the released protein bearing a 
novel modification which can be exploited for selective functionalisation. A range of 
conditions will be explored for the development of the ‘catch’ and ‘release’ steps of this 
reaction, and a suitable solid-phase support will be selected. Various approaches to the 
downstream functionalisation of the catch-and-release modified substrate will be investigated, 
and the preferred system will be applied to small molecule, peptide and finally protein 
substrates. The successful outcome of this work will be to deliver a three-step modification 
protocol which can provide selective functionalisation of a small protein with a synthetic label 
such as a fluorophore. 
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Chapter 2 Results & Discussion 1: Modification of a 
tyrosine residue 
2.1 Introduction: Three-step modification of tyrosine 
In previous work in the Hulme group, the utility of an azobenzene moiety as a cleavable linker 
has been explored.66 In that application, the azobenzene group was installed in the early stages 
of the synthesis and it was employed purely as a cleavage point to be severed following 
reaction at the terminal end of the molecule. In the current work, azobenzene formation is 
achieved through electrophilic aromatic substitution (SEAr) of the phenol ring of a Tyr residue, 
allowing the immobilisation of a biomolecule onto a solid-phase. Formation of the azobenzene 
moiety and subsequent reductive cleavage using dithionite therefore constitute the ‘catch’ and 
‘release’ stages of a novel three-step protein modification strategy (Figure 2-1). 
 
Figure 2-1 The three-step strategy for modification of a Tyr residue. SEAr: the ‘catch’ step 
involves immobilisation of the substrate through reaction of the Tyr phenol ring with a resin-
bound diazonium salt to form an azobenzene moiety. Reductive cleavage: Using sodium 
dithionite, the azobenzene moiety is cleaved to release an o-aminophenol modified Tyr residue. 
Selective functionalisation: the unique o-aminophenol motif is exploited in a selective manner 
to equip the biomolecule with a functional label. 
Due to its electron-rich phenol side chain, the Tyr residue can be modified through an SEAr 
reaction with an electrophilic diazonium salt, forming the azobenzene species. Using a 
diazonium salt which is immobilised on a bulky solid-phase support provides a degree of 
selectivity in instances where multiple Tyr residues are present, as only the most exposed 
residues are available for modification. Following removal of any unbound substrate by 
washing the resin, the modified biomolecule is then released by introduction of the 
biocompatible reducing agent sodium dithionite.66 Cleavage of the diazo group results in the 
release of an o-aminophenol modified substrate, which is then washed from the resin. The 
modified biomolecule now contains a unique synthetic handle among the endogenous reactive 
sites of a native sequence protein, and there are several reported strategies to exploit this in a 
selective manner. The post-cleavage functionalisation step should ideally allow the 
incorporation of a range of functional labels in order to expand the possible application of this 
modification strategy to as wide a base as possible. 
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While the final iteration of this work will feature a solid-phase platform, this chapter will 
discuss the initial development and optimisation of each of the constituent steps of the 
modification strategy. These were first explored in-solution using small molecule and peptide 
equivalents of the final biomolecular targets. 
2.2 Synthesis of Tyr-bearing substrates 
2.2.1 Ac-Tyr-OMe 
For the development of the Tyr modification chemistry, simple small molecule and peptide 
substrates were used before progression onto more complex biomolecules. The N- and C-
terminally protected amino acid Ac-Tyr-OMe 2 was used for much of this work and the 
compound was synthesised in two steps from H-Tyr-OH (Scheme 2-1). 
 
Scheme 2-1 Synthesis of the N- and C-terminally protected Tyr residue 2, which was used for 
the development of the Tyr modification chemistry. (a) MeOH, acetyl chloride, 0 °C – rt, 3 h; 
(b) Acetic anhydride, NaOAc, H2O, 0 °C, 30 min. 
It was necessary to protect the reactive N- and C-termini to aid analysis of the Tyr-modification 
reactions by HPLC and TLC, as the highly polar H-Tyr-OH showed poor retention on a C18 
column, and failed to move from the baseline on a normal-phase silica TLC plate. Initially, 
the carboxylic acid was converted to a methyl ester by Fischer esterification, with in situ 
generation of HCl by the reaction of acetyl chloride and MeOH to give 1. Following 
purification by recrystallisation, the N-terminus was acetylated by addition of acetic anhydride 
in basic conditions. Performing the reaction in water resulted in the precipitation of the product 
2, which was washed with diethyl ether and isolated in high yield and purity. 
2.2.2 Ac-Tyr(3-NH2)-OMe 
For development of the post-cleavage chemistry, an o-aminophenol modified Tyr residue was 
also synthesised. Commercially available 3-nitrotyrosine [H-Tyr(3-NO2)-OH] was protected 
at the N- and C-termini in a similar manner to the H-Tyr-OH equivalent (Scheme 2-2). 
Reduction of the nitro group was then attempted, however this transformation proved difficult 
to achieve in high yield and purity and so several conditions were trialled to achieve clean 
conversion to the o-aminophenol species 5 (Table 2-1). 
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Scheme 2-2 Synthesis of an o-aminophenol modified Tyr residue. Protection of the N- and C-
termini of 3-nitrotyrosine followed the steps used for H-Tyr-OH. Various conditions were 
screened for reduction of the nitro group. (a) MeOH, acetyl chloride, 0 °C – rt, 3 h, 75h; (b) 
Acetic anhydride, NaOAc, H2O, 0 °C, 30 min, 68%; (c) Fe, CaCl2, EtOH/H2O 95:5, 60 °C, 1 
h, 62%; (d) 10% Pd/C, H2, DCM, rt, 48 h, 23%; (e) Na2S2O4, H2O, rt, 90 min, 69%. 
Entry Reducing agent Workup and purification Yield (%) Notes 
(c)67 Fe, CaCl2 
Passed through celite 
plug, flash 
chromatography 
62 
Heated to 60 °C, 
EtOH/H2O solvent 
(d)68 10% Pd/C, H2 
Passed through celite 
plug, flash 
chromatography 
23 
Low yield, long 
reaction time (48 h) 
(e)69 Na2S2O4 
Salt precipitated with 
MeOH, flash 
chromatography 
69 
Reaction in water at rt, 
single reducing agent 
Table 2-1 Comparison of the three approaches taken to selective reduction of the 3-
nitrotyrosine derivative. Purification of the o-aminophenol product by flash chromatography 
was complicated by its high polarity, resulting in lower than expected isolated yields. 
Initially, selective reduction of the nitro group was performed using Fe powder and CaCl2; 
these conditions act through a catalytic transfer hydrogenation mechanism.67 Purification of 
the resulting o-aminophenol was performed by flash chromatography, however this was 
complicated by the high polarity of the product, causing a narrow band on the silica gel to 
spread into a long streak as it progressed down the column. Nitro group reduction was also 
attempted using H2 and 10% Pd/C; this reaction progressed slowly and ultimately resulted in 
a low yield of only 23%. The most operationally straightforward nitro reduction method 
involved the use of Na2S2O4 in H2O at room temperature. This reaction was judged to reach 
completion by TLC within 90 min, and the majority of the dithionite salt was removed by 
filtration after it was precipitated by addition of MeOH. Dithionite reduction was selected as 
the preferred method for this step due to its operational simplicity and production of the 
cleanest product; following flash chromatography a yield of 69% was achieved on a ~2 g scale. 
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2.2.3 Leu-Enkephalin 
The pentamer peptide Leu-enkephalin (Figure 2-2) was selected as a substrate on which to 
demonstrate the Tyr modification strategy. Leu-enkephalin is an agonist of the δ-opioid 
receptor in humans and contains a single Tyr residue in its native sequence.70, 71 It has been 
used in several literature reports to showcase Tyr-selective modification strategies, and so was 
considered appropriate for this work.65, 72, 73 
 
Figure 2-2 Leu-enkephalin, the pentamer peptide chosen to demonstrate the Tyr modification 
strategy. (a) A model of the Leu-Enkephalin ligand bound to the human δ-opioid receptor. 
Structure retrieved from the PMDB database, PMDB ID: PM0079713.71 (b) The structure of 
the synthesised Leu-enkephalin derivative, with an acetyl cap on the N-terminus and the C-
terminus modified as a primary amide. 
Synthesis of the peptide was achieved by solid-phase peptide synthesis (SPPS) using Rink 
amide AM polystyrene resin and an Fmoc protection strategy (Figure 2-3). The resin is based 
on an aminomethyl polystyrene solid-phase, which must be swollen in DCM for maximum 
accessibility to the reactive sites. The resin bears a terminal Fmoc-protected amine and once 
deprotected in 20% piperidine in DMF, coupling of the first Fmoc-protected amino acid was 
performed using DIC and Oxyma coupling reagents. DIC was used due to the solubility of its 
urea by-product in organic solvents (in contrast to the insoluble by-product of DCC) which 
allows removal of the urea from the solid-phase by washing. Oxyma was included as a co-
coupling reagent as this has been shown to reduce the occurrence of amino acid racemisation 
under coupling conditions.74 Fmoc deprotection and amino acid coupling was repeated in an 
iterative manner until the desired peptide sequence had been achieved. After each deprotection 
or coupling step, a small portion of the beads were removed and tested for the presence of free 
amine using the 2,4,6-trinitrobenzenesulfonic acid (TNBS) test.75 To perform this qualitative 
test, TNBS was added to the beads under basic conditions; under these conditions a free amine 
will attack the sulphonate-substituted position of the aromatic ring and displace the sulphonate 
leaving group, forming a red coloured conjugate. Any ambiguity in the TNBS test was 
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followed by repetition of the previous deprotection or coupling step in order to minimise the 
production of deletion-containing or truncated sequences, which make final purification of the 
desired peptide difficult. 
 
Figure 2-3 The SPPS workflow. After swelling the resin, the Fmoc-protected terminal amine 
was deprotected. Amide coupling of an Fmoc-protected amino acid was performed, before 
deprotection of the newly installed amino acid. These two steps were reiterated until the 
desired peptide sequence was complete. The N-terminus was then capped with an acetyl group 
before cleavage from the resin and global deprotection of the amino acid side chains. After 
each coupling and deprotection step, a portion of resin beads were tested for the presence of 
free amine using the TNBS test (inset). 
After the desired sequence was complete, the N-terminus was capped with an acetyl group, 
before global deprotection of the acid-labile side chain protecting groups and cleavage from 
the resin. These steps were performed simultaneously by the introduction of a TFA cleavage 
cocktail which included triisopropylsilane (TIS) as a cation scavenger. Capping of the N-
terminus as an acetamide and the C-terminus as an amide (which is achieved as a result of 
cleavage from the Rink amide AM polystyrene resin) was performed in order to simplify the 
synthesis, analysis and purification of the substrate. While this better mimics the behaviour of 
a mid-chain peptide, it should be noted that this also has a detrimental effect on the peptide’s 
solubility. Analysis and purification of the synthesised peptide was performed by HPLC, 
giving the desired species Ac-LeuEnk-NH2 6 in 96% purity and 56% yield. 
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2.3 Electrophilic aromatic substitution 
In the development of each step of the catch-and-release modification strategy, each reaction 
was tested on the simplified single amino acid substrate in-solution, before moving onto more 
complex substrates and the solid-phase. To demonstrate the SEAr reaction with a phenolic 
substrate, p-aminobenzoic acid (PABA) was used to model an immobilised aniline, which 
would be used in the solid-phase system (Scheme 2-3), with the carboxylic acid group 
representing the anchor point to the resin. The aniline was first functionalised as a diazonium 
salt, before SEAr with a phenol-containing substrate. 
 
Scheme 2-3 Azobenzene formation using Ac-Tyr-OMe 2 or Phenol as the nucleophile and 
PABA as the starting material for diazotisation. The percentages shown are isolated yields. 
The UV/Vis absorbance of each product is given (recorded by HPLC-PDA), showing the 
azobenzene absorbance at 328 and 359 nm respectively. 
Diazotisation of PABA was achieved by addition of sodium nitrite under acidic conditions. 
These conditions allow in situ formation of the reactive nitrosonium ion (Scheme 2-4) by 
sequential protonation of the nitrite anion to form HONO and then H2O+NO. The nitrosonium 
ion is then formed by elimination of the H2O leaving group. 
 
Scheme 2-4 Formation of the reactive nitrosonium ion from sodium nitrite in HCl. 
Nucleophilic attack of an aniline on the nitrosonium ion forms a nitrosamine intermediate 9 
(Scheme 2-5). Sequential protonation of the terminal oxygen of the nitrosamine forms the 
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H2O+ leaving group, which allows formation of the diazonium salt 10 through the loss of a 
water molecule. 
 
Scheme 2-5 Diazotisation of an aniline by NO+ in acidic conditions. 
While the diazotisation of an aniline by this method requires harsh acidic conditions, the 
following SEAr reaction with a phenol proceeds at neutral or basic pH. Although the 
substitution reaction is accelerated in basic conditions, neutral pH was preferred in this 
instance for compatibility with future protein substrates. Therefore, after diazotisation the 
reaction mixture was neutralised to ~pH 7 using NaOH and K2CO3, monitored using pH paper. 
Introduction of a phenol at this stage resulted in azobenzene formation through the SEAr 
mechanism (Scheme 2-6). The terminal nitrogen of the diazonium salt first undergoes 
nucleophilic attack from the phenol ring to give the intermediate 11. Deprotonation of this 
intermediate restores aromaticity in the phenol ring and results in formation of the stable 
azobenzene 12. Due to the absorbance at ~350 nm of the azobenzene moiety, the reaction 
mixture took on an orange/red colour as the product formed. 
 
Scheme 2-6 Electrophilic aromatic substitution of a para-substituted phenol with a diazonium 
salt, resulting in modification at the ortho position of the phenol ring. In Tyr, the para position 
is blocked by the β-carbon of the amino acid side chain. 
Due to the ortho- and para- directing effects of the OH group, it was expected that we would 
achieve ortho-substitution of the Ac-Tyr-OMe substrate upon reaction with a diazonium salt, 
as the para position is blocked by the β-carbon of the amino acid. By NMR, the azobenzene 
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product from this reaction 13 exhibited the expected splitting pattern corresponding to single 
modification of the phenol ring at the ortho position (Figure 2-4a). By comparison, the splitting 
pattern observed upon azobenzene modification of phenol suggested substitution at the para 
position, resulting in a plane of symmetry in each aromatic ring of azobenzene product 14. 
Despite the ortho- and para- directing effects of the OH in phenol, no o-substituted product 
was observed in this case, perhaps because the para position is less sterically hindered than 
the ortho positions.  
 
Figure 2-4 Ortho- and para- substitution of different phenolic substrates. (a) The Tyr-derived 
azobenzene (top) showed ortho-substitution, as demonstrated by the d, dd, d splitting patterns 
of the aromatic peaks between 7.0 and 7.7 ppm. The phenol-derived azobenzene (bottom) 
demonstrates para substitution, resulting in symmetrical peaks in the aromatic region which 
each integrate to 2 protons. The peak heights were normalised to an amide peak (*) present 
in the R group. (b) The OH of the Tyr-derived azobenzene gave a surprisingly sharp peak, 
presumably due to H-bonding with a nitrogen in the diazo group. The phenol OH in the para- 
substituted compound was extremely broad by comparison. Both NMR spectra were recorded 
in DMSO-d6. 
A recurring theme in the NMR of Tyr-derived azobenzenes was the observation of a 
surprisingly sharp OH peak, which was not seen in the para-substituted phenol-derived 
products (Figure 2-4b). This was justified by potential H-bonding between the OH of the 
ortho-substituted phenol and a nitrogen of the diazo group, which would stabilise the normally 
labile proton and reduce peak broadening. This postulation was supported by the observation 
of a very broad OH peak in para-substituted azobenzenes derived from phenol.  
With a synthetic route to the azobenzene-linked Tyr now established, the chemistry of the 
‘catch’ step was successfully demonstrated. The next step in the modification strategy was to 
cleave the azobenzene linker to release the modified Tyr-bearing cargo. 
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2.4 Reductive cleavage of the azobenzene moiety 
The use of azobenzene as a cleavable motif for reversible bioconjugation was first described 
by Sharon et al., who developed a bifunctionalised cross-linking agent which was used to 
cross-link membrane proteins.76 At the core of the linker was an azobenzene moiety which 
allowed decoupling of the protein conjugates under the mild reducing conditions of aqueous 
sodium dithionite (Na2S2O4). Biotinylated azobenzene-containing linkers have since been 
employed by Bogyo et al.,77 Hulme et al.66 and Wagner et al.78 to enrich protein samples 
through exploitation of the interaction of biotin with its avidin or streptavidin binding partner. 
This approach allowed the researchers to exploit these famously strong binding interactions 
with subsequent release of the enriched cargo under mild conditions. Besides the dithionite 
cleavage strategy used in this work, various reducing agents have been reported to cleave the 
diazo bond which is central to the azobenzene group. Among these approaches, metal-
mediated reactions employing titanium,79 nickel,80 zinc,81 and palladium82 have all been shown 
to achieve reductive cleavage of the diazo bond to give the corresponding anilines. 
Considering a biochemical approach, azoreductase enzymes found in the intestine have been 
shown to achieve the same transformation, however these are intracellular enzymes which are 
not particularly structurally stable, limiting the scope of their application in a reaction flask.83 
Another alternative reducing agent is found in the form of hydrazine hydrate, however, despite 
a standalone account of azobenzene cleavage using this reagent,84 subsequent work 
demonstrated that this reagent was successful in reduction of the azobenzene to the hydrazine 
intermediate, but did not achieve complete cleavage to the respective anilines.85-87 Compared 
to these alternatives, dithionite is an attractive reagent for azobenzene cleavage, as it is 
commercially available, inexpensive, water soluble and mild with respect to protein 
substrates.83 In addition, using an excess of dithionite results in quantitative conversion to the 
fully reduced aniline products.88 This is particularly important in the solid-phase system 
envisioned, as partial reduction to the hydrazine product would not allow release of the 
modified substrate from the resin. 
 
Scheme 2-7 The reductive cleavage of an azobenzene group is achieved through reduction to 
the intermediate hydrazine, followed by reduction to the corresponding anilines. Each step 
involves the addition of two electrons and two hydrogens to the azobenzene substrate. 
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The mechanism of reductive cleavage of an azobenzene moiety relies on the delivery of a total 
of four electrons and four protons from an appropriate reducing agent (Scheme 2-7). This 
transformation can be seen as two sequential steps, with the initial reduction of the azobenzene 
group to its hydrazine equivalent; and following this, further reduction to the corresponding 
anilines. The current work uses the mild reducing agent sodium dithionite to sever the diazo 
double bond, and while the exact mechanism remains the subject of discussion, it is thought 
that the ability of dithionite to act as a reducing agent relies on its degradation in water to form 
two SO2−• molecules. This radical anion is able to act as a single electron reducing agent to 
donate the electrons necessary for diazo reduction, with protons coming from the aqueous 
solvent.83 
Cleavage trials were undertaken using a Tyr-bearing azobenzene and different concentrations 
of aqueous dithionite (Figure 2-5a). The cleavage reaction was monitored by UHPLC-PDA, 
where the azobenzene starting material (with a distinctive absorbance at 330 nm) was 
converted to two anilines with shorter retention times and distinct PDA spectra. The 
conversion was also noticeable by eye, as a bright orange solution of the azobenzene species 
in 300 mM dithionite became completely colourless within 1 min (Figure 2-5b). 
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Figure 2-5 Reductive cleavage of the azobenzene moiety in solution. (a) The reaction 
conditions for the azobenzene cleavage trials. (b) The azobenzene starting material has a 
distinctive absorbance at 329.5 nm, which is lost upon reductive cleavage, and not seen in 
either cleavage product (Rt shown is from UHPLC, Method 2, System 3). (c) Frames from a 
video of a solution of azobenzene in 300 mM dithionite which was completely colourless within 
1 min. 
300 mM aqueous dithionite was the highest concentration used in the trials, however it was 
found that in solution, dithionite concentrations of 300 mM, 100 mM, 50 mM, 10 mM and 5 
mM all resulted in complete conversion to the cleavage products by the first time point of 15 
min. Within this time frame, none of the semi-reduced hydrazine derivative was observed. 
While this represents extremely efficient reduction of the azobenzene group, prior reports of 
the use of dithionite for reduction reactions on solid-phase call for concentrations up to 300 
mM, and this was heeded for the future application of reductive cleavage on an immobilised 
azobenzene substrate.66 
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2.5 o-Aminophenol as a functional handle 
The catch-and-release protein modification system produces an o-aminophenol modified 
substrate, which must then be labelled with a functional molecule. Successful labelling of the 
catch-and-release modified protein requires selectivity for the o-aminophenol handle over 
other reactive sites, and this reaction should proceed under biocompatible conditions. The 
chosen modification strategy should therefore involve biocompatible reagents, it should be 
efficient at low concentrations and should occur in a primarily aqueous solvent, at a mild pH 
and temperature.89 
While the o-aminophenol motif is considered to be unique in the proteins of interest for this 
study, it should be noted that there is potentially a biochemical route to the same product. 
Nitration of a Tyr residue to give 3-nitrotyrosine is a known PTM,90 and subsequent reduction 
to 3-aminotyrosine may be possible by reaction with biological reducing agents (previously 
this has been demonstrated with haeme-containing proteins).91, 92 The Tyr nitration PTM arises 
through exposure to reactive nitrogen-based species, but is not highly abundant and appears to 
show some selectivity for specific residues in certain proteins.93, 94 If Tyr nitration is a concern 
in a protein with a known amino acid sequence, it can be readily identified by MS. 
Alternatively, where the sequence of the protein is unknown, Tyr nitration can be identified 
using an anti-nitrotyrosine antibody.95* The majority of literature reports which describe o-
aminophenol-specific modification come from proteomic approaches to quantify Tyr nitration 
in protein samples, and therefore require nitro-reduction to furnish the reactive species. As 
described previously, dithionite has proven an efficient and biocompatible reducing agent for 
conversion of 3-nitrotyrosine to 3-aminotyrosine, and is therefore often used for this 
conversion. 
The selected 3-aminotyrosine modification approaches shown in Scheme 2-8 can be grouped 
based on the manner in which they target the o-aminophenol moiety. One approach is to 
exploit the aromatic amine which has been installed on the Tyr ring. This amine has a lower 
pKa than the aliphatic amines present in the protein sequence and so, theoretically, can be 
selectively modified in an amide bond forming reaction, or in a route requiring diazonium salt 
formation (Scheme 2-8a & b). An alternative approach is to exploit the redox potential of the 
electron-rich aromatic ring which now bears two electron donating substituents in OH and 
NH2. By oxidation of this system using a biocompatible oxidant, the resulting o-iminoquinone 
                                                     
* All proteins used for this project were commercially sourced and no PTMs were identified 
by the vendors. The most frequently used proteins were analysed by MS and the observed 
mass matched the theoretical mass of the native sequence. 
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may be modified using hetero-Diels-Alder or Michael addition chemistry (Scheme 2-8c & d). 
Each of these approaches were explored in more detail in order to select the most appropriate 
post-cleavage modification method. 
 
Scheme 2-8 Selected approaches to the functionalisation of an o-aminophenol moiety. (a) 
Amide bond formation with the aromatic amine at pH 5. (b) Conversion of the aromatic amine 
to an azide, before CuAAC with an alkyne (c) Oxidation to form a diene, before hetero-Diels-
Alder reaction with a dienophile. (d) Oxidative coupling by Michael addition using an 
oxidising agent and a nucleophilic aniline. 
 
2.5.1 Amide bond formation 
In the area of proteomics, quantification of Tyr nitration in various disease models has been 
investigated as a potential marker for oxidative and nitrosative stress.96 While detection of 3-
nitrotyrosine using antibodies is well established,95 MS techniques have been used to identify 
the specific sites of modification in nitrated proteins. Unfortunately, nitro modification of a 
Tyr residue appears to limit peptide fragmentation by electron-based techniques, and so to 
circumvent this, several derivitisation methods have been reported. Nitro reduction to give the 
o-aminophenol group has been shown to increase peptide coverage by electron-based 
fragmentation techniques,97 and specific labelling of this group has also been used to attach 
small organic labels (including biotin) to identify and enrich the previously nitrated species.90 
As the only aniline in an otherwise unmodified biomolecule, the aromatic amine in o-
aminophenol has a lower pKa (4.8 in its protonated form) than aliphatic amines which could 
act as competitive nucleophiles.98 Therefore, with careful pH control it is theoretically possible 
to favour modification of this site over other endogenous nucleophiles (Figure 2-6). Most 
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commonly, o-aminophenol modification has been achieved through coupling to an NHS-
ester,54, 94, 99 however a similar approach has been reported with a sulfonyl chloride.96 
 
Figure 2-6 Selective modification of o-aminophenol using an NHS-ester labelling reagent. 
Due to the lower pKa of the aromatic amine compared with the aliphatic amines such as the 
Lys side chain and the N-terminus, selective modification should be possible with careful pH 
control.48, 54 
At pH 5, the aniline of o-aminotyrosine is mostly deprotonated and behaves as a nucleophile, 
while the Lys side chain and N-terminus remain mostly in their charged forms. However, these 
pKa values are an average descriptor of each residue, and electrostatic effects in the local 
environment, as well as the degree of solvation of the residue, can have a significant impact 
on their effective pKa.100, 101 For example, the ε-NH2 of a Lys residue which is surrounded by 
basic residues is likely to have a lower pKa and therefore appear more nucleophilic than a 
residue in an acidic local environment. Likewise, the pKa of the α-NH2 of the N-terminus 
varies depending on the electron withdrawing or donating properties of the amino acid 
sidechain. In addition, the thiol sidechain of Cys is a potentially competitive nucleophile. 
Perhaps for these reasons, amide bond forming reactions of o-aminophenol modified residues 
have not yet been reported on intact proteins, and instead have been used only on 
enzymatically digested peptide fragments. In these examples, amines in the peptides which 
might react in competition with the o-aminophenol were acetylated while the Tyr modification 
was still in its nitro- form, before reduction and amide bond formation with the single free 
amine.94, 99 This would suggest that the reaction with an NHS-ester at pH 5 is not sufficiently 
selective to avoid off-target modification of other endogenous nucleophiles, and so this 
approach was not considered to be suitable for this project. 
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2.5.2 Conversion to an azide and CuAAC 
The o-aminophenol moiety enjoys a privileged position, bearing the only aromatic amine in 
an otherwise unmodified native sequence protein. Using now familiar chemistry it is therefore 
possible to diazotise this group to facilitate selective labelling (Scheme 2-9). Through 
treatment with sodium nitrite in acid, the aromatic amine readily forms a diazonium salt. While 
in the SEAr reaction, treatment of a phenol with this diazonium species would result in 
azobenzene formation; using sodium azide as the nucleophile, it is possible to convert the 
diazo group directly to an aromatic azide (as in 15), which can be selectively modified using 
copper-catalysed azide-alkyne cycloaddition (CuAAC).102 This methodology was tested using 
the commercially available alkyne methyl propiolate, which resulted in the triazole-
functionalised Tyr residue 16. 
 
Scheme 2-9 Conversion of an o-aminophenol to an aromatic azide, followed by CuAAC. (a) 
i) HCl, NaNO2, H2O, 0 °C, 10 min. ii) NaN3, H2O, 0 °C, 6 h. (b) Methyl propiolate, 
CuSO4∙5H2O, sodium ascorbate, t-amyl alcohol/H2O, rt, 16 h. 
It is important to note the potential dangers associated with the azide formation reaction, as it 
involves addition of sodium azide to a solution which had previously contained HCl. Under 
acidic conditions sodium azide is known to form the toxic, volatile and explosive hydrazoic 
acid, and so this reaction was performed behind a blast shield and only on a small scale (<1 
mmol).  
The generic substitution of an aromatic diazonium salt with a nucleophile is a well-studied 
transformation. A notable example is the Sandmeyer reaction, which involves the functional 
group transformation of a diazonium salt to a halide. Adaptations of the Sandmeyer reaction 
include the use of thiol, alcohol and cyano nucleophiles among others, while recent reports 
apply similar conditions to install a trifluoromethyl group or a radiolabelled iodine onto a 
diazotised substrate.103, 104 The use of an azide anion as a nucleophile in a Sandmeyer-type 
transformation has also been well explored due to the utility of the azide group as a masked 
amine or in various ‘click’ chemistries.102, 105-107 Despite this fact, the mechanism by which 
this transformation occurs has only recently been described.108  
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Using a combination of theoretical and experimental methods, Cossio et al. found that, 
contrary to the previously proposed SN2 mechanism, the conversion of a diazonium salt to an 
azide is in fact instigated by addition of the azide anion to the terminal nitrogen of the 
diazonium salt (Scheme 2-10). It was found that a high energy pentazene intermediate was 
formed, which then loses N2 to give the desired aromatic azide.108 An interesting implication 
of this revised mechanism is that only the terminal nitrogen in the azide product has actually 
originated from the azide nucleophile, while the other two nitrogens were already present in 
the diazonium salt. Another point of interest is the similarity between the initial step of this 
mechanism and that of the SEAr reaction used to form an azobenzene. The difference in the 
case of azide formation is that the pentazene intermediate formed by the initial nucleophilic 
attack on the diazonium salt is very high in energy and therefore short-lived, while the 
azobenzene product is sufficiently stable to be isolated and purified. 
 
Scheme 2-10 The azide conversion of a diazonium salt. Contrary to the expected substitution 
reaction, the azide-forming reaction is now thought to progress via addition of the azide to the 
diazonium salt to form an unstable pentazene intermediate.108 Following the loss of N2, the 
aromatic azide is formed. 
Following successful functionalisation with an azide, a number of bioorthogonal reactions 
were available for the modified Tyr residue. The preferred approach in this instance was to 
use CuAAC, due to the relative ease with which alkyne-functionalised fluorescent labels are 
synthesised, the aqueous compatibility of the system and the low cost of the Cu catalyst.109 
Alternative azide labelling reactions include Ru-catalysed azide-alkyne cycloaddition 
(RuAAC)110, strain-promoted azide-alkyne cycloaddition (SPAAC)111, and Staudinger 
ligation.112 
A fluorescent alkyne in the form of dansyl alkyne 17 was synthesised in high yield from the 
commercially-available dansyl chloride. This was added to the azido-tyrosine derivative 15, 
and the Cu+ species was generated in situ in a t-amyl alcohol/H2O solvent mix. The reaction 
was monitored by HPLC-PDA, and in addition to the distinct retention times of the starting 
materials and product, the PDA absorbance spectra provided supplementary evidence of the 
functional group conversion. The azido-Tyr derivative 15 exhibited a distinctive absorbance 
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at ~296 nm, which has previously been shown to arise from azidophenol compounds.113 In the 
CuAAC product, the absorbance of the dansyl group was largely swamped by that of the Tyr 
moiety, however a shallow absorbance at around 340 nm was also observed, and this is 
supported by literature reports of similar triazole-linked dansyl groups (literature example λex 
335 nm, λem 520 nm).114 The purified click product 18 was further characterised by NMR and 
MS, confirming its identity, but the HPLC-PDA method proved a useful tool to monitor the 
reaction. 
 
Scheme 2-11 Synthesis of a fluorescent Tyr derivative using CuAAC chemistry. (a) 
Propargylamine, NEt3, DCM, 0 °C, 1 h. (b) CuSO4∙5H2O, NaAsc, t-amyl alcohol/H2O (2:1), 
rt, 18 h. 
A high yield of the click-conjugated Tyr derivative 18 was achieved in 18 h at room 
temperature, demonstrating a potential route to functionalisation of a catch-and-release 
modified Tyr substrate. However, there are some issues with the diazotisation, azide-formation 
CuAAC modification strategy, not least the need for harsh acidic conditions to diazotise the 
o-aminophenol moiety in the first step. As such, it would seem that this modification strategy 
is best suited to small molecule and peptide substrates, as protein substrates are likely to 
become denatured in these conditions. Further to this, in looking forward to a future protein 
substrate it would be preferable to minimise the number of reaction steps and reduce the need 
for purification wherever possible. 
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2.5.3 Hetero-Diels-Alder approach 
Many bioconjugation strategies rely on the nucleophilic character of a target residue, and the 
nucleophilicity of the amine in the o-aminophenol moiety has so far been explored in the amide 
bond-forming and diazotisation-azide formation approaches. Selectivity based on 
nucleophilicity is complicated by the presence of competing nucleophiles among the 20 
canonical amino acids. In particular, nucleophilic amines, thiols and hydroxyl groups pose 
potential competition for reaction with an electrophilic modifying agent. An alternative 
modification approach involves oxidative activation of the o-aminophenol moiety (Scheme 
2-12). This approach opens the possibility for more nuanced reactivity with a complementary 
labelling reagent and therefore may achieve greater selectivity for the modified residue over 
potentially competitive sites. 
 
Scheme 2-12 Hetero-Diels-Alder modification of an o-aminophenol. When exposed to a 
suitable oxidising agent, an o-iminoquinone is formed. An appropriate amide-substituted 
dienophile bearing a functional synthetic group (R) allows formation of a morpholine ring via 
[4+2] cycloaddition. Subsequent oxidation results in the unsaturated benzoxazene 21.115 
As one of the few electron-rich aromatic amino acids, Tyr is known to be redox active,90 and 
oxidation of Tyr and its derivatives have been reported via both enzymatic and chemical 
routes.57 Oxidation of a Tyr-related residue results in the production of a higher oxidation state 
species such as a quinone or iminoquinone. The tyrosinase enzyme has been reported to 
oxidise solvent-exposed Tyr residues, which can then participate in selective covalent 
modification.116, 117 In terms of chemical approaches, Francis et al. have pioneered selective 
oxidation techniques to target Tyr derivatives with small molecule oxidising agents.89 Initially, 
much of this work involved the use of sodium periodate as an oxidant of o-aminophenols. 
Other oxidising agents which have been explored include ceric ammonium nitrate and a range 
of silver, cerium and copper salts; however the most promising biocompatible oxidant which 
was assessed was potassium ferricyanide [K3Fe(CN)6].89 The ferricyanide oxidant has since 
featured in several reports, where it has been used to activate a Tyr-derived target for 
bioconjugation. Crucially, this mild oxidant has shown efficient oxidation of catechol and o-
aminophenol groups (to o-quinone and o-iminoquinone respectively), but does not oxidise off-
target sites such as the side chains of Cys, Met and Trp residues.89 A benefit of using a small 
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molecule oxidant compared to an enzymatic reagent is the ease of handling, as well as 
straightforward separation of the oxidising agent from the protein substrate following 
modification. 
Upon oxidation of an o-aminophenol, the hydroxyl group is converted to the ketone form, and 
the amine to its imino counterpart. This o-iminoquinone (Scheme 2-9 19) has been used as a 
tuned diene for hetero-Diels-Alder mediated modification using a suitable dienophile in the 
form of an acrylamide (20).115 The hetero-Diels-Alder reaction is an appealing method for 
bioconjugation as these reactions tend to progress with a high rate constant and are feasible in 
aqueous buffer at mild temperatures.118 However, this reaction has also been shown to produce 
a heterogeneous mixture of conjugation products, which is undesirable as analysis and 
purification of protein bioconjugates is more complex than with their small molecule 
counterparts.119, 120 In addition, attempts to recreate this transformation on small molecule 
substrates were unsuccessful in our hands, and for this reason the hetero-Diels-Alder strategy 
was abandoned in favour of an alternative oxidative coupling strategy. 
2.5.4 Oxidative coupling 
Following the report of the hetero-Diels-Alder strategy for modification of an o-aminophenol, 
Francis et al. developed an alternative oxidative coupling reaction which supersedes its 
predecessor in terms of selectivity.89 Over several reports, this coupling strategy has been 
shown to exhibit high efficiency under biocompatible conditions, with no reported cross-
reactivity or oxidation of susceptible native residues.121-124 The bioconjugation product is 
achieved using the favoured K3Fe(CN)6 oxidant at pH 6.5. As before, oxidation of the o-
aminophenol moiety to its o-iminoquinone equivalent activates the modified Tyr residue for 
selective bioconjugation (Scheme 2-13). In this instance however, addition of a nucleophilic 
aniline results in Michael addition to the modified Tyr side chain, giving the conjugate addition 
product 22. Following further tautomerisation and oxidation steps, the imine group undergoes 
hydrolysis to afford the desired bioconjugate in the form of iminoquinone 23. Through 
computational modelling and NMR studies, Frances et al. have shown that this is the preferred 
conformation of the oxidative coupling product,121 and the iminoquinone product was also 
found to exhibit high stability across a range of temperatures, pH and upon incubation with 
various nucleophiles.121 
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Scheme 2-13 The mechanism of the oxidative coupling reaction. Oxidation of the o-
aminophenol forms the reactive o-iminoquinone structure. Conjugation of the label is 
achieved by Michael addition of the aniline to the o-iminoquinone. Following tautomerisation 
and further oxidation, the imine is hydrolysed to give the iminoquinone product. 
Initial attempts to recreate the oxidative coupling reaction involved the use of simplified 
substrates: 2-amino-p-cresol (to mimic the modified Tyr residue) and p-toluidine (to represent 
the functionalised aniline) (Figure 2-7). The reactants were initially used in a 1:1 stoichiometry 
with 5 equivalents of the K3Fe(CN)6 oxidising agent, to a final reactant concentration of 3 mM. 
After 3 h at room temperature, two new peaks were identified by HPLC in a 34:66 ratio (by 
HPLC peak area at 210 nm), alongside unreacted p-toluidine. Curiously, no unreacted 2-
amino-p-cresol could be seen, suggesting that the o-aminophenol starting material was being 
consumed without cross coupling to the aniline. The new peaks were isolated and analysed by 
MS and the major species was identified as the desired product 24. The side-product peak 
showed a + 16 Da increase in mass compared with the desired product, corresponding to an 
additional oxygen atom. It is proposed that this by-product results from dimerisation of the o-
aminophenol starting material to give the iminoquinone 25. With incomplete oxidation of the 
o-aminophenol species, this dimerisation could result from nucleophilic attack from the amine 
of one non-oxidised equivalent of o-aminophenol on one oxidised equivalent, in a similar 
manner to that proposed in the previous mechanism. 
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Figure 2-7 Oxidative coupling of an o-aminophenol substrate. (a) The reaction conditions 
used with reactants in a 1:1 stoichiometry. (b) HPLC trace at 210 nm of the reaction mixture, 
showing a 34:66 ratio of dimer to product. Unreacted p-toluidine was also observed, but no 
unreacted 2-amino-p-cresol was seen (expected at 7.28 min). (c) Following adaptation of the 
conditions, the dimer to product ratio was reduced to 7:93. (d) Each of the peaks formed 
during the reaction were isolated. (e) MS of the isolated samples confirmed that the major 
peak corresponded to the desired product, while the minor peak appeared to result from 
dimerisation of the o-aminophenol reactant. 
The dimerisation of the o-aminophenol species was not expected to affect the final protein 
functionalisation step of the catch-and-release strategy, as protein modification is generally 
performed on low concentration samples with an excess of modifying reactant. Furthermore, 
the modified Tyr residues in a protein will be less reactive to dimerisation due to their 
comparatively lower solvent accessibility and fixed position in the protein sequence. However, 
conditions were explored to minimise dimerisation in the small molecule reaction. By 
doubling the number of equivalents of oxidant to 10, and performing the reaction at one third 
of the previous concentration (1 mM with respect to starting materials, previously 3 mM), not 
only did the reaction reach completion within 30 min but the ratio of dimer to product was 
reduced to 7:93 (by HPLC peak area at 210 nm). 
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The oxidative coupling strategy was next attempted using a fluorescent aniline in the form of 
the commercially-available fluoresceinamine and the Tyr-derivative 5 (Figure 2-8). Using the 
optimised conditions from the previous reaction, significant dimerisation of the Tyr-derived 
starting material was observed by HPLC, which may suggest that fluoresceinamine and/or Ac-
Tyr(3-NH2)-OMe 5 are less reactive in the oxidative coupling reaction than the reactants in 
the previous example. By increasing the number of equivalents of the aniline starting material, 
the ratio of dimer to product was significantly reduced (Table 2-2). These final conditions gave 
complete conversion by HPLC of the Tyr-derived starting material within 2 h. The product 
was identified by HPLC-PDA with a new absorbance at 442 nm, which was similar to that 
reported for the fluorescein moiety in acidic pH (at pH 4, λex 437 nm)125, at neutral pH the 
fluorescein moiety has been reported to have λex 490 nm, λem 523 nm.125 
 
Figure 2-8 Oxidative coupling of fluoresceinamine with the o-aminophenol modified Tyr 
residue. (a) The reaction conditions used to achieve oxidative coupling of fluoresceinamine to 
5. (b) PDA spectrum of the product shows incorporation of the fluorophore as a new 
absorbance at 442.2 nm appears. (c) Under irradiation with 365 nm light, the purified product 
(right) shows fluorescence.  
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[Ac-Tyr(3-NH2)-OMe] 
(mM) 
[Fluoresceinamine] 
(mM) 
[K3Fe(CN)6] 
(mM) 
Dimer/Product ratio 
(HPLC at 210 nm) 
1 1 10 45:55 
1 5 10 16:84 
1 10 10 11:89 
Table 2-2 Optimisation of the oxidative coupling reaction with fluoresceinamine as the 
nucleophile. The best ratio of dimer to product was achieved with 10 equivalents of 
fluoresceinamine compared to the o-aminophenol starting material. All reactions were 
performed at room temperature for 2 h, followed by desalting using a prepacked C18 SPE 
cartridge. Analysis was performed by HPLC-PDA at 210 nm absorbance. 
The oxidative coupling strategy has been shown to produce a fluorescently-labelled Tyr 
derivative, with scope for future optimisation for protein substrates through manipulation of 
the reactant and oxidant stoichiometry, and the final concentration with respect to the tyrosine-
derived substrate. Crucially, this transformation was performed in near-neutral buffer at rt, 
avoiding the harsh and potentially denaturing conditions used in the diazotisation, azide 
formation, CuAAC approach. For this reason, this strategy was favoured for the post-cleavage 
functionalisation step of the catch-and-release modification strategy. 
 
2.6 Conclusion 
In this chapter, the three-step modification strategy for Tyr-bearing biomolecules was 
introduced. Although a solid-phase platform will ultimately be used to achieve selectivity 
among multiple Tyr residues, the chemistry of each step was first explored in-solution. To aid 
the development of this system, single amino acids derived from Tyr were synthesised, 
alongside a Tyr-containing peptide, Leu-enkephalin, which will be employed in the following 
chapter. In the development of the ‘catch’ step of the modification strategy, electrophilic 
aromatic substitution of phenolic substrates with a diazonium salt was demonstrated, and the 
regioselectivity of this transformation was confirmed by NMR. To ‘release’ the Tyr-bearing 
substrate, cleavage of the azobenzene linker is required, and this was assessed using aqueous 
sodium dithionite at various concentrations. Although complete reductive cleavage was 
observed within 15 min with even the lowest concentration trialled, it is expected that 
dithionite cleavage on-resin will require higher concentrations, as has been demonstrated in 
the literature.66 Next, four approaches were considered for the post-cleavage functionalisation 
of the modified biomolecule. Amide bond formation with the aromatic amine was discarded 
due to a lack of selectivity, however, functionalisation with a click handle in the form of an 
azide was demonstrated via a diazotisation-azide formation approach. CuAAC was used to 
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furnish a Tyr residue bearing a fluorescent label. However this approach was ultimately 
considered to involve too many synthetic steps, while exposing the modified substrate to 
potentially denaturing conditions. As such, this strategy would be unsuitable for protein 
substrates, but may remain applicable to smaller peptides. Oxidation of the 3-aminotyrosine 
ring was next considered as a route to selective functionalisation. A Hetero-Diels-Alder 
reaction with an acrylamide reactant was ruled out due to the reported production of poorly 
defined bioconjugates,120 however this approach led to the exploration of the oxidative 
coupling reaction which involved Michael addition of an aniline to the o-iminoquinone 
produced through ferricyanide oxidation of an o-aminophenol. The conditions of this reaction 
were optimised for two different anilines, which resulted in the production of a Tyr-derivative 
bearing a fluorescein label. This oxidative coupling strategy was considered the most 
promising for use with a protein substrate and so it was adopted for future work. After the 
establishment of each constituent reaction in the three-step Tyr-modification strategy, the next 
challenge was to move this onto a solid-phase platform, and this stage of the project will be 
explored in Chapter 3. 
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Chapter 3 Results & Discussion 2: Development of 
a solid-phase platform 
3.1 The rationale for a catch-and-release approach 
Using the chemistry discussed in Chapter 2, it should be possible to selectively label a protein 
substrate through the reactive Tyr residues. In order to achieve further selectivity for only the 
most exposed Tyr residues, the system was reproduced on a solid-phase where it was 
envisioned that SEAr modification would occur via a surface-surface interaction between the 
protein and the resin-bound diazonium salt (Scheme 3-1).  
 
Scheme 3-1 An overview of the catch-and-release modification strategy using a solid-phase 
platform. SEAr: The Tyr-bearing molecule is ‘caught’ on the solid-phase by SEAr with an 
immobilised diazonium salt. Reductive cleavage: The modified biomolecule is released by 
reductive cleavage of the azobenzene linker, and bears a unique aromatic amine on the 
modified Tyr side chain. Selective functionalisation: Using an oxidative coupling strategy, 
selective conjugation of a fluorophore (F) is achieved. 
With this adaptation, the ‘catch’ and ‘release’ steps refer to immobilisation of the biomolecule 
on a solid-phase, and its subsequent release upon reductive cleavage of the linker. In addition 
to providing selectivity for exposed Tyr residues, a singly modified protein will become 
tethered to a bulky resin bead, limiting the opportunity for secondary modification. The use of 
a solid-phase platform serves a further role in allowing step-wise separation of diazotisation 
(which requires harsh acidic conditions) and introduction of the proteins substrate (in neutral 
pH buffer). Finally, the capture of a biomolecule on a solid-phase resin allows the 
straightforward separation of modified and unmodified substrate, as the unmodified material 
is washed from the resin prior to release of the modified substrate under reducing conditions. 
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3.2 Streptavidin resin 
The first solid-phase platform that was considered was resin-bound streptavidin (SAv) which, 
once functionalised with an aniline for diazotisation, would provide significant steric bulk 
around the diazonium salt in order to favour exposure-based selectivity. SAv resin is 
commercially available and consists of cross-linked agarose beads functionalised with the ~56 
kDa SAv protein via a covalent linker (Figure 3-1).126, 127 The exact nature of this linker is not 
explicitly described by the vendor, but it is most likely constructed through formation of an 
amide bond with the side chain of a Lys residue in the protein. SAv exists as a tetramer, with 
each subunit binding one biotin molecule, and as there is some cooperativity between SAv 
subunits during biotin binding, it is assumed that the protein is immobilised in its tetrameric 
form.126 
 
Figure 3-1 SAv-functionalised agarose resin was used as the solid-phase platform. (Left) The 
resin is composed of 6% crosslinked agarose, which contains the D-galactose and 3,6-
anhydro-L-galactopyranose subunits. (Right) A streptavidin tetramer is shown with biotin 
ligands bound to it (green spheres). The protein is most likely immobilised on resin via a 
covalent linkage with a Lys residue, forming an amide linker (PDB ID: 1SWE).  
SAv is structurally similar to Avidin (Av), and both of these proteins bind biotin with high 
affinity (SAv: Kd ≈ 10
-14 M; Av: Kd ≈ 10
-15 M).127 Although SAv binds biotin with slightly 
lower affinity than Av, it was favoured for the current application as, in contrast to Av, it does 
not bear any carbohydrate post-translational modifications (PTMs) which are thought to cause 
non-specific protein-protein binding. In order to use SAv resin in the catch-and-release system, 
it first required functionalisation with an aniline from which a diazonium salt could be 
generated. SAv functionalisation was achieved through derivatisation of the biotin ligand, 
which is a strategy that is commonly employed in Chemical Biology for ‘pull-down’ 
experiments of biotinylated substrates from complex mixtures.128 As such, through the 
synthesis of a biotinylated aniline, functionalisation of the resin could be achieved by 
incubation of the modified ligand with the SAv resin.  
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3.2.1 Synthesis of a biotinylated aniline 
When biotin is bound to the SAv binding site, the ureido headgroup of the biotin ligand is 
largely buried and is involved in cooperative H-bonding with five residues in the protein 
sequence (Figure 3-2).129 However, the valeric acid side chain points out of the binding pocket 
towards the solvent and is therefore relatively accessible. This site therefore represents an 
attractive target for derivatisation using straightforward amide bond forming chemistry. 
 
Figure 3-2 The organisation of biotin in the binding site of SAv. The urea group is the most 
deeply buried region of the biotin ligand, while the carboxylic acid is the most solvent-exposed 
(PDB ID: 1SWE). 
The biotinylated aniline 33 was synthesised starting from D-biotin, and the terminal carboxylic  
acid was first activated as an NHS-ester using N-hydroxysuccinimide and DCC in DMF at 
room temperature. Due to the poor solubility of the NHS-activated biotin derivative 27, the 
product was purified by trituration with ether, after removal of DMF in vacuo. This 
purification method avoids the use of flash chromatography, which may cause hydrolysis of 
the NHS-ester. A linker was next installed between the biotin and aniline moieties using a 
short Boc-protected diamine 28, which resulted in formation of the biotin derivative 29.  
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Scheme 3-2 Synthesis of a biotinylated Boc-protected aniline for application in the catch-and-
release system. (a) NHS, DCC, DMAP, DMF, rt, 18 h; (b) 28, NEt3, DMF, rt, 18 h; (c) Boc2O, 
NEt3, Dioxane/H2O (2:1), rt, 18 h; (d) NHS, DCC, DCM, rt, 18 h; (e)i) TFA, DCM, rt, 2 h; ii) 
NaHCO3, 31, MeCN, rt, 18 h; (f) TFA, DCM, rt, 2 h. 
A Boc-protected aniline with an NHS-ester in the para position was next synthesised in two 
steps from para-aminobenzoic acid (PABA). The aniline was first protected using Boc2O to 
give 30, before activation of the carboxylic acid as an NHS-ester. The resulting amine-reactive 
reagent 31 was once again purified without the use of flash chromatography to avoid 
hydrolysis of the NHS-ester. Deprotection of the biotin derivative 29 was achieved in TFA 
with monitoring by TLC with ninhydrin staining. After removal of the solvent and TFA under 
a stream of nitrogen, the residue was redissolved in saturated sodium bicarbonate, before 
introduction of 31. The resulting Boc-protected biotinylated aniline 32 was then deprotected 
in TFA/DCM to give the desired biotinylated aniline 33 (4 steps from D-biotin, 43% overall 
yield). With the necessary reagent in hand to equip SAv resin with an aniline, diazotisation 
and azobenzene formation was attempted, first in-solution before moving onto the solid-phase. 
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3.2.2 Azobenzene formation and unforeseen biotin modification 
To prepare the biotinylated aniline 33 for azobenzene formation with a Tyr-derived substrate, 
the aniline was first diazotised in acidic conditions with NaNO2, before neutralisation and 
introduction of Ac-Tyr-OMe 2 to form the SEAr product 13 (Figure 3-3). Suspicions were 
aroused that this product was not the intended biotinylated azobenzene, due to analysis by ESI-
TOF MS, which did not agree with the expected mass of the product. In fact, instead of the 
expected [M+H]+ signal at 654.2704, m/z signals were observed at 653.2603, 683.2605 and 
705.2426 (in a sample which gave a single peak by HPLC). The signals at 683.2605 and 
705.2426 were particularly interesting as they appeared to correspond to a single species 
bearing a proton and sodium adduct respectively, the 653.2603 signal presumably resulted 
from degradation of this species. 
 
Figure 3-3 Azobenzene formation with a biotinylated diazonium salt gave rise to an unknown 
product 13. (a)i) HCl, NaNO2, H2O, 0 °C, 20 min; ii) 2, NaHCO3, 0 °C – rt, 15 min. Inset: the 
unknown masses observed by MS, compared to the theoretical mass.  
In order to explore this further, NMR studies were performed in DMSO-d6 due to the poor 
solubility of the biotinylated product 13. Using an NMR solvent which does not cause H/D 
exchange of labile protons became important, as it emerged that only one NH from the biotin 
urea group could be seen in the azobenzene product 13, shifted downfield from those in D-
biotin from ~6.3‒6.4 ppm to 8.80 ppm. The MS and NMR results were best explained by 
addition of a nitrosyl group to the biotin urea, resulting in the unintended nitrosylated product 
13 (Figure 3-4). 
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Figure 3-4 Nitrosylation of the biotin moiety under azobenzene forming conditions. (a) The 
addition of NO was supported by HRMS. (b) By COSY NMR, only one urea NH was identified, 
and this was found to be located on the same side of the fused bicycle as the valerate chain 
[N(3’)H], suggesting modification at the N(1’) position.  
To determine the regiochemistry of the nitroso- modification, the compound was characterised 
by COSY NMR. There was a strong COSY interaction between the remaining urea-NH and 
the biotin CH adjacent to the valerate chain, suggesting that the modified site must be on the 
opposite side of the fused ring system [N(1’)]. This finding was further explored using D-biotin 
as a nitrosylation substrate. 
3.2.3 Biotin nitrosylation 
Biotin nitrosylation is not a well reported transformation despite the importance of biotin in 
biological systems and the common use of both biotin and azobenzene chemistry in Chemical 
Biology. However, nitrosobiotin is not entirely unknown, as two papers (Jansen and Stokes in 
1962 and Sanzini et al. in 1977) were found which describe its preparation using NaNO2 in 
acidic conditions.130, 131 Unfortunately, the characterisation of nitrosobiotin was limited to 
UV/Vis, IR spectroscopy and elemental analysis, and so there was no determination of the 
regiochemistry of the transformation. Beyond this, a passing mention of a ‘1-nitrosoimidazole 
product’ was reported as an unintended by-product by Welzel et al. when they attempted to 
modify an antibiotic natural product with a biotin ligand using diazonium chemistry.131 
Although this statement appeared to assign the modification to the N(1’) position, the only 
supporting data provided was 13C NMR and MS, which did not allow regiochemistry to be 
established. The justification for modification at the N(1’) position may be through analogy to 
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carboxybiotin, as it is the N(1’) position which is modified in biotin during its role in CO2 
transfer.133 However, as there is no published data to support the regiochemistry of biotin 
nitrosylation, it was explored using modern analytical techniques. 
D-Biotin was successfully converted to nitrosobiotin 34 through in situ generation of the 
nitrosonium ion using TFA and NaNO2. The reaction was performed at room temperature and 
was judged complete by UHPLC after 2 h (Figure 3-5). As before with the modified biotin 
substrate, the remaining NH of the biotin urea was identified at 8.80 ppm, and was found by 
COSY NMR to correspond to the N(3’) position.  
 
Figure 3-5 The nitrosylation of D-biotin. (a) The reaction conditions which give rise to 
nitrosobiotin 34, the key atoms of the biotin urea group are labelled by the convention used 
by Strzelczyk et al.134 (b) By COSY NMR, the nitrosylated site was found to be N(1’), as the 
remaining NH was identified on the same side as the valeric acid chain. (c) The X-ray crystal 
structure of nitrosobiotin confirmed the location of modification. (d) By HPLC-PDA, the 
nitroso-modification was found to cause two new absorbance maxima at 246 and 399 nm. 
An X-ray crystal structure was obtained of nitrosobiotin 34, following recrystallisation from 
H2O:EtOH (1:1). This provided further evidence that biotin was modified at the N(1’) position, 
although it was not immediately clear why there would be a difference in reactivity between 
the N(1’) and N(3’) sites. There is no significant difference in the electronics of these positions, 
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and despite the presence of the valeric acid chain on the N(3’) side, this is shown in X-ray 
structures as an elongated chain which would not seem to provide sufficient steric interference 
to reduce the reactivity of the N(3’) position. However, work by Mazurek et al. has found 
through in silico calculations that a folded conformation of biotin (in which the valeric acid 
chain bends back towards the urea group) may be stabilised by intramolecular H-bonding 
between the N(3’) position and the terminal carboxylic acid (Figure 3-6).134 
 
Figure 3-6 The conformations of biotin. (a) In X-ray crystal structures, the extended form of 
the valeric acid chain is stabilised by intermolecular H-bonding. However when biotin was 
modelled in a vacuum, intramolecular H-bonding between the N(3’) position and the terminal 
carboxylic was found to stabilise folded conformations. (b) The optimised structures reported 
by Mazurek et al. Images reproduced with permission from the publisher. 134 
Further evidence to support the existence of the proposed folded biotin conformations was 
described by Li et al.135 Using quantum chemical calculations to assess the different rates of 
H/D exchange at the N(1’) and N(3’) positions, the researchers found that the N(1’) position 
had an exchange rate 6 times greater than that of the N(3’) position, and this was supported by 
experimental data. This result was further explained by the finding that the relative proportion 
of extended, semi-folded and folded biotin in water was 24:3.6:1.135 While the proportion of 
folded biotin was found to be low, the folding and unfolding of the valeric acid chain is a 
dynamic process, and therefore the different reactivities of the N(1’) and N(3’) positions can 
be ascribed to the fact that all biotin molecules in the sample will spend some time in the folded 
conformation. This work serves as a useful reminder that the X-ray structure of a crystalline 
material represents its conformation once fixed in space, and may not capture the dynamic 
conformational changes which occur in the solution-phase. With the rise of computational 
chemistry, modelling these solution-phase changes should become more commonplace, and 
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hopefully this will provide data on molecular structure which will complement that found by 
X-ray crystallography. 
In order to obtain a sample of the intended biotinylated linker without the nitroso- 
modification, the target compound 36 was synthesised by performing azobenzene formation 
prior to attachment of the biotin label (Scheme 3-3). 
 
Scheme 3-3 Synthesis of biotinylated Tyr 36 which avoids biotin nitrosylation. (a) 28, EDC, 
HOBt, DMF, rt, 18 h; (b)i) TFA, DCM, rt, 3 h; ii) Biotin-NHS 27, sat. NaHCO3, DMF, rt, 18 
h. 
The synthesis of 36 essentially reverses the order of steps used for the synthesis of nitroso-
modified 13, starting from the PABA-derived azobenzene 7. Using amide coupling reagents, 
this compound was modified with the Boc-protected diamine 28, before deprotection and 
amide coupling with biotin-NHS 27. The product was confirmed by NMR and MS as 36, the 
biotinylated, azo-linked Tyr derivative which did not carry the nitroso modification.  
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Figure 3-7 Comparison of the 1H NMR of nitrosylated biotin linker 13 and the biotin linker 
36. In the nitrosyl-modified molecule, the N(3’)H of the nitrosourea group (*) exhibits a 
diagnostic chemical shift at 8.80 ppm. The biotin linker displays two peaks at 6.41 and 6.34 
ppm, corresponding to the urea NH protons (*). 
By 1H NMR in DMSO-d6, the distinction between 13 and 36 was clear when considering the 
urea NH peaks (Figure 3-7). As described previously, the N(3’)H peak in nitroso-containing 
13 was observed at 8.80 ppm as a singlet which integrated to 1 proton. By comparison, the 
two urea NH peaks in 36 were identified at 6.41 and 6.34 ppm, each presenting as a singlet 
which integrated to 1 proton. The downfield shift of the remaining urea peak following nitrosyl 
modification confirms its electron-withdrawing properties, which cause deshielding of the 
N(3’) position.  
In an unexpected result, it was found that the nitrosylated biotin linker 13 retained the ability 
to bind to SAv resin, allowing the immobilisation of an azo-linked Tyr derivative onto a solid-
phase for the first time in this project. Sub-stoichiometric portions of the preformed linker (3 
nmol in 1 mL) were introduced to 0.2 mL of SAv resin and incubated at room temperature for 
15 min with agitation on a rotator. The eluate was then drained from the resin and analysed by 
UHPLC-PDA with observation at 330 nm, corresponding to the absorbance of the azobenzene 
group [Figure 3-8 (a)]. The expected binding capacity of the resin was >17 nmol of 
biotinylated material,1 and it was found that after 6 × 3 nmol portions had been incubated with 
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the resin, the amount of unbound ligand in the eluate hit a maximum and began to plateau, 
indicating that there was no further binding of 13 to the immobilised protein. 
 
Figure 3-8 Binding of biotin derivatives to SAv. (a) Despite modification of the urea group, 
the nitrosylated biotin linker 13 showed the expected binding curve when incubated with SAv 
resin. 3 nmol aliquots were incubated with 0.2 mL resin for 15 min at rt. Unbound ligand was 
washed from the resin and analysed by UHPLC. After ~18 nmol, the SAv binding sites 
appeared saturated. Expected resin capacity was >17 nmol for 0.2 mL resin (> 85 nmol/mL). 
(b) The interactions between biotin and key residues in the SAv binding pocket are shown. 136 
While the nitrosylated linker appeared to bind to SAv, it is unknown how the binding affinity 
of nitrosylated derivatives would compare with the native ligand. By examination of the biotin 
binding site in SAv [Figure 3-8 (b)], there are several H-bonding interactions which give rise 
to the high binding affinity of the biotin ligand. In particular, the urea group appears crucial to 
stabilisation of the bound ligand, with five interactions highlighted between SAv residues and 
the urea moiety. Nitrosyl modification of the N(1’) position will likely affect these interactions 
through increased steric bulk and alteration of the electronics of the urea group [as evidenced 
by the downfield shift of the N(3’)H NMR signal described previously]. The final iteration of 
the catch-and-release method will involve diazotisation of the aniline after immobilisation on 
the SAv resin, so it is not clear whether the nitrosyl modification will still occur when the 
biotin headgroup is already bound to the protein. However, given the apparent ability of both 
the nitrosyl-modified and unmodified biotin substrate to bind to SAv, the catch-and-release 
method was attempted on SAv resin, initially using small molecule and peptide substrates. 
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3.2.4 Catch-and-release using SAv resin 
In order to activate the SAv resin for Tyr capture, it was functionalised with an aniline using 
the biotinylated reagent 33 [Scheme 3-4 (a)]. Following aniline functionalisation, on-resin 
diazotisation was required to activate the resin for Tyr-specific capture [Scheme 3-4 (b)]. 
Finally, with introduction of the Tyr-bearing substrate, azobenzene formation would occur 
upon SEAr modification of the Tyr phenol ring [Scheme 3-4 (c)]. 
 
Scheme 3-4 Overview of the SAv resin-based modification strategy. (a) The biotinylated 
aniline 33 was loaded onto SAv resin in neutral pH buffer. (b) The immobilised aniline was 
next diazotised using NaNO2 in acidic conditions. (c) Upon introduction of a Tyr-bearing 
substrate, SEAr occurs, resulting in formation of an azobenzene group.  
Aniline functionalisation of the resin was performed by addition of biotinylated aniline 33 in 
buffer (pH 7.2, 10% DMSO for solubility) with agitation on a rotator for 2 h at room 
temperature. After aniline loading, the resin was washed with buffer until the eluate was found 
to contain no aniline by UHPLC. Initial attempts at on-resin diazotisation employed HCl or 
TFA with NaNO2 to generate the reactive nitrosonium ion in situ, however it was observed 
that this resulted in release of the biotinylated aniline, presumably due to denaturation of the 
SAv protein, or decomposition of the resin itself.  
In order to achieve diazotisation under milder conditions, acetic acid was used (0.6 M, ~pH 
2.5). After removal of the diazotisation reagents by vacuum filtration, Ac-Tyr-OMe 2 was 
introduced to the resin in buffer (pH 7.2, 10% DMSO for solubility). The mixture was agitated 
on a rotator at room temperature for 18 h, during which time the resin developed an orange 
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colour due to the absorbance of the azobenzene linker. Excess Ac-Tyr-OMe was removed by 
washing the resin and the eluate was analysed by UHPLC until no starting material remained. 
An aqueous solution of sodium dithionite was then introduced and the resin was agitated at 
room temperature for 18 h. The eluate was analysed by UHPLC, and a new peak was identified 
which was distinct from the unmodified substrate [Figure 3-9 (a)]. The cleavage product was 
identified in a qualitative manner by matching retention time and PDA spectrum with a 
synthetic standard of Ac-Tyr(3-NH2)-OMe 5. 
  
Figure 3-9 Catch and release of small molecule and peptide substrates using SAv resin. Ac-
Tyr-OMe 2 (a) and Ac-Leu-enkephalin-OMe 6 (b) were successfully modified using the 
activated SAv resin, the o-aminophenol modified product was identified by UHPLC. 
Using the Leu-enkephalin-derived substrate 6, catch-and-release modification was performed 
as before, with identification of the cleavage product by UHPLC (Figure 3-9b), by comparison 
with a synthetic standard 37. In both cases, the cleavage product had a shorter retention time 
on the reverse-phase UHPLC column than the unmodified substrate, due to the addition of an 
amine which increases the overall polarity of the catch-and-release product, however the PDA 
absorbance spectrum was largely unchanged by the modification. 
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3.2.5 Myoglobin as a protein substrate 
Horse heart myoglobin (Mb) was identified as a suitable protein substrate for catch-and-release 
modification as it contains two Tyr residues in the native sequence. In addition, Mb is 
commercially available and inexpensive, and is frequently used as a calibrant for MS 
instruments, so it was known to ionise well in ESI-MS. 
 
Figure 3-10 The structure of horse heart myoglobin (PDB ID: 5D5R). There are two Tyr 
residues in the native sequence of the protein: Y103 (green) whose side chain is surface-
exposed, and Y146 (yellow) which has the phenol group pointing towards the protein interior. 
Myoglobin also has a haeme group which is shown in pink.  
By retrieval of the Mb X-ray crystal structure from the Protein Data Bank (PDB), the two Tyr 
residues Y103 and Y146 were visualised, alongside the iron-containing haeme group which 
gives the protein its red colour (Figure 3-10). While both Tyr residues were found close to the 
protein surface, the reactive ortho positions of Y103 pointed outward towards solvent, while 
the Y146 side chain pointed towards the protein interior. By RP-HPLC, it was found that the 
haeme group becomes dissociated from the protein under the denaturing conditions of the LC 
system, and is observed as a separate peak with an absorbance at 398 nm (Figure 3-11). 
 
Figure 3-11 RP-HPLC of horse heart myoglobin. (a) The haeme group was dissociated from 
the protein and these were observed as distinct peaks by HPLC (observation at 280 nm). (b) 
The PDA absorbance spectra of the haeme peak and the Mb protein peak.  
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3.2.6 Catch-and-release of Mb 
The protocol for the catch-and release reaction was adapted slightly for use with a protein 
substrate. To allow for analysis by MS, a size exclusion spin cartridge was used to desalt the 
cleavage product. Otherwise, the protocol remained largely unchanged, and UHPLC analysis 
with a C4 column was used to follow the progress of the wash and cleave steps. Following 
reductive cleavage, the protein was analysed by FT-ICR MS. The released protein sample was 
found to contain primarily unmodified Mb, with additional peaks attributed to the unmodified 
protein bearing a phosphate adduct [Figure 3-12 (a)]. A signal corresponding to the expected 
modified protein was identified, but this appeared at <2% relative intensity when compared 
with the unmodified species. The haeme group was also identified in the mass spectrum, giving 
a mass which corresponded to [M]+ [Figure 3-12 (b)]. After consulting the literature, this was 
identified as the haeme group bearing a positive charge with no additional adduct, and is 
known to arise from oxidation of the central Fe atom from the 2+ to the 3+ oxidation state.137 
 
Figure 3-12 Catch and release of a protein substrate. (a) By FT-ICR MS, the released protein 
sample was found to primarily consist of unmodified Mb. A small amount of modified protein 
was seen at less than 2% relative intensity. (b) The dissociated haeme group was identified as 
the [M]+ ion, also known as ferri-haeme, which has been reported to arise from oxidation of 
the iron centre to Fe3+. 
MS analysis of the Mb catch-and-release product had shown that there was very little modified 
protein present in the sample. This result was initially puzzling, as the eluate from the wash 
step had been monitored by UHPLC, and the resin was washed until clear of protein. Upon 
addition of dithionite, the protein peak had then reappeared. While SAv resin had been selected 
to provide steric bulk, it was concluded that there may have been non-specific binding between 
Mb and SAv during the experiment, giving rise to retention of Mb on the resin without the 
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expected modification of the substrate. Presumably, this non-covalent interaction was then 
disturbed by the increased salt concentration upon addition of dithionite, leading to release of 
Mb without the +15 Da change in mass expected from the amine modification. The reported 
isoelectric point of SAv is ~6, therefore it would have a slightly negative charge under the 
reaction conditions of pH 7.2.138 Mb, by comparison, has an isoelectric point ~7 and is likely 
to have close to a neutral net charge under reaction conditions.139 It is quite possible that the 
negatively charged SAv protein is responsible for the non-specific retention of the protein 
substrate, and while a nearly neutral Mb has shown retention on the resin, this effect is likely 
to be exacerbated in proteins with a higher isoelectric point, which would bear a net positive 
charge under reaction conditions. The proposed benefit of using a readily-available 
immobilised protein as the catch-and-release platform was ultimately undermined by the 
complications of non-specific binding and so, in order to avoid this effect with future protein 
substrates, a simplified resin was sought which did not bear an immobilised protein. 
 
3.3 Affi-Gel 10 resin 
Affi-Gel 10 resin by Bio-Rad was selected as a suitable, non-protein bearing solid-phase for 
the next iteration of the catch-and-release modification strategy. As with the SAv resin, the 
beads are composed of cross-linked agarose, which consists of two sugar subunits, D-galactose 
and 3,6-anhydro-L-galactopyranose (Figure 3-13). Rather than relying on functionalisation of 
the resin via the SAv-biotin interaction, an NHS-ester functionalised variant of the agarose gel 
was used, which allows modification of the resin through a straightforward amide bond-
forming reaction. Documentation supplied by Bio-Rad suggests that the agarose resin is 
equipped with an NHS-ester through an ether linkage with a hydroxyl group on one of the 
sugar subunits.140 
 
Figure 3-13 Affi-Gel 10 resin from Bio-Rad. The reported average diameter of a polymerised 
agarose bead is shown, alongside the structure of the polymer subunits (D-galactose and 3,6-
anhydro-L-galactopyranose) (Left) and the loading of the NHS-ester functional group (Right), 
which is attached via an ether linkage to a hydroxyl group on the cross-linked polymer. 
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Benefits of the move to Affi-Gel resin include an increased substrate binding capacity of 15 
µmol/mL (from >85 nmol/mL biotin binding with the SAv resin). In addition, the new resin 
could be equipped with an aniline in one step using a commercially available diamine, thus 
avoiding the synthesis of biotinylated linkers which were required in the previous work. 
3.3.1 Functionalisation of Affi-Gel resin 
In order to accommodate the new solid-phase, the catch-and-release protocol was adapted as 
shown in Scheme 3-5. The resin was equipped with the required aniline for diazotisation by 
incubation with an excess of p-phenylenediamine, the simplest symmetrical aromatic diamine. 
This reagent was commercially available and inexpensive, and was used in excess in order to 
avoid the need for an amine protecting group strategy.  
 
Scheme 3-5 Functionalisation of Affi-Gel 10 resin for use in the catch-and-release system. (a) 
The NHS-ester functionalised resin was equipped with an aniline using the symmetrical 
diamine p-phenylenediamine. (b) Diazonium salt formation using NaNO2 in acidic conditions. 
(c) Azobenzene formation with a Tyr-bearing substrate. 
As the diamine is symmetrical, amide formation at either end results in the same product, while 
using it in excess reduces cross-linking of the resin beads, as it favours modification of a single 
amine. Aside from this adjustment, the diazotisation and SEAr steps remained unchanged from 
those developed with SAv resin. 
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3.3.2 Catch-and-release using Affi-Gel 
The catch-and-release performance of the Affi-Gel resin largely matched that of the SAv resin 
when considering small molecule and peptide substrates, with qualitative analysis by UHPLC 
and comparison with synthetic standards as before. In this instance, the modified peptide was 
sufficiently concentrated after desalting on a C18 flash cartridge to allow direct observation by 
ESI-TOF.  
 
Figure 3-14 Catch-and-release of small molecule and peptide substrates using Affi-Gel 10. 
(a) Ac-Tyr-OMe 2 was modified using the catch-and-release protocol. The product was 
identified by UHPLC with comparison to the standard 5. (b) Leu-enkephalin 6 was modified 
in the same manner, the product was identified by UHPLC, with confirmation by ESI-MS. 
Just as with the SAv resin, the catch-and-release process was monitored by UHPLC and a 
shorter retention time was observed for each product compared to the respective starting 
material (Figure 3-14). With successful modification of a small molecule and peptide 
substrate, the Aff-Gel platform was next used for catch-and-release modification of Mb. 
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3.3.3 Catch-and-release of Mb 
Affi-Gel resin was next used for catch-and-release of Mb, with analysis by UHPLC-MS. 
Compared to an unmodified Mb standard there was no significant shift in retention time upon 
catch-and-release modification of the protein (Figure 3-15). It was clear from the protein 
charge envelope that the modified sample differed from the standard, and this was confirmed 
following MaxEnt deconvolution, which converts multiple charge states to the deconvoluted 
uncharged mass (discussed further in Chapter 4).  
 
Figure 3-15 Catch-and-release modification of Mb using Affi-Gel resin. (a) By LC-MS, 
modified Mb was identified at 6.68 min (Total Ion Chromatogram is shown). (b) ESI-MS of 
the unmodified Mb standard. The charge envelope of Mb is shown (left) alongside the MaxEnt 
deconvoluted spectrum (right). (c) The charge envelope and deconvoluted spectrum of 
modified Mb showed primarily singly modified Mb (1), alongside some unmodified (0) and 
twice modified protein (2). The same peaks were also identified bearing a phosphate adduct 
(*). 
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The unmodified standard gave a mass of 16,951 Da, and it was gratifying to observe that the 
most prominent species in the modified sample showed a mass of 16,966 Da, corresponding 
to the +15 Da mass change indicative of the –NH2 modification. Some unmodified and twice 
modified protein were also observed in this sample, alongside peaks displaying a phosphate 
adduct. This result represented a breakthrough in the catch-and-release project, as the first 
example of protein modification using an immobilised diazonium salt system. There remained 
some unanswered question as to the selectivity of the protocol, and this is explored further in 
Chapter 4. 
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3.4 Residue specificity 
The residue specificity of the catch-and-release protocol was next explored, as there have been 
previous literature reports of diazonium salt reactivity with electron-rich aromatic amino acids 
other than Tyr, in particular Histidine (His)141 and a hydroxyl-modified aromatic residue: 5-
hydroxytryptophan.142 In order to explore the residue specificity of the catch-and-release 
system, a peptide-based approach* was used to assess the likelihood of the immobilised 
diazonium salt showing cross-reactivity to amino acids other than Tyr. The anti-GFP (α-GFP) 
nanobody was identified as a potential future target for protein modification, as it bears much 
of the binding capability of a full-sized antibody, but at ~13 kDa, it is roughly one tenth of the 
size.143 The combination of binding affinity and small size are key attributes for a protein-
based probe, and so the α-GFP nanobody sequence was used as a template from which a useful 
peptide sequence could be selected, synthesised and modified. 
3.4.1 anti-GFP nanobody sequence 
Among seven Tyr residues in the nanobody sequence, Y081 was of particular interest (Figure 
3-16). This residue is found on the opposite face from the binding region of GFP, and appeared 
to show high surface-accessibility. As a target for a peptide-based project, Y081 was also 
appealing as there are several polar residues nearby, which would aid the solubility of a 
synthetic peptide based on a Y081-containing sequence. 
 
Figure 3-16 The anti-GFP nanobody bound to GFP (PDB ID: 3OGO). The GFP protein is 
shown in yellow, Tyr residues in the nanobody are shown as green spheres. Y081 is highlighted 
as an attractive target, as it is not involved in the nanobody-GFP binding interaction, and 
appears highly surface-accessible. 
  
                                                 
* Synthesis, purification and catch-and-release modification of the peptides was performed by 
project student Christina Burr; MS analysis was performed by CB & CA. 
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The native sequence which was selected for synthesis was 74DDARNTVY81 (Figure 3-17), and 
this was synthesised by SPPS in a similar manner to Leu-enkephalin in Chapter 2. Five 
canonical amino acids were identified which may be expected to show some cross-reactivity 
with the diazonium salt, and these were substituted into the peptide sequence in place of A076, 
to give six synthetic peptides with the sequence Ac-DDXRNTVY-OMe. The ‘X’ amino acids 
comprised nucleophilic or aromatic residues which may act as competitive nucleophiles with 
the intended Tyr residue. Each peptide was modified using the catch-and-release protocol, 
before analysis of the peptide modification site. 
 
Figure 3-17 An anti-GFP derived peptide sequence for catch-and-release modification. A 
peptide sequence containing Y081 was selected for synthesis, the Ala residue was identified 
as a site for substitution of other potentially reactive amino acids. The sequence also bears an 
Arg residue, which is a trypsin cleavage site. 
Initially, this project was conceived to allow assessment of the peptide-tagging site by 
UHPLC-MS, following enzymatic digestion of the tagged peptide. Using trypsin for the 
enzymatic digestion step would achieve cleavage at the C-terminal of R077 (Figure 3-17), 
effectively separating the peptide into two peptide fragments, each comprising four amino 
acids. UHPLC-MS of these digest products would then allow identification of the modification 
site on either the Tyr-containing or X-containing fragment. In practice, enzymatic digestion of 
the model peptide Ac-DDARNTVY-OMe gave rise to peptide fragments which did not retain 
well on the C18 column of the UHPLC. This did not bode well for the catch-and-release 
modified peptides, as these had an additional amine which would only serve to reduce the 
ability of the fragment to retain on a reverse-phase column. Instead, the decision was taken to 
analyse the intact catch-and-release modified peptides using top-down fragmentation by 
collision-induced dissociation (CID – discussed further in Chapter 4). The benefit of this 
approach over enzymatic digestion is the opportunity to achieve greater resolution of the site 
of modification, depending on the peptide sequence coverage achieved.  
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3.4.2 MS/MS of peptides 
Following catch-and-release modification, the peptides were analysed by UHPLC-MS/MS. 
The intact masses were first analysed to identify the extent of modification for each peptide 
substrate. In most cases, the intact mass matched the theoretical peptide mass +15 Da, 
corresponding to a single modification, and these masses were isolated and fragmented under 
20‒50 V collision voltage (Figure 3-18). Sufficient coverage was obtained in each instance to 
identify Tyr as the site of modification, as expected. 
 
Figure 3-18 Top-down fragmentation of catch-and-release modified peptides by CID.   
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There was no evidence for cross-reactivity with Trp, Phe, Lys, Cys or Ala in the peptide screen, 
however in the case of Ac-DDHRNTVY-OMe, double modification was observed by LC-MS. 
Top-down fragmentation of this species revealed a +15 Da modification of the Tyr residue, as 
well as a +15 Da modification on the His-bearing end of the peptide [Figure 3-18 (e)]. Clearly, 
the catch-and-release system was not completely specific to Tyr-modification, and so future 
substrates would need to be analysed by top-down fragmentation to identify the precise 
location of modification, with particular attention to His residues as a potential site of cross-
reactivity. 
Histidine in fact shows even lower abundance in the proteome than tyrosine, and so while the 
peptide-based project had identified a potential pitfall in the application of the catch-and-
release system, it was not considered sufficient to derail the project. In future tagging 
applications, careful analysis of the modified protein will instead be performed to identify 
cross-reactivity of any type. 
3.5 Conclusion 
In this chapter the catch-and-release chemistry which was developed in Chapter 2 was 
successfully transferred onto a solid support, initially through the use of SAv resin and a 
biotinylated aniline, and finally using the NHS-activated Affi-Gel 10 resin. The 
regiochemistry of the nitrosylation of biotin was explored following the unexpected synthesis 
of a nitrosobiotin derivative, and it was found that this modified substrate retains the ability to 
bind to SAv. Catch-and-release modification of small molecule and peptide substrates was 
performed, as well as successful modification of a protein substrate. Finally, the potential for 
cross-reactivity in the catch-and-release system was assessed and histidine was identified as a 
potentially competitive nucleophile for reaction with a diazonium salt. In future, protein 
substrates will be examined for the accessibility of histidine residues, and this will be 
considered as a potential modification site in post-cleavage analysis. 
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Chapter 4 Results & Discussion 3: Protein-tagging 
4.1 In silico assessment of protein substrates 
The application of the catch-and-release modification system was demonstrated in Chapter 3 
using Tyr-containing substrates including a single amino acid, peptides and the model protein 
myoglobin. By inspection of the crystal structure, myoglobin contains only a single accessible 
tyrosine, and catch-and-release modification resulted in predominantly single modification. In 
order to further probe the selectivity of the solid-phase modification platform, other protein 
substrates were sought which bear multiple viable targets in the form of accessible Tyr 
residues. A further five substrates were selected [ribonuclease A (RNase A); soybean trypsin 
inhibitor (SBTI); β-lactoglobulin A (β-Lac); lysozyme C (HEWL); cytochrome C (Cyt. C)] 
which were commercially available, fell within the desired size limit (~10-20 kDa) and 
contained multiple Tyr residues. 
In using a solid-phase platform for protein modification we expected to be able to achieve 
single modification of a protein substrate and to discriminate between multiple reactive sites 
based on surface-exposure. This can be justified by considering the dimensions of the agarose 
bead to which the Tyr-reactive diazonium salt is tethered, which has a reported diameter of 
75‒300 µm.140 In the first instance, using an immobilised diazonium salt should favour 
modification at only the most exposed Tyr residues as the mobility of the electrophile is 
reduced, thus limiting access to more buried sites on the protein. Following modification, the 
protein is then covalently attached to the significant bulk of a resin bead, limiting the 
opportunity for secondary modification through a combination of steric effects and reduced 
diffusion of the immobilised protein through the solvent. The goal for this work was to exploit 
these effects for the development of a catch-and-release system which would provide single 
modification of a protein at a defined, predictable site, namely the most highly exposed Tyr. 
In order to assess the availability of Tyr residues in protein substrates, in silico methods were 
applied using the protein crystal structure, PyMOL software and the solvent-accessible surface 
area calculation.144 
4.1.1 Tyrosine surface exposure 
Beyond the primary structure of the polypeptide backbone, proteins exhibit higher order 
structure which is crucial to their function. Within a protein monomer, higher order structure 
is defined by a mixture of covalent and non-covalent intramolecular interactions. Covalent 
interactions which are important to protein structure include disulfide bridges between Cys 
residues, while non-covalent interactions may be polar (e.g. H-bonding) or non-polar (e.g. π-
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stacking) in nature. In the resulting three-dimensional structure, a general trend is observed 
where amino acids with polar side chains are enriched on the protein surface where they may 
play a role in solubility and function [Figure 4-1 (a), grey side chains].145 In contrast, non-
polar amino acid side chains are most often found in the protein interior, where they are 
shielded from solvent and form hydrophobic pockets and clefts [Figure 4-1 (a), red side 
chains].145  
 
Figure 4-1 Amino acid hydrophobicity in bovine serum albumin (BSA) (PDB ID: 4J5S). Amino 
acid sidechains are coloured to represent their position on the Eisenberg hydrophobicity 
scale. (a) Hydrophobic amino acid side chains (red) tend to be found in the protein interior 
forming hydrophobic pockets. (b) Tyr residues (shown as spheres) display a range of surface-
exposure across the protein sequence due to Tyr’s ability to form both polar and non-polar 
interactions. (c) The Eisenberg hydrophobicity scale where Tyr ranks close to the mean of 0.31 
Due to its aromatic ring and polar head group, the Tyr side chain is considered amphipathic 
and scores close to the mean in Eisenberg’s hydrophobicity scale (a consensus model used to 
rank the hydrophobicity of canonical amino acids).31, 146 Tyr has the ability to form polar 
hydrogen bonds and also to participate in non-polar π-stacking interactions, leading to varied 
levels of surface exposure across the protein sequence [Figure 4-1 (b)].147 Using in silico 
methods to interrogate the crystal structures of several proteins deposited in the PDB, a range 
of Tyr solvent-accessibility values have been observed, spanning from the highly surface-
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exposed to those which were completely buried in the protein interior.148 For this reason, Tyr 
can be considered an apt target with which to achieve selectivity based on surface-exposure. 
4.1.2 The solvent-accessible surface area calculation 
In order to rank the Tyr residues in a protein from most to least exposed, and therefore most 
to least likely to be modified in the catch-and-release system, a solvent-accessible surface area 
(SASA) calculation was performed using PyMOL software and the crystal structure of the 
protein of interest.144 The SASA calculation was first proposed as a method by which to 
interrogate protein surface topology in 1971,149 and is accessible as an embedded function in 
PyMOL. 
 
Figure 4-2 The solvent-accessible surface area calculation. The Van der Waals (VdW) radius 
of each atom is first expanded by the radius of a solvent molecule. The surface coverage of 
data points is set by the ‘dot density’ and each dot is assigned as either ‘exposed’ or ‘buried’ 
depending on its state of overlap with a neighbouring atom. The ‘exposed’ data points are 
then used to calculate the SASA. A common analogy for the SASA calculation involves rolling 
a ball of solvent over the protein’s surface. [The truncated peptide sequence shown is RNase 
A (1-16) (PDB ID: 4J5Z)]. 
A common analogy used to explain the SASA calculation refers to a sphere of solvent rolling 
over the surface of the protein, with the output of the calculation representing the contact area 
between the solvent and the atom of interest (Figure 4-2). A high SASA value therefore 
represents a large solvent contact area, which is interpreted as a measure of high surface-
exposure. In practice, to model the ‘rolling’ of a solvent molecule, the Van der Waals radius 
of each atom in the protein is expanded by 1.4 Å to approximate the interaction with a water 
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molecule.150 Each data point on this expanded surface is then assessed by an algorithm which 
identifies regions where the expanded radii of neighbouring atoms overlap.151, 152 The regions 
of overlap represent areas where solvent is excluded, and this is therefore subtracted from the 
total expanded surface area to give the solvent-accessible surface area with the units Å2. 
In order to execute the SASA calculation in PyMOL, the user first selects the atoms to be 
interrogated, in this case these are the reactive ortho positions of the Tyr phenol ring (named 
‘CE1’ and ‘CE2’, following IUPAC abbreviation rules).153 The user can perform the SASA 
calculation via the ‘Action’ menu in the Viewer Window [Figure 4-3 (a)], with a readout 
appearing in the External GUI. Alternatively, the same process can be performed using the 
Command Line in the GUI [Figure 4-3 (b)]. 
 
Figure 4-3 Manual approaches to execute the SASA calculation. (a) The SASA calculation 
can be found in the drop-down 'Action' menu in the Viewer Window. (b) Alternatively, the 
SASA calculation can be executed by typing commands directly into the Command Line 
(highlighted in red) in the External GUI. 
A default solvent radius of 1.4 Å was used to probe the protein surface, modelling the solvent-
accessibility of a water molecule. This variable could be altered to reflect the size of the 
residue-specific electrophile (in this case a diazonium salt). However, as demonstrated in the 
‘rolling ball’ analogy, it is necessary to approximate the solvent probe to a spherical object of 
defined radius, and this becomes less realistic when modelling larger, linear molecules 
compared to a small solvent molecule such as water. In order to test the effect that increasing 
solvent radius had on the SASA output, Tyr residues in BSA were assessed using solvent radii 
of 1.4 Å, 1.9 Å and 2.4 Å (Figure 4-4). From these results it was apparent that using a large 
solvent radius reduced the sensitivity of the SASA calculation. In particular, residues with 
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intermediate (Y137, Y410) and low exposure (Y030, Y084) were barely distinguishable using 
a solvent radius of 2.4 Å, whereas the 1.4 Å radius calculation allowed comparison of these 
residues, whose SASA values were recorded as between 3.54-10.59 Å2. A 1.4 Å radius was 
therefore used for future SASA calculations as it allowed evaluation of the highest number of 
Tyr residues, even those with intermediate or low exposure. It should be noted that the SASA 
calculation does not specifically model Tyr modification as it occurs in the catch-and-release 
system; rather, it provides an assessment of the relative exposure of each reactive site, which 
is taken as a predictor for the likely site of modification. 
 
Figure 4-4 The effect of increasing solvent radius on the SASA calculation. (a) The solvent 
radius variable defines the size of the expanded Van der Waals radius used (VdW surface 
shown for a single Tyr residue). (b) Three solvent radius settings (1.4 Å, 1.9 Å, 2.4 Å) were 
used for the SASA evaluation of Tyr residues in BSA (PDB ID: 4F5S). A solvent radius of 1.4 
Å (white bars) gave superior resolution of intermediate and low exposure residues. All 
calculations were performed with a dot density of 2. 
Aside from the solvent radius, a second SASA variable to consider was the ‘dot density’, which 
can take a numerical value of 1-4 and dictates the density of data points on the expanded Van 
der Waals radius of the atom [Figure 4-5 (a)]. A high dot density gives a more accurate SASA 
output as there is more complete coverage of the surface and therefore more data points to 
report as ‘buried’ or ‘exposed’. However, the cost of using a high dot density setting is the 
increased processing time required to perform the calculation.  
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Figure 4-5 The effect of dot density on the SASA calculation. (a) The dot density value dictates 
the number of data points on the modelled surface (shown here for the reactive ortho positions 
on a Tyr phenol ring).(b) The SASA of each Tyr residue in BSA (PDB ID: 4F5S) was calculated 
using three dot density (dd) settings. Total Tyr SASA and execution times were as follows: dd 
= 1 (137.82 Å2, 41.71 s); dd = 2 (141.95 Å2, 121.11 s); dd = 4 (141.32 Å2, 1793.01 s). all 
calculations were performed with a solvent radius of 1.4 Å. 
The output of the SASA calculation was compared when using a low, medium or high dot 
density in order to find the optimal setting. Using BSA as an example, the SASA output of the 
twenty native sequence Tyr residues were found to follow a similar trend [Figure 4-5 (b)]. 
While the lowest accuracy setting (dd = 1) gave a total Tyr SASA which was comparatively 
low (137.82 Å2), the total Tyr SASA of the medium (dd = 2) and high accuracy (dd = 4) 
settings were in reasonable agreement (141.95 Å2 and 141.32 Å2), providing evidence that a 
compromise between data point coverage and processing time could be struck without 
significantly affecting the reliability of the calculation.  
Compared to the somewhat conserved total Tyr SASA values, the processing cost of each dot 
density setting was markedly different. The execution time for the SASA calculation of all 
reactive Tyr sites in BSA was recorded in PyMOL, and results ranged from 41.71 seconds for 
the low accuracy setting (dd = 1) to 1793.01 seconds for the highest accuracy setting (dd = 4). 
Although execution time will vary depending on factors including the number of Tyr residues 
in the protein, the number of chains in the crystal structure and on the processing capacity of 
the system used for the calculation, the highest accuracy dot density setting was considered 
too time-consuming for the current application. As such, the intermediate dot density setting 
(dd = 2) was selected as a good compromise between accuracy and processing time. 
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4.1.3  ‘Whole residue’ versus ‘reactive site’ SASA 
The SASA evaluation of endogenous amino acids in proteins has so far only considered the 
reactive positions of the residues of interest, in our case these are the ortho positions of the 
Tyr phenol side chain. Literature reports of similar methods to assess amino acid surface-
exposure have not necessarily used this approach and have instead considered the exposure of 
the whole amino acid residue.44, 45, 154  
 
Figure 4-6 Comparison of the ‘whole residue’ and ‘reactive position’ approaches to SASA 
calculations. (a) The structures of RNase A and HEWL used in the work by Weil et al.44 In 
each instance the Lys residue at position 1 (K001, shown as spheres) was found to be modified. 
(b) The whole residue approach (top) and ‘reactive site’ approach (bottom) were compared 
for RNase A and (c) HEWL. Assessment of the N-terminus SASA is included in the ‘reactive 
site’ approach and modified residues are identified with *. 
These two approaches were compared using data reported by Weil et al.,44 who achieved 
selective mono-labelling of a Lys residue in two native sequence proteins by treatment with 
sub-stoichiometric portions of an amine-reactive NHS-ester. As the targeted amino acid in this 
case is Lys, the reactive site in question is the nucleophilic ε-NH2 of the Lys side chain. The 
proteins used in the study were RNase A and HEWL which both have a Lys residue at the N-
terminus. In each case, the modified residue was identified by MS/MS as K001 [Figure 4-6 
(a)] and this was justified using a ‘whole residue’ solvent-accessibility profile of the protein 
in question. Using the same crystal structures as the published work, the proteins were assessed 
for SASA on a ‘whole residue’ and ‘reactive site’ basis [Figure 4-6 (b) and (c)]. The published 
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work reported that K001 in RNase A was found to have the highest solvent-accessibility and 
this was supported by the ‘whole residue’ SASA analysis. However, by the ‘reactive site’ 
method, K001 was only the fourth most exposed reactive site behind K060, K037 and K031. 
In addition, the N-terminus was found to have high exposure and therefore this site should also 
be considered as a potential labelling position. In fact, given the reactivity of the N-terminal 
α-amine (whose pKa is around 2 units lower than the Lys ε-NH2),48 it is quite possible that this 
was the true location of modification in the reported work. The authors identified the location 
of modification by MS/MS, however this would not allow distinction between the N-terminus 
and the side chain ε-NH2 of the same residue. HEWL was report to be modified at K001 despite 
this residue ranking as the third most exposed Lys by the ‘whole residue’ method.44 However, 
the ‘reactive site’ approach identified K001 as the most exposed Lys ε-NH2, which would 
better explain the findings. In this case the N-terminus was not highly exposed, but 
modification at this position should not be ruled out due to the higher reactivity of this amine. 
 
Figure 4-7 The contributing atoms in a Lys residue when using the ‘whole residue’ and 
‘reactive site’ SASA calculations. (a) The ‘whole residue’ approach considers the exposure of 
non-reactive atoms in the amino acid as well as the reactive ε-NH2. (b) The ‘reactive site’ 
approach considers only the reactive atoms and allows separate assessment of the N-terminus 
and the Lys ε-NH2. (c) The ‘whole residue’ approach is likely to overstate the exposure of N- 
and C-terminal residues as they are attached to the polypeptide chain on one side only. 
The primary concern about using a ‘whole residue’ approach is its consideration of non-
reactive atoms in the amino acid (Figure 4-7). For a mid-chain Lys residue this means that 
atoms in the peptide backbone as well as the carbon atoms in the side chain make a contribution 
to the ‘whole residue’ SASA value, despite the fact that they are not reactive to an NHS-ester. 
Compared to a mid-sequence residue, the ‘whole residue’ approach is also likely to overstate 
the solvent-accessibility of an N- or C-terminal amino acid because it is attached to the 
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polypeptide chain on one side only. In this case the backbone and non-reactive side chain 
atoms of a terminal residue are likely to be more exposed to solvent than in an amino acid 
which is flanked by residues on either side [Figure 4-7 (c)]. Finally, in taking a ‘whole residue’ 
approach there is no means to separate the reactive N-terminus from the side chain of the N-
terminal residue, and this is especially problematic when using an NHS-ester for protein-
tagging as the N-terminus is more nucleophilic than the Lys ε–NH2.48 For these reasons, the 
‘reactive site’ approach was preferred for SASA assessment of amino acids in this project. 
4.1.4 Automation of the SASA calculation 
Manual control of the SASA calculation had so far proved useful for interrogating single 
targets but this was ultimately an inefficient way to screen a large number of residues. To 
expedite the process, the task was automated by the development of a program which can run 
in PyMOL and export the results of the SASA calculation into a .txt file for easy analysis and 
presentation.* The script was written in the PyMOL-compatible language Python to send the 
necessary commands to perform the SASA calculation. This was primarily focussed on Tyr as 
the native sequence target, but it has also been expanded to assess the exposure of other 
common endogenous targets (Lys, Cys, and the α-NH2 of the protein N-terminus) as well as 
His to assess the potential for cross-reactivity. For the sake of clarity, the following description 
of the SASA automation script will consider the Tyr target only, as each amino acid variant 
uses a similar structure.  
The automated SASA script largely follows the steps which one would take to perform the 
calculation manually (Table 4-1). As PyMOL has a well-defined amino acid and atomic 
naming system, the initial selection of the reactive ortho positions on the Tyr phenol ring 
involved sending the command “select (resn Tyr and name CE1)(resn Tyr and name CE2)”. 
However, selection of all reactive positions at once does not allow the distinction of separate 
Tyr residues, and so a list of delineated reactive positions was created to allow SASA 
evaluation of single atoms. This task involved separating the atoms using all the identifying 
information available (PDB number, chain identifier, residue number, amino acid name, atom 
name). The list was then used to populate a dictionary to which the SASA output of each atom 
could be attached (in Python the atom identifiers are termed ‘keys’, and the SASA output 
‘values’). Before execution of the SASA calculation, the ‘dot_solvent’ and ‘dot_density’ 
variables were set as described previously. The SASA calculation of each reactive site was 
                                                     
* The development of the automated SASA script was performed by project student Mirek 
Kosar, expansion of the script to include SASA analysis of Lys and the N-terminus was 
performed by CA. 
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executed using the “get_area” command, and the resulting values were added to their 
respective keys to give a complete dictionary. As there are two reactive sites on the Tyr ring 
(‘CE1’ and ‘CE2’), the SASA output of each atom can be given separately or as a summed 
‘SASA per residue’ value. 
Operational Step Key Commands 
Graphical 
Annotation 
Select reactive positions target_sel = (resn, name) 
 
Delineate selected atoms 
list.append(pdb, chain, resi, 
resn, name) 
 
Set solvent radius,  
dot density 
cmd.set(‘solvent_radius’, 1.4) 
cmd.set(‘dot_density’, 2) 
 
Calculate SASA of each 
selected atom 
cmd.get_area(resi, name) 
 
Output SASA to .txt file 
f.write(‘Residue: %s, SASA: 
%f’) 
Residue SASA(Å2) 
Y001 3.02 
Y002 7.76 
Y003 29.36 
 
 
Table 4-1 An outline of the key steps in the automated SASA calculation program. To overcome 
the laborious process of manually selecting each reactive position, the script constructs lists 
and dictionaries to identify and separate these sites, then collates the SASA output in a .txt file. 
The peptide sequence shown is Leu-Enkephalin (PDB ID: 5E3A). Key: resn = amino acid 
name; name = atom name; pdb = PDB ID; chain = chain number; resi = residue number. 
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For the current application the summed ‘SASA per residue’ output was preferred as this allows 
the user to rank each amino acid based on the surface-exposure of the combined reactive 
positions. Further to this, it would be unlikely that the final protein modification could be 
located to a single atom using the available analytical techniques, so separating the two ortho 
positions of a single residue was of no practical use. To convert the SASA results into a format 
which was easy to handle, a blank .txt file named ‘tyr_sasa_out.txt’ was created by the Python 
command ‘open(‘tyr_sasa_out.txt’, ‘w’)’. Into this file was written the atom identifiers and 
their associated SASA output. From here, the SASA results may be transferred to graph-
plotting software such as Excel or Origin, giving a straightforward method to evaluate Tyr 
exposure by residue, and assess the target protein’s suitability for the catch-and-release system. 
 
Figure 4-8 Tripeptide GYG (2-D representation, left) was used to calculate a benchmark 
SASA value for the ortho-positions of the Tyr phenol ring. The peptide structure was drawn in 
ChemSketch and ‘cleaned’ in PyMOL to give the optimised 3-D structure (right). 
In order to better understand the SASA output, the calculation was performed on a tripeptide 
in which a Tyr residue was flanked by two Glycine residues. The GYG peptide is the simplest 
representation of a mid-chain Tyr residue as the Gly residues on either side bear no side chains 
which would affect Tyr accessibility. This model has been used as a benchmark of high 
solvent-accessibility in other formats including the Molecular Operating Environment 
software used by Weil et al.44, 155 The molecule was drawn using ChemSketch software (Figure 
4-8),156 and transferred into PyMOL where the ‘clean’ operation was used to refine the 3-D 
structure by optimising bond angle, bond length, H-bonding and electrostatic effects.157 The 
SASA command was then executed to give an output of 23.10 Å2 against which other Tyr 
residues could be benchmarked. 
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4.2 Protein substrates for catch-and release modification 
The automated SASA script was used to assess protein candidates for catch-and-release 
modification. A desirable protein substrate would have multiple Tyr residues with varied 
SASA values to allow discrimination based on surface-exposure. In addition, the protein 
should be of a similar size to future nanobody or other small protein substrates (~10‒20 kDa) 
and should be soluble at ~pH 7. Following the observation of cross-reactivity with His residues 
in peptides, the SASA scripts include the calculation of solvent-accessibility of His residues. 
None of the candidate proteins were discounted due to their His SASA results, but the values 
were noted in case of future discovery of His modification by MS/MS. Six candidate proteins 
were selected (Figure 4-9) with a range of properties including MW (12‒21 kDa), pI (4.5‒12), 
as well as the number (2‒6) and exposure of Tyr residues (0‒38 Å2).  
 
Figure 4-9 Assessment of Tyr SASA in six protein substrates. Tyr residues which are highly 
exposed (SASA >70% of GYG tripeptide) are coloured green, intermediately exposed residues 
are coloured yellow (10-70%), and the least exposed Tyrs are coloured red (<10%). The 
haeme groups in Mb and Cyt. C are shown in purple. The GYG peptide benchmark is shown 
as a dashed line at 23.10 Å2. (PDB ID’s: 3NPO; 2B4Z; 4YM8; 5D5R; 4J5Z; 1BA7). 
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4.2.1 Ribonuclease A as a catch-and-release candidate 
Of the proteins considered, RNase A was highlighted as a particularly interesting substrate as 
it has six Tyr residues in the native protein sequence with a range of SASA values [Figure 
4-10 (a)]. There were three Tyr residues with high exposure (SASA: >20 Å2), one of 
intermediate exposure (SASA: ~8 Å2), and two Tyrs which were mostly buried (SASA: <5 
Å2). This analysis suggested that it would be possible to selectively target the more exposed 
Tyrs in the protein sequence (Y076, Y092 and Y115, coloured green in Figure 4-10) without 
labelling the others (Y025, Y073, Y097). As RNase A has three highly exposed Tyrs, it was 
also considered an interesting target to test the hypothesis that the solid-phase catch-and-
release system would favour single modification of the protein, even when other reactive sites 
were available and highly exposed. 
 
Figure 4-10 The conserved solvent-accessibility profile of native sequence RNase A 
structures. (a) The crystal structure used for SASA evaluation of Tyr residues in RNase A (PDB 
ID: 4J5Z). (b) X-ray crystal structures of native sequence RNase A were retrieved from the 
PDB (n = 75). The average of these results was compared with an NMR solution structure 
(average of 32 conformers is shown) and a neutron diffraction structure, and all showed a 
similar solvent-accessibility profile. The GYG peptide-derived benchmark is shown as a 
dashed line. 
RNase A is a well-studied protein, with >100 X-ray structures deposited in the PDB. Of these 
deposits, 75 examples were found of the native sequence protein and these were evaluated for 
Tyr SASA [Figure 4-10 (b)]. The solvent-accessibility profile was found to be well conserved 
among the X-ray crystal structures, and the average of this data set matched well with the 
structure previously used. While X-ray crystal structures were the most abundant RNase A 
deposits in the PDB archive, there were also structures which had been solved using NMR and 
neutron diffraction. The NMR structure was particularly interesting as this shows the 
conformation of the protein in solution rather than a solid-phase crystal structure. Between the 
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32 conformers which make up the NMR-derived deposit, the standard deviation was 
significantly higher than that observed between the entire set of X-ray derived structures, 
reflecting the dynamic nature of a protein in solution. Despite this variability, the average 
NMR-derived solvent-accessibility profile was in reasonable agreement with the average X-
ray derived profile. The neutron diffraction structure was also in excellent agreement with the 
X-ray derived profile, providing evidence that the crystal structure used was representative of 
the wider structural evidence, and that this agrees with the conformation of the protein in 
solution. 
4.3 Optimisation of the catch-and-release protocol 
4.3.1 Analysis and desalting of a protein sample 
In moving from small molecules and peptides to proteins, it was necessary to adapt the catch-
and-release methodology due to the limited availability and increase in complexity of the 
protein substrates. In particular, analysis of the catch-and-release product was more difficult 
with a protein target compared to a small molecule. At each key step of the catch-and-release 
reaction, UHPLC analysis of the resin eluate was used to monitor progress. When using small 
molecule and peptide substrates, analysis by UHPLC using a C18 column allowed distinction 
of unmodified and modified substrates by their respective retention times. However, with 
protein substrates it was necessary to use a C4 column for analysis and the addition of a single 
amino group proved to be an insufficient modification to cause a change in protein retention 
time. As such, the ‘wash’ step (coming after protein conjugation to the solid-phase and before 
reductive cleavage) was especially crucial for separation of unmodified and modified 
substrate. The wash eluate was therefore monitored by UHPLC until there was complete 
disappearance of the protein peak (Figure 4-11).  
 
Figure 4-11 The disappearance of unmodified RNase A in the resin eluate over 20 column 
volume (CV) washes. 
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As the presence of modified protein could not be identified by a shift in retention time, it was 
now monitored by the disappearance of the protein peak in the ‘wash’ eluate, followed by 
reappearance in the ‘cleavage’ eluate. The samples were later characterised by MS to confirm 
the extent of protein-tagging, however the UHPLC was used for ‘real time’ reaction 
monitoring. 
The catch-and-release cleavage product is collected in 300 mM Na2S2O4 and this sample must 
be desalted to remove the reducing agent before the following oxidative coupling reaction can 
occur. For small molecules, a C18 solid-phase extraction column was used for this purpose, 
however a protein substrate would bind to this media and could not be eluted in the standard 
MeOH or MeCN without becoming denatured. More common methods for protein desalting 
include dialysis, size-exclusion chromatography (SEC) and passage through a molecular-
weight cut-off (MWCO) membrane. 
 
Figure 4-12 The workup of the protein catch-and-release reaction. (a) SEC: using a size-
exclusion spin cartridge, the passage of the salt through the resin bed is hindered by diffusion 
into the resin’s pores. The macromolecule is too large to enter the pores and passes more 
quickly through the resin. (b) MWCO: the sample is desalted by successive concentration and 
dilution with buffer, using a membrane which allows the passage of microsolutes only.  
Desalting method 
Protein recovery  
from H2O (%) 
Protein recovery  
from Na2S2O4 (%) 
SEC (100 µL) 95.0 8.1 
MWCO (500 µL) 91.0 54.1 
Table 4-2 Table: Comparison of protein recovery using two desalting methods. No significant 
difference in recovery was observed for an RNase A standard in water, but the MWCO method 
gave significantly better recovery of RNase A from a 300 mM Na2S2O4 solution. 
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The use of dialysis was initially discounted as it is more commonly used on higher volume 
and higher concentration samples than the catch-and-release reaction produces. Instead, 
commercially-available SEC and MWCO spin cartridges were compared, using a centrifuge 
to pass the sample through the chosen media. Both approaches gave high protein recovery 
when trialled on a protein standard in water. However, when a sample containing 300 mM 
Na2S2O4 was used there was a significant loss of protein in each instance, however the MWCO 
cartridge outperformed SEC in terms of protein recovery and so this method was adopted for 
sample desalting. 
Despite these adaptations, early attempts at protein catch-and-release modification were 
extremely low yielding, reflecting the reduced accessibility of the diazonium salt to a Tyr 
residue in a protein as compared to a small molecule or peptide. This phenomenon is due in 
part to the reduced surface-exposure of Tyr residues in proteins, however the nature of the 
Affi-Gel resin may also be a contributing factor to this. The resin used in the Affi-Gel 10 
product is a cross-linked polymer more often used for size-exclusion chromatography. 
Molecules below the exclusion limit (5,000,000 Da) can pass through pores in the media, 
gaining access to any activated sites which are buried within the internal volume of the resin 
bead. While the proteins under consideration have a MW below the exclusion limit, their 
diffusion into the resin interior will be slower than that of a small molecule or peptide, 
restricting access to the activated sites. It was hoped that restricted access to the active sites 
would enhance the selectivity of the catch-and-release system, and so other variables were 
considered to optimise the protocol and increase the yield of the reaction. 
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4.3.2 Electronic effects in diazo chemistry 
Following literature precedent, it was found that both the ‘catch’ and ‘release’ steps of the 
catch-and-release system could be optimised by reducing the electron density of the resin-
bound aromatic ring [Figure 4-13 (a)]. It has been shown that the introduction of an electron-
withdrawing group (EWG) to the aromatic ring of a diazonium salt serves to increase the 
stability of the diazonium cation.158 In a system which relies on limited accessibility for 
selectivity, increasing the stability of the diazonium ion should serve to increase the window 
of time in which azobenzene formation can occur, thus improving the ‘catch’ step of the 
modification system. In order to improve the ‘release’ step, the azobenzene group should allow 
efficient reductive cleavage by Na2S2O4. For the design of a highly labile azobenzene moiety, 
it has been reported that there should be a large disparity in electron density between the aryl 
rings on either side of the diazo bond.159 In the current work, Tyr fulfils the role of an electron-
rich arene, with an electron donating hydroxyl group in the ortho position to the reactive site. 
Reducing the electron density of the opposing aromatic ring should therefore result in a highly 
labile azobenzene construct. In this way, a single substitution on the resin-bound aryl ring 
should improve the overall yield of the catch-and-release system through simultaneous 
improvement of both the ‘catch’ and ‘release’ steps. 
 
Figure 4-13 Optimising the catch and release system through electronic effects. (a) Electronic 
effects on the stability of a diazonium salt and the optimal arrangement for a highly labile 
azobenzene moiety. (b) The importance of symmetry in the aromatic diamines used for this 
work. 
To preserve the one-step functionalisation of the resin, symmetrical diamines were preferred, 
leading to the consideration of meta-substituted aromatic diamines. When used in excess these 
reagents allow amide conjugation to the resin, while leaving an immobilised aniline for 
diazotisation, thus negating the need for amine protecting groups [Figure 4-13 (b)]. 
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Aromatic diamines with -CO2H and -CF3 substitutions in the meta position were used in the 
catch-and-release protocol for the modification of RNase A [Figure 4-14 (a)]. In comparison 
to p-phenylenediamine, both electron-poor diamines gave an improved yield of the cleavage 
product. In agreement with the literature-based prediction, the more highly EWG (-CF3) gave 
the highest yield, representing a nearly 7-fold improvement when compared with p-
phenylenediamine. 
 
Figure 4-14 Optimisation of the catch-and-release of RNase A using different diamines. (a) 
By switching from R=H to R=EWG, the diazonium salt cation is stabilised. (b) Cleavage of 
the azobenzene linker is accompanied by a loss of colour in the resin. (c) The yield of modified 
protein was increased by adding an EWG to the diamine, the most electron-withdrawing group 
(-CF3) gave the highest yielding reaction. 
 
4.3.3 Reaction time and the persistent diazonium ion 
Using the optimised system, a significant increase in yield was also observed with increasing 
reaction time. The initial conditions for catch-and-release modification required 24 h 
incubation of the protein with the immobilised diazonium salt, although it was suspected that 
the diazonium salt would either react or become quenched long before this time point. In 
particular, hydrolysis of the diazonium salt to give the corresponding phenol was considered 
the most likely route of degradation given the use of aqueous buffer as solvent in this reaction. 
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The displacement of a diazonium salt by a nucleophile is entropically favoured due to the 
production of N2(g) and this driving force is exploited in substitution reactions in organic 
chemistry, notably in named reactions such as the Sandmeyer and Balz-Schiemann reactions. 
A similar transformation can occur in an aqueous environment with a water molecule acting 
as the nucleophile, resulting in hydrolysis of the diazonium salt and production of a phenolic 
product. The rate of diazonium salt hydrolysis is known to increase with increasing 
temperature and pH, and this places the degradation route in direct competition with the 
desired SEAr reaction, which is also accelerated in basic conditions (Figure 4-15). 
 
Figure 4-15 Hydrolysis of the diazonium salt (right) may be a competitive and undesired side 
reaction when attempting SEAr (left) in basic aqueous conditions. 
The catch-and-release reaction was performed at room temperature and pH 7.2 for optimum 
compatibility with protein substrates. However, it is likely that these neutral conditions also 
limit the rate of the undesired diazonium hydrolysis reaction, thus stabilising the diazonium 
ion for sufficient time to allow the desired SEAr reaction to take place. In fact, it was observed 
that the yield of the SEAr reaction with RNase A continued to increase with reaction time >24 
h, reaching a maximum of ~70% at 48 h. This suggests that the reactive diazonium species 
remains unquenched for at least 24 h, and this is assumed to be a combined effect of the 
stabilising ability of the EWG on the diazonium cation and the mild temperature and neutral 
pH used for the reaction. 
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Figure 4-16 Increasing the catch-and-release reaction time. (a) The yield of the catch-and-
release reaction continued to improve until 48 h, suggesting the diazonium salt had not yet 
been quenched. (b) By ESI-MS, the 48 h product was found to be primarily doubly labelled. 
Shown is the MaxEnt deconvoluted spectrum, which will be discussed in the following section. 
The observed masses are shown with the increase in mass from the unmodified protein in 
brackets. Theoretical masses: 1 modification – 13,697 Da; 2 modifications – 13,712 Da; 3 
modifications – 13,727 Da. 
Despite the improved yield with 48 h and 72 h reaction times, MS analysis of these protein 
samples revealed the presence of multiple modifications, whereas 24 h favoured single 
modification. Opting for selectivity over reactivity, the 24 h reaction time was adopted and 
this was justified by the high protein recovery allowed by the solid-phase system. Even in a 
low yielding reaction, there was a high recovery of unmodified protein in buffer with no 
additional reagents, allowing the user to recycle unreacted substrate. 
4.3.4 Resin age 
The yields for the optimised catch-and-release reaction were reproducible when using fresh 
resin but dropped off quickly upon storage of the resin after opening. The resin is 
functionalised with NHS-esters as described previously, and shipped for storage as a slurry in 
propan-2-ol. The manufacturers advise storage of the resin for up to one year in a -20 °C 
freezer in order to preserve 80% of original activity.140 Each container had enough resin to 
perform ~25 catch-and-release experiments and once opened the containers were dated, sealed 
and stored in a -20 °C freezer. The most obvious route of degradation is by hydrolysis of the 
NHS-ester to give a carboxylic acid, which is not reactive to an amine at neutral pH without 
the addition of a coupling reagent.160 Due to the difficulty in transferring the resin without 
drying it out, the propan-2-ol was replenished frequently during use and this could have 
introduced water to the container, increasing the rate of NHS-ester hydrolysis (Scheme 4-1). 
Resins of various ages (1 week; 1-2 months; >1 year) were used to assess the extent of 
degradation by performing the catch-and-release reaction simultaneously using each batch. 
Replicates of these experiments were performed with the coupling reagents DCI and Oxyma 
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used for the initial amide conjugation step, allowing coupling of the diamine to any carboxylic 
acid which had resulted from NHS-ester hydrolysis.  
 
Scheme 4-1 Recovery of aged resin by introduction of coupling reagents. Over time, the resin-
bound NHS-ester is likely to undergo hydrolysis with water introduced from solvent 
replenishment. The resulting carboxylic acid is not reactive to the diamine alone, but the 
desired conjugation product can be achieved by activation of the carboxylic acid using DCI 
and Oxyma. 
In each reaction the diamine was added to the resin in DMSO:propan-2-ol, 10:90 (with or 
without the addition of coupling reagents) and agitated on a rotator for 4 h at rt. Using the 
standard protocol [no coupling reagents, Figure 4-17 (a): black bars], there was no significant 
difference in the performance of the 1 week and the 1-2 month old resins. However, these 
results represented ~70% reduction in yield when compared with fresh resin (246 µM). When 
using coupling reagents for diamine conjugation [Figure 4-17 (a): grey bars], the yield using 
the 1 week and 1-2 month old resins was recovered to >90% of that achieved with the fresh 
resin. These results suggest that after 1 week there was significant hydrolysis of the NHS-ester 
groups (perhaps exacerbated by replenishment of the propan-2-ol) which resulted in a drastic 
reduction in reactivity that was only recovered with the addition of peptide coupling reagents. 
The oldest resin used (date first opened was >1 year prior to reaction) gave a significantly 
reduced yield of modified protein. Even with the addition of coupling reagents, the yield was 
only recovered to 67% of the fresh resin. This suggests that the resin undergoes irreparable 
degradation beyond the 1 year shelf life as advertised, with the result that azobenzene 
formation was reduced (as observed by eye, the oldest resin was a less intense orange colour 
[Figure 4-17 (b)].  
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Despite the manufacturer’s claim of resin stability in storage for up to 1 year, it was found that 
under current usage significant hydrolysis of the resin’s NHS-esters occurred within one week 
of opening. To avoid this affecting future results, the whole resin volume was functionalised 
with 3,5-diaminobenzotrifluoride immediately upon opening in order to allow storage at -20 
°C as the more stable amide. 
 
Figure 4-17 NHS-ester hydrolysis in Affi-Gel 10. (a) The comparison of resins of three 
different ages, amide conjugation was performed in the absence (black) or presence (grey) of 
coupling reagents (CR). (b) The appearance of the three ages of resin upon azobenzene 
formation using the standard protocol (no coupling reagents) (left to right: 1 week; 1-2 
months; >1 year). 
 [Cleavage product] (µM), % of fresh resin 
Resin age No coupling reagent With coupling reagents 
Fresh 246, 100% - 
1 week 67, 27% 223, 91% 
1-2 month 67, 27% 227, 92% 
>1 year 36, 15% 166, 67% 
Table 4-3 The UHPLC-calculated concentrations of catch-and-release modified RNase A in 
three ages of resin in the absence and presence of coupling reagents. 
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4.4 Catch-and-release of protein substrates 
4.4.1 The relationship between SASA and yield 
With an optimised protocol in hand, catch-and-release modification of a selection of proteins 
was undertaken. Given the solid-phase nature of the system, unbound protein was recovered 
in neutral pH buffer and in cases where the yield of modified protein was low, this sample 
could be recycled and reused if needed. Quantification of the unmodified and modified 
fractions by UHPLC and comparison with a calibration curve showed >93% total protein 
recovery in all cases [Figure 4-18 (a)].  
 
Figure 4-18 Yield for the protein catch-and-release reactions. (a) While the yields for some 
of the substrates were low, accounting for recovered unbound protein resulted in >93% total 
protein recovery in all cases. (b) The yield % is plotted against the SASA of the most exposed 
Tyr residue in each protein, with the GYG benchmark given as a grey dashed line. The three 
highest yielding proteins each had a Tyr residue close to or above the SASA of the GYG 
benchmark. 
Protein Yield (%)  
Unbound 
protein (%) 
Recovered 
yield (%) 
Highest Tyr 
SASA (Å2) 
RNase A 32.8 64.7 92.9 27.6 
SBTI 13.5 83.5 81.8 37.9 
β-Lac 0.6 95.5 13.3 15.3 
Mb 2.6 95.5 57.8 8.2 
HEWL 13.8 80.5 70.8 21.7 
Cyt. C 1.8 94.6 33.3 11.2 
Table 4-4 The modified and unmodified proteins were quantified using UHPLC and from 
this data, yields were calculated. The recovered yield is given as the yield of modified 
protein after subtraction of the recovered unmodified substrate. The SASA values of the most 
exposed Tyr residue in each substrate is also given. 
The yield of each reaction was plotted against the highest Tyr SASA for each protein [Figure 
4-18 (b)]. Despite the limited scope of the protein screen, the three proteins which showed the 
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highest yields all had Tyr residues around or above the SASA of the GYG benchmark. RNase 
A was the highest yielding example and was therefore taken forward for MS analysis and 
oxidative coupling functionalisation. 
 
4.4.2 An alternative route to o-aminophenol-modified RNase A 
The o-aminophenol modification of Tyr has been previously explored in literature due to the 
role of Tyr nitration as a post-translational modification (PTM). This modification occurs by 
exposure of a Tyr residue to the radical nitrating agent nitrogen dioxide (˙NO2) which is 
produced in biological systems from nitrite- (NO2-) or peroxynitrite- (ONOO-) dependant 
pathways.161 In order to simulate this PTM, the small and highly reactive reagent 
tetranitromethane (TNM) has previously been used to modify RNase A.147 This reagent has 
been shown to selectively nitrate the ortho position of the Tyr phenol ring to give 3-
nitrotyrosine, mimicking the native PTM. Reduction of 3-nitrotyrosine to 3-aminotyrosine 
with Na2S2O4 has been used as part of a modification strategy to quantify protein Tyr nitration, 
and this gives an alternative route to an o-aminophenol modified protein (Scheme 4-2).122, 162 
The TNM nitration followed by reduction strategy was selected as an interesting comparison 
to the catch-and-release methodology as the size and accessibility of the two Tyr-reactive 
species are completely juxtaposed. It can be assumed that TNM will have access to sites on 
the protein that the resin-tethered diazonium salt cannot reach, and thus we expect a different 
modification profile for the solution-phase and solid-phase approaches. 
 
Scheme 4-2 Modification of RNase A using the TNM nitration, reduction strategy. 
While it is sometimes described as a mild nitrating agent, TNM has also been investigated for 
use in explosives and as a fuel additive, leading one team of researchers who were 
investigating the mechanism of phenol nitration to comment: 
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“It should be noted that a mixture of TNM and pyridine has occasionally exploded several 
hours after mixing.”163 
With this in mind, TNM was handled with great care and reactions involving this reagent were 
performed behind a blast shield. A sample of RNase A was nitrated with 20 equivalents of 
TNM for 24 h. Upon treatment with Na2S2O4, the 3-nitrotyrosine moiety was reduced to give 
3-aminotyrosine, with a corresponding loss of the 357 nm absorbance peak (Figure 4-19). The 
resulting o-aminophenol modified RNase A was desalted by MWCO spin cartridge and 
assessed by MS for comparison with the catch-and-release modified sample.  
 
Figure 4-19 The reduction of nitro-modified RNase A by Na2S2O4 and the corresponding loss 
in absorbance at 357 nm. 
 
4.4.3 ESI-MS analysis of proteins 
Compared to small molecules, the analysis of proteins by ESI-MS becomes complicated due 
to the increase in the number of ionisable sites. For this reason, it is common to observe high 
charge states which form a wide charge envelope (Figure 4-20). Using a deconvolution tool 
such as MaxEnt on MassLynx software, these multiple charge states can be deconvoluted to 
give the uncharged mass of the parent species (Figure 4-20). An unmodified RNase A standard 
was interrogated by this method, and the observed mass was found to be in excellent agreement 
with the theoretical mass based on the reported amino acid sequence. 
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Figure 4-20 ESI-MS of RNase A and the MaxEnt deconvolution tool. The broad charge 
envelope encompassing the 8+ to 15+ charge states is shown. This was deconvoluted using 
the MaxEnt tool in MassLynx software to give the uncharged parent mass, which agreed with 
the calculated mass of 13,682 Da. 
The unmodified RNase A standard was next compared with the solid-phase and solution-phase 
modified samples (Figure 4-21). The deconvoluted mass of each sample was calculated from 
the charge envelope, and all assigned peaks fell within 1 Da of the theoretical mass. The catch-
and-release modified RNase A was found to be primarily singly modified, with the peak at 
13,697 Da appearing most abundant. A small amount of unmodified and twice modified 
protein was also observed, however there were no significant peaks corresponding to higher 
levels of modification. This result supports the hypothesis that the extent of modification can 
be limited using a solid-phase approach, as we have achieved primarily single modification of 
a protein which contains six native targets. In contrast, the sample modified by solution-phase 
nitration and reduction showed higher levels of modification. The most abundant species at 
13,741 Da corresponds to RNase A with four NH2 modifications, and some of the 5 x modified 
species was also identified. There were no significant peaks suggesting modification of all six 
Tyr residues however, so it is possible that even the small nitrating reagent TNM failed to 
reach the most buried Tyr residue (Y097).  
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Figure 4-21 Comparison of the solid-phase and solution-phase approaches to RNase A 
modification by ESI-MS. The charge envelope and deconvoluted mass (inset) are given for 
each sample. (a) The unmodified RNase A standard gave a deconvoluted mass of 13,682 Da. 
(b) The catch-and-release modified sample showed primarily the singly modified species at 
13,697 Da. (c) The TNM-derived sample showed higher levels of modification, with the 4 x 
modified species appearing most abundant at 13,741 Da. The same peaks were also identified 
with phosphate adducts (+P). 
This work serves as a successful demonstration of the solid-phase approach and its ability to 
limit the extent of protein modification. In order to rationalise this in terms of accessible sites 
on the protein surface, it was necessary to identify the specific site, or sites, of modification in 
the protein sequence. This work was undertaken by top-down fragmentation of the denatured 
protein on the 12T FT-ICR instrument in the University of Edinburgh.† 
  
                                                     
† Top-down fragmentation of modified RNase A was performed by Dr C. Logan McKay, 
sample preparation and data analysis was performed by CA. 
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4.4.4 Top-down fragmentation of modified RNase A 
In order to achieve good sequence coverage in top-down fragmentation techniques, the protein 
should be denatured to allow the exposure of buried residues. Unfortunately RNase A is a 
rather robust substrate which contains four disulphide bridges, and so these had to be reduced 
to allow sufficient unfolding of the protein. The reduction and denaturation of the protein was 
performed with TCEP and guanidine immediately prior to infusion into the MS. Initially 
fragmentation was attempted by collision-induced dissociation (CID), and the singly modified 
parent ion (m/z 1055.19, corresponding to the 13+ charge state) was isolated before being 
accelerated through a chamber containing neutral gas molecules. Upon collision, the energy 
transferred may cause fragmentation of the parent ion and these fragments are then analysed 
by MS. Using this technique, RNase A appeared only to be fragmented at the C-terminal end 
of the protein sequence and so fragmentation by electron-capture dissociation (ECD) was 
attempted instead. ECD is a relatively recent technique compared to CID, and while the exact 
mechanism of dissociation remains the subject of some debate, the event is initiated by protein 
capture of an electron resulting in formation of a radical species which is prone to bond 
cleavage.164 ECD is a preferred method in certain circumstances as it is thought to be a fast 
and relatively mild approach to protein fragmentation. Interestingly, it is also known to cleave 
disulphide bonds which may explain the improved sequence coverage which resulted in this 
case. If TCEP reduction of the RNase A disulphides was incomplete, or if the resulting free 
thiols had re-oxidised before infusion, then this would hinder the fragmentation of the protein 
by CID, but shouldn’t significantly affect fragmentation by ECD. 
Following ECD fragmentation, the MS of the resulting peptides was recorded. Using the 
online tool Prosight PTM,165, 166 peptide fragments were identified which matched the 
predicted c-/z- fragmentation pattern of o-aminophenol modified RNase A by ECD-MS. Using 
the software the +15 Da modification (from addition of the NH2 group) was placed 
sequentially on each Tyr residue in the protein sequence. The sequence-coverage was assessed 
in each case by the number and placement of assigned peptides. By this method, the +15 Da 
modification was assigned to Y115, with sufficient coverage achieved to separate this position 
from the other Tyr residues in the protein (Figure 4-22). 
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Figure 4-22 Top-down fragmentation of catch-and-release modified RNase A. (a) The 
modified protein was fragmented by ECD and the modification was assigned to Y115, the third 
most exposed Tyr residue (red). (b) The three most exposed Tyr residues are shown in green. 
The relevant SASA values are Y076: 27.58 Å2; Y092: 23.71 Å2; Y115: 20.64 Å2. (PDB ID: 
4J5Z). 
The same process was applied to look for possible His modification, and it was observed that 
while there was no evidence for modification of three of the four native His residues, Y115 
could not be distinguished from H105 by ECD fragmentation alone. Fortunately, despite the 
limited sequence coverage of CID fragmentation, this method did provide separation of the 
key C-terminal region, allowing distinction between H105 and Y115. Therefore the 
modification was assigned to Y115, and this result was also supported by bottom-up analysis. 
Relating this back to Tyr surface-accessibility, it was interesting to note that Y115 was not the 
most exposed Tyr residue in the sequence. With a SASA value of 20.64 Å2, the modified 
residue was still considered to be highly exposed (falling within close range to the GYG 
benchmark of 23.10 Å2) however Y076 and Y092 had previously been identified as the two 
most exposed residues. In order to rationalise this, the local environment of each residue was 
explored to identify possible discrepancies between these three highly exposed positions. 
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4.4.5 Hydrogen bonding of Tyr residues 
The first local effect which was considered to understand the difference in reactivity of the 
three Tyr residues Y076, Y092 and Y115 was H-bonding. Using the RNase A crystal structure 
(PDB ID: 4J5Z), these positions were examined to find polar contacts in which the Tyr 
hydroxyl group may take part.  
 
Figure 4-23 Polar contacts of the three most exposed Tyr residues in RNase A. Y076 was 
found to have a polar contact with a water molecule in the crystal structure. Y092 made a 
polar contact with the backbone amide of a nearby aspartic acid residue. Y115 made a polar 
contact with the hydroxyl group of the intermediately exposed Y073 residue. (PDB ID: 4J5Z). 
The Y076 residue was found to make a polar contact with a nearby water molecule in the 
crystal structure, while the Y092 residue shared an interaction with the amide from the peptide 
backbone of an aspartic acid residue (D038). Y115 meanwhile was found to share an 
interaction with the phenolic OH of Y073. None of these interactions are of the type we would 
expect to enhance the reactivity of a Tyr residue; such an interaction would come for example 
from a carboxylate ion, which could hydrogen bond with the OH of the Tyr and reduce the 
pKa of the phenol (Figure 4-24). This would allow easier deprotonation of the Tyr to form the 
phenolate ion and drive nucleophilic attack from the ortho position of the ring in a general 
base catalysis-type mechanism. 
 
Figure 4-24 Depiction of the type of intramolecular interaction likely to increase the reactivity 
of the Tyr residue by reducing the pKa of the side chain phenol. 
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4.4.6 Electrostatics at the protein surface 
Having assessed the polar contacts of the three most exposed Tyrs and found no clear 
difference in their potential reactivity, the electrostatic potential of the protein surface was next 
considered. Although the Affi-Gel resin bears a neutral linker to the NHS-ester group, once 
this has been functionalised as the amide-conjugated diazonium salt, a single resin bead will 
bear multiple positively-charged terminal groups. As such, it is possible that we would 
encounter some charge-charge repulsion between a positively charged face of the protein and 
the functionalised surface of the resin. Using PyMOL, the protein contact potential can be 
displayed using the vacuum electrostatics function and this can be used as a qualitative tool to 
explore the charged surface of a protein of interest. The function averages the electrostatic 
contributions of residues such as lysine, arginine, aspartic acid and glutamic acid which bear 
a charge at neutral pH, and plots this as a false-coloured surface on the protein.  
The protein contact potential of RNase A was generated and the surfaces around the three most 
highly exposed Tyr residues (Y076, Y092 and Y115) were examined (Figure 4-25). Y076 was 
found to have a strong positively charged region located immediately next to the reactive ortho 
position of the phenol ring. In fact, this positive charge arises from K061, and it is the 
positively charged terminal amine of the K061 side chain which sits directly beside the reactive 
position of the phenol in the crystal structure. Despite the close proximity in space of Y092 
and D038 (which bears a negatively charged side chain at neutral pH), Y092 forms a hydrogen 
bond to the backbone amide of this residue and the sidechain points away from the Tyr phenol 
ring. The negative potential of the D038 side chain also appears to be cancelled out by the 
positively charged Lys and Arg residues which sit on either side of it (K037 and R039). 
Furthermore, the Y092 residue has a Lys residue immediately next to it in the protein sequence 
(K091), making the surface surrounding this residue quite positively charged. Finally, there 
were no positively or negatively charged residues identified in close proximity to the Y115 
residue, and in comparison to the two other highly exposed residues, this Tyr was found to sit 
on a surface which was relatively flat and uncharged. These findings support the hypothesis 
that charge-charge repulsion may play a role in the selectivity of the catch-and-release protein-
tagging platform. Future work in this area could include a negatively charged functional group 
in the resin-bound construct to give an overall neutral resin once functionalised with a 
diazonium salt. 
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Figure 4-25 Electrostatics of RNase A visualised on PyMol, Blue surfaces are more positively 
charged, red surfaces are more negatively charged. The most highly exposed Tyr residues 
(Y076 and Y092) were not found to be modified and this may be explained by their proximity 
to positively charged residues (Lys and Arg). In contrast, Y115 presents on a flat, mostly 
uncharged surface of the protein. (PDB ID: 4J5Z). 
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4.5 Oxidative coupling on a protein substrate 
In order to take advantage of the newly installed o-aminophenol functionality, the oxidative 
coupling strategy first reported by Francis et al.122 was applied to the catch-and-release 
modified RNase A. As in the case of the catch-and-release chemistry, some adaptations were 
made to the procedure in moving from small molecules to proteins. In particular, a MWCO 
cartridge was used to separate the product from the small molecule reagents after completion 
of the reaction. The reagents themselves were also used in greater excess than in the small 
molecule example. Ten equivalents of the oxidising agent K3Fe(CN)6 had previously been 
used for oxidative coupling of small molecules, however this proved insufficient when applied 
to the protein substrate. This could perhaps be due to residual Na2S2O4 which may not have 
been completely removed from the protein sample by desalting with a MWCO cartridge and, 
as a reducing agent, would potentially counteract the oxidising ferricyanide. The published 
conditions of 80 mM K3Fe(CN)6 were adopted for the protein samples,122 representing over 
1500-fold excess compared to the 50 µM protein. The anilines used for protein labelling were 
selected to have a UV absorbance which would allow detection of the product by HPLC-PDA 
even without a discernible change in Rt. These were used in a 20:1 stoichiometry to the protein 
giving a final concentration of 1 mM. The reaction was performed in pH 6.5 buffer for 18 h 
with agitation on a rotator at rt [Figure 4-26 (a)]. Following purification of the protein by 
successive washing and concentration on a MWCO cartridge, the protein products were 
identified by HPLC-PDA, bearing the distinctive absorbance peaks of the chosen fluorophores 
[Figure 4-26 (b)]. The fluorescein-conjugated sample was taken onto SDS-PAGE analysis to 
further confirm that the fluorophore was attached and not simply co-eluting with the protein 
peak on HPLC. By SDS-PAGE, an unmodified RNase A sample and a FITC-labelled RNase 
A sample (with up to ten fluorescent labels conjugated via Lys residues) were compared with 
the product of the oxidative coupling reaction [Figure 4-26 (c)]. The oxidative coupling 
product produced a band which was identified by Coomassie stain at the correct MW for RNase 
A, and this band was also shown to be fluorescent, alongside the FITC-labelled standard. It 
should be noted that while a single fluorescein modification cannot be resolved from the 
unmodified sample by the position of the gel band (fluorescein modification MW: 345 Da), the 
FITC-labelled sample contains up to ten fluorophores, resulting in a higher band on the gel 
and production of a strong signal when scanned for fluorescence. This work demonstrates the 
utility of an o-aminophenol modification as a synthetic handle, and together with the selective 
modification achieved through the catch-and-release reaction, this completes a novel protein-
labelling strategy which targets Tyr residues in a selective manner. 
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Figure 4-26 Oxidative coupling (OC) of modified RNase A. (a) The reaction scheme for the 
oxidative coupling of an aniline to o-aminophenol-modified RNase A. Three fluorescent 
anilines (ArNH2) were used: fluoresceinamine (1), aminoazobenzene (2) and pararosaniline 
(3). (b) PDA analysis of the OC products gave new absorbance peaks resulting from 
incorporation of the fluorophore (1: 442 nm, 2: 341 nm, 3: 568 nm). (c) SDS-PAGE of the 
fluoresceinamine OC product with coomassie stain and inverted fluorescence. The OC product 
was compared with unmodified RNase A and a FITC-labelled standard. 
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4.6 Conclusion 
To conclude, this Chapter has built on the small molecule and peptide work shown in Chapters 
2 and 3, both in solution and on solid-phase, to deliver a protocol for the selective modification 
of a native sequence protein which contains multiple Tyr residues. Using in-silico tools, it has 
been possible to assess the availability of each potentially reactive residue through the 
application of the SASA calculation. By the development of an automated script to perform 
this duty, and through the expansion of the code to encompass other potentially targetable 
residues, this method may be used in future protein-tagging applications. Following catch-
and-release of multiple protein substrates, it was observed that the highest yielding examples 
displayed a highest Tyr SASA close to or above the GYG benchmark, and it would be 
interesting in future work to explore this relationship through expansion of the number of 
protein candidates and in-depth MS analysis of the modified product.  
In RNase A it was found that the most exposed Tyr was not in fact the residue which had been 
labelled, instead labelling of another highly exposed Tyr was achieved. Through consideration 
of intramolecular interactions and protein surface electrostatics, there is an avenue to refine 
future predictions of reactivity, especially if these functions can be incorporated into the 
automated SASA scripts.  
Oxidative coupling of a fluorescent aniline to the catch-and-release modified RNase allowed 
visualisation of the labelled product by PDA and in-gel fluorescence scanning. In future, the 
nature of the aniline may be changed to achieve protein labelling with a PEG chain, a biotin 
group or another functional small molecule, increasing the application of the current work. 
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4.7 Future work 
Future work will primarily involve application of the developed catch-and-release system to 
research-appropriate substrates. As a potential target, the anti-GFP nanobody is a substrate of 
interest, as labelling this with a fluorophore would allow co-localisation microscopy 
experiments with GFP as a proof of principle. SASA analysis of α-GFP from the published 
co-crystal structure with GFP (Figure 4-27) suggests that modification of the most exposed 
Tyr residue, Y081 would not interfere with binding, as it is located on the opposite face of the 
protein from the binding interface. 
 
Residue Avg. SASA (Å2) Std. Dev. 
Y033 17.02 1.55 
Y038 15.52 0.78 
Y061 17.03 0.63 
Y081 21.74 1.65 
Y095 0.00 0.00 
Y096 6.89 0.49 
Y105 17.15 2.94 
Figure 4-27 SASA evaluation of the 7 Tyr residues in the anti-GFP nanobody (PDB ID: 
3OGO). The SASA value of each Tyr residue was averaged over the four chains contained in 
the crystal structure, the results ranged from the buried Y095 residue to the most exposed 
Y081, which sits on the opposite face of the protein from the GFP binding interface. 
Beyond α-GFP, nanobodies are a class of substrates which would be generally suitable for 
fluorescent labelling, as they would provide a small fluorescent probe which is preferred for 
modern super-resolution imaging techniques. Unfortunately, few crystal structure deposits of 
nanobodies currently exist, limiting the use of the SASA calculation in this instance. 
Alternatively, the catch-and-release system could be used for the reversible immobilisation of 
proteins for purposes such as biophysical assays. By immobilisation of a protein substrate on 
an SPR chip, this could prove a useful means of characterising protein interactions, while 
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selective modification would provide a homogeneous display of the immobilised protein as 
each biomolecule would be anchored to the support by the most reactive Tyr residue. 
 
Figure 4-28 A potential application of the catch-and-release chemistry is in the reversible 
immobilisation of proteins for use in biophysical assays. 
Finally, the solid-phase modification platform and cleavable linker design could be used to 
expand the application of catch-and-release modification to other amino acids. Using a Tyr-
inspired three-vector linker, a range of reactive groups could be used for protein capture, 
before cleavage with dithionite and functionalisation through a click handle. 
 
Figure 4-29 A possible expansion of the catch-and-release approach to encompass other 
amino acid targets. This approach would retain the linker design established in this work, with 
the addition of a conventional click handle such as an alkyne, and a variable site to 
incorporate a range of other amino acid targeting functional groups. 
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Chapter 5 Experimental 
5.1 General Methods 
All non-aqueous reactions were performed under nitrogen atmosphere using oven-dried 
glassware that was cooled in a desiccator prior to use. MeOH, DCM and acetonitrile were 
dried and purified by a solvent purification system using activated alumina. Unless otherwise 
stated, all reagents were commercially sourced and used without further purification. Organic 
layers were dried using magnesium sulphate unless otherwise stated. Saturated aqueous 
solutions of inorganic salts are represented as (volume, sat. aq.). Triethylamine was distilled 
over CaH2 prior to use. 
Thin layer chromatography was performed using Merck silica gel 60F254 foil-backed plates 
with visualisation under ultraviolet light (254 nm), or using KMnO4 (aq.) or ninhydrin staining. 
Rf values are given, with the solvent system quoted as a v:v ratio. Column chromatography 
was performed using Merck Kieselgel 60 (Merck 9385) silica under positive pressure from a 
hand pump. Eluent compositions are given as v:v ratios. 
Melting points were determined on a Gallenkamp Electrothermal melting point apparatus and 
are uncorrected. 
Optical rotations were measured on a PolAAr 20 series polarimeter with a path length of 1.0 
dm at the sodium D line (589 nm) and are reported as follows: [α]D, concentration (g/100 mL), 
solvent. All optical rotations were measured at room temperature. 
Infra-red spectra were recorded on a Shimadzu IRAffinity-1 machine. The samples were 
analysed neat, and wavelengths of maximum absorbance (υmax) are quoted in cm-1. 
1H and 13C NMR spectra were obtained on Bruker instruments at the stated frequency. The 
data is presented as follows: Chemical shift (in ppm on the δ scale relative to δTMS = 0 ppm), 
integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, m = 
multiplet, td = triplet of doublets, dd doublet of doublets, dt = doublet of triplets, br = broad), 
coupling constants (in Hertz, Hz) and the assigned peaks are shown in italics (e.g. CO2H). 
Small molecule and peptide products were analysed by ESI-MS using a Bruker MicroTOF2 
instrument. Mass-to-charge ratios (m/z) of parent peaks and significant fragments are 
identified, along with their relative intensities (%). 
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Protein analysis by SDS-PAGE was performed using a 12 well 4-12% NuPAGE Bis-Tris Gel 
(Novex) in a Bolt Mini Gel Tank (Novex). The running buffer was NuPAGE MES SDS, the 
MW ladder used was SeeBlue 4-250 kDa (Invitrogen). The protein samples were mixed with 
Laemmli buffer and heated to 100 °C for 5 min, before loading into the sample wells. The gel 
was developed for 35 min at 200 V. Fluorescent bands were detected using a Typhoon 9400 
Variable Mode Imager (Amersham Biosciences). The same gel was then stained with 
InstantBlue (Expedeon) and developed for 15 min on a shaking table. 
5.2 LC Methods 
5.2.1 U/HPLC-PDA methods 
Reaction monitoring and analysis was performed by reverse-phase chromatography using 
either a HPLC with photo-diode array detector or a UHPLC with photo-diode array detector. 
HPLC was performed using a Waters 600E pump, a Waters 717plus autosampler and a Waters 
996 PDA equipped with a Phenomenex SphereClone ODS C18, 5 µm, 4.6 x 150 mm column 
(System 1). UHPLC was performed on a Waters Acquity UPLC PDA equipped with a Waters 
Acquity UPLC BEH300 C4, 1.7 µm, 2.1 x 100 mm column (System 2) or a Waters Acquity 
UPLC BEH130 C18, 1.7 µm, 2.1 x 100 mm column (System 3). The U/HPLC traces were 
exported as ASCII data using Empower software by Waters. The traces were processed using 
Origin (version 8.5.1) by OriginLab Corporation, and baseline subtraction was performed 
using the trace obtained from a blank injection. Retention time (Rt) was taken from the 
unprocessed spectrum; where conversion by U/HPLC is given, this was calculated using the 
peak area calculation tool in Empower on the unprocessed spectrum at 210 nm absorbance. 
Method 1: System 1; flow rate 1 mL min-1; ambient column temperature, total method time 
20 min; PDA absorbance spectrum recorded from 200-800 nm. 
Time (min) 
% H2O 
(+0.1 % v/v TFA) 
% MeCN 
(+0.1 % v/v TFA) 
0 95 5 
10 5 95 
12 5 95 
15 95 5 
 
  Chapter 5: Experimental 
 114 
Method 2: System 2 or System 3; flow rate 0.2 mL min-1; column temperature 60 °C; total 
method time 12 min, PDA absorbance spectrum recorded from 200-400 nm. 
Time (min) 
% H2O 
(+0.1 % v/v TFA) 
% MeCN 
0 95 5 
0.5 95 5 
10.5 5 95 
10.9 5 95 
11 95 5 
 
5.2.2 Preparative HPLC method 
Preparative RP-HPLC was performed using a Waters 600E pump with a Waters 486 tuneable 
absorbance detector, using a Phenomenex Luna C18(2), 5 µm, 21.2 x 250 mm column  
(System 4). Isocratic solvent systems were used for purification using H2O + 0.1% TFA and 
MeCN + 0.1% TFA; the flow rate was 18 mL min-1. Samples were dissolved in DMSO, and ≤ 
0.25 mL was injected by Rheodyne. 
 
5.2.3 UHPLC-MS method 
MS analysis of intact protein samples was performed using a Waters Acquity UPLC equipped 
with a Waters Acquity UPLC BEH300 C4, 1.7 µm, 2.1 x 100 mm column and a Waters 
SYNAPT G2 mass spectrometer (System 5). The UHPLC-MS method was modelled on the 
UHPLC-PDA method, with an initial 2.5 min of equilibration at which time the UHPLC outlet 
was diverted to waste. 
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Method 3: System 5; flow rate 0.2 mL min-1; column temperature 60 °C; total method time 
15 min. 
Time (min) 
% H2O (+0.1 % 
v/v FA) 
% MeCN (+0.1% 
v/v FA) 
0 95 5 
2.5 95 5 
12.5 5 95 
12.9 5 95 
13 95 5 
 
5.3 Solid-phase peptide synthesis 
Resin preparation 
All peptides were synthesised using Rink Amide AM resin (200-400 mesh, 0.69 mmol/g). The 
resin was weighed into a SPE tube, and swelled in DCM for 30 min with agitation on a rotator 
at rt. The resin was drained by vacuum filtration and washed with DMF. The Fmoc-protected 
resin was deprotected using 20% piperidine in DMF with agitation on a rotator for 10 min at 
rt. 
TNBS free amine test 
After each coupling and deprotection step, a small portion of resin beads was removed and 
added to an Eppendorf with a small volume of DMF. Using a plastic pastette, ~5 drops of 
DIPEA solution (10% in DMF) and 1 drop of TNBS solution (5% aq.) were added. The 
Eppendorf was agitated on a rotator for 10 min at rt and subjected to centrifugation. The beads 
were washed with DMF and visual inspection determined the presence of free amine (red 
beads) or the absence of free amine (colourless beads). 
Coupling of amino acids 
On-resin amide coupling was performed by mixture of an Fmoc-protected amino acid (3 
equiv.), Oxyma (3 equiv.) and DIC (3 equiv.) in DMF, which was then added to the resin and 
agitated on a rotator for 1 h at rt. The resin was drained by vacuum filtration and excess 
reagents were washed from the solid phase (3 x DMF, 3 x DCM, 1 x DMF). The TNBS test 
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was performed on a small portion of resin beads, and the coupling step was repeated if any red 
beads were observed. 
Fmoc deprotection 
Fmoc deprotection was performed by addition of piperidine (20% in DMF) to the resin, 
followed by agitation on a rotator for 10 min at rt. The resin was drained and washed with 
DMF and the TNBS test was performed on a small portion of resin beads. The deprotection 
step was repeated if any colourless beads were observed. 
Acetyl capping 
Following completion of the desired peptide sequence, the N-terminus was protected as an 
acetamide by addition of acetic anhydride (20 equiv.) and DIPEA (20 equiv.) to the resin, with 
agitation on a rotator for 1 h at rt. The resin was washed (3 x DMF, 3 x DCM, 1 x DMF) and 
the TNBS test was performed on a small portion of resin beads, the capping step was repeated 
if any red beads were observed. 
Cleavage and global deprotection 
The synthesised peptide was cleaved from the resin by addition of the cleavage cocktail 
(TFA:TIS:H2O, 95:2.5:2.5 by volume) and agitation on a rotator for 3 h at rt. Peptides 
containing a Cys residue were cleaved with a cocktail containing a disulphide-reducing agent 
(TFA:TIS:H2O:EDT, 92.5:2.5:2.5:2.5 by volume). The eluate from the resin was collected in 
a Falcon tube and the resin was washed with TFA. TFA was removed under a stream of N2, 
and the peptide was triturated with cold diethyl ether. The peptide was purified by preparative 
RP-HPLC, and lyophilised to give the final product as a colourless amorphous solid. 
Resin storage 
If overnight storage was required before completion of the synthesis, the immobilised Fmoc-
protected peptide was washed (4 x MeOH) and suspended in MeOH for 10 min. The resin was 
drained and washed with diethyl ether (3 x), before drying by vacuum filtration and storage at 
-20 °C. The resin was swelled as before prior to continuation of peptide synthesis. 
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5.4 SAv catch-and-release methods 
5.4.1 Small molecule and peptide substrates 
SAv resin (0.2 mL settled resin, ≥ 17 nmol biotin binding capacity) was added to a 3 mL SPE 
tube fitted with a polyethylene frit and a tap. The resin was equilibrated with 2 CV buffer 
(phosphate buffer, 100 mM, pH 7.2) and the biotinylated aniline 33 (0.3 mL, 10 mM in 
DMSO:buffer, 10:90, 3 µmol) was added. The resin was agitated on a rotator at rt for 2 h and 
excess aniline was washed from the resin using buffer (~10 CV, the eluate was analysed by 
UHPLC until the aniline peak had disappeared). NaNO2 (21 mg, 304 µmol) was mixed with 
acetic acid solution (0.3 mL, 0.6 M) and added to the resin. The reaction mixture was agitated 
for 1 h at rt, and the resin was then washed with buffer (2 CV), before addition of the Tyr-
bearing substrate (0.3 mL, 1 mM, 300 nmol). The reaction mixture was agitated on a rotator 
for 18 h at rt. The resin was then washed with buffer (20 CV, the eluate was analysed by 
UHPLC until the substrate peak had disappeared). Freshly prepared Na2S2O4* (0.6 mL, 100 
mM. 60 µmol) was added to the resin and the mixture was agitated at rt for 18 h. The resin 
was drained and washed with buffer (5 CV) to release the modified substrate. The product was 
desalted using a C18 flash cartridge, with elution in MeOH. 
5.4.2 Myoglobin catch-and-release method 
SAv resin (0.2 mL settled resin, ≥ 17 nmol biotin binding capacity) was added to a 3 mL SPE 
tube fitted with a polyethylene frit and a tap. The resin was equilibrated with 2 CV buffer 
(phosphate buffer, 100 mM, pH 7.2) and the biotinylated aniline 33 (0.3 mL, 10 mM in 
DMSO:buffer, 10:90, 3 µmol) was added. The resin was agitated on a rotator at rt for 2 h and 
excess aniline was washed from the resin using buffer (~10 CV, the eluate was analysed by 
UHPLC until the aniline peak had disappeared). NaNO2 (21 mg, 304 µmol) was mixed with 
acetic acid solution (0.3 mL, 0.6 M) and added to the resin. The reaction mixture was agitated 
for 1 h at rt, and the resin was then washed with buffer (2 CV), before addition of Mb (0.3 mL, 
0.6 mM, 180 nmol). The reaction mixture was agitated on a rotator for 18 h at rt. The resin 
was then washed with buffer (20 CV, the eluate was analysed by UHPLC until the substrate 
peak had disappeared). Freshly prepared Na2S2O4 (0.6 mL, 100 mM. 60 µmol) was added to 
the resin and the mixture was agitated at rt for 18 h. The resin was drained and washed with 
buffer (5 CV) to release the modified substrate. The product was desalted using a size-
exclusion spin cartridge.  
                                                     
* Na2S2O4 has been reported to deteriorate in the presence of atmospheric H2O or in aqueous 
solution, 122 it was therefore stored in a desiccator and solutions were prepared immediately 
prior to use. 
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5.5 Affi-Gel catch-and-release methods 
5.5.1 Small molecule and peptide substrates 
Affi-gel 10 resin (1 mL settled resin in IPA) was added to a 5 mL SPE tube fitted with a 
polyethylene frit and a tap. p-Phenylenediamine (17 mg, 157 µmol) was dissolved in IPA (3 
mL) and added to the resin, which was then agitated on a rotator for 4 h at rt. The resin was 
washed with MeOH (5 CV), before addition of ethanolamine (10 µL, 166 µmol) in IPA (3 
mL) to block any remaining NHS-esters. The resin was agitated for 1 h at rt and washed with 
IPA (3 CV) and water (3 CV). NaNO2 (35 mg, 507 µmol) was mixed with acetic acid solution 
(3 mL, 0.6 M) and added to the resin. The reaction mixture was agitated for 1 h at rt, and then 
washed with buffer (2 CV phosphate buffer, 100 mM, pH 7.2), before addition of the Tyr-
bearing substrate (3 mL, 5 mM in buffer, 15 µmol). The reaction mixture was agitated for 18 
h at rt. The resin was drained and washed with buffer (10 CV, eluate was analysed by UHPLC 
until the substrate peak had disappeared). Na2S2O4 (3 mL, 300 mM) was added and the resin 
was mixed on a rotator for 18 h. The modified substrate was collected by draining and washing 
the resin (2 CV H2O), the product was desalted using a C18 flash cartridge, with elution in 
MeOH. 
5.5.2 Protein substrates 
Affi-gel 10 resin (1 mL settled resin in IPA) was added to a 5 mL SPE tube fitted with a 
polyethylene frit and a tap. An aromatic diamine (p-phenylenediamine, 3,5-diaminobenzoic 
acid or 5-(trifluoromethyl)-1,3-phenylenediamine, 150 µmol) was dissolved in DMSO:IPA (3 
mL, 10:90) and added to the resin, which was then agitated on a rotator for 4 h at rt. The resin 
was washed with MeOH (5 CV), before addition of ethanolamine (10 µL, 166 µmol) in IPA 
(3 mL) to block any remaining NHS-esters. The resin was agitated for 1 h at rt and washed 
with IPA (3 CV) and water (3 CV). NaNO2 (35 mg, 507 µmol) was mixed with acetic acid 
solution (3 mL, 0.6 M) and added to the resin. The reaction mixture was agitated for 1 h at rt, 
and then washed with buffer (2 CV phosphate buffer, 100 mM, pH 7.2), before addition of the 
protein substrate (3 mL, 1.95 mM in buffer, 5.85 µmol). The reaction mixture was agitated for 
18 h at rt. The resin was drained and washed with buffer (25 CV, eluate was analysed by 
UHPLC until the substrate peak had disappeared). Na2S2O4 (3 mL, 300 mM) was added and 
the resin was mixed on a rotator for 18 h. The modified substrate was collected by draining 
and washing the resin (1 CV buffer), the product was desalted using a MWCO spin cartridge. 
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5.6 Experimental procedures for Chapter 2 
Methyl (2S)-2-amino-3-(4-hydroxyphenyl)propanoate hydrochloride, 1  
MeOH (14 mL) was cooled to 0 °C in an ice bath and acetyl chloride 
(0.80 mL, 11.3 mmol) was added dropwise (gas evolved). The solution 
was stirred at 0 °C for 15 min, before portion-wise addition of L-
tyrosine (0.68 g, 3.77 mmol). The reaction mixture was allowed to 
warm to room temperature, then heated to reflux for 3 h. Solvent was removed in vacuo and 
the resultant solid was recrystallised from MeOH to give the methyl ester 1 as colourless 
needles (0.64 g, 74%). 
Rf (DCM:MeOH, 80:20) = 0.66; mp 185-187 °C, MeOH, lit.167 188-189 °C, MeOH; [α]D = -
6.0 (c 0.50, H2O) lit.167 -5.2 (c 2.40, H2O); IR (neat, cm-1) 3335 (OH), 1742 (C=O) 1614 (C=C), 
1591 (C=C), 1514 (C=C); 1H NMR δ (500 MHz, CD3OD) 7.09 (2H, d, J = 8.5 Hz, ArH), 6.81 
(2H, d, J = 8.5 Hz, ArH), 4.26 (1H, dd, J = 7.5, 5.9 Hz, NH2CH), 3.84 (3H, s, CO2CH3), 3.19 
(1H, dd, J = 14.5, 5.9 Hz, CHAHB), 3.09 (1H, dd, J = 14.5, 7.5 Hz, CHAHB); 13C NMR δ (126 
MHz, CD3OD) 169.2 (CO), 157.1 (ArC), 130.1 (2ArCH), 124.2 (ArC), 115.5 (2ArCH), 54.0 
(CH), 52.2 (CH3), 35.3 (CH2); m/z (ESI+, MeCN/H2O) 218 ([M+Na]+, 30%), 196 ([M+H]+, 
100), 179 ([M-OH+H]+, 80), 136 ([M-CO2CH3]+, 50). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.167  
Methyl (2S)-2-acetamido-3-(4-hydroxyphenyl)propanoate, 2  
The ammonium salt 1 (1.75 g, 7.56 mmol) was dissolved in water (10 
mL) and cooled to 0 °C in an ice bath. NaOAc (15.1 mL, 75.5 mmol; 5 
M aq.) was added to the reaction mixture, followed by acetic anhydride 
(1.07 mL, 11.3 mmol). The reaction was monitored by TLC until judged 
to have reached completion (30 min) by which time a white precipitate had formed. The 
reaction mixture was filtered, the precipitate was washed with diethyl ether (2 × 20 mL) and 
dried in vacuo to give the acetamide 2 as a colourless solid (1.73 g, 97%).  
Rf (DCM:MeOH, 80:20) = 0.76; mp 130-132 °C, lit.168 136-137 °C; [α]D = +32.0 (c 1.00, 
MeOH) lit.168 +29.7 (c 0.41, MeOH); IR (neat, cm-1) 3547 (NH), 3319 (OH), 1728 (C=O), 
1657 (C=O), 1614 (C=C), 1545 (C=C), 1514 (C=C); 1H NMR δ (500 MHz, CD3OD) 7.03 
(2H, d, J = 8.5 Hz, 2ArH), 6.72 (2H, d, J = 8.5 Hz, 2ArH), 4.60 (1H, dd, J = 8.6, 5.9 Hz, 
NHCH),  3.70 (3H, s, CO2CH3), 3.05 (1H, dd, J = 13.9, 5.9, CHAHB), 2.87 (1H, dd, J = 13.9, 
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8.6 Hz, CHAHB), 1.93 (3H, s, CH3CO); 13C NMR δ (126 MHz, CD3OD) 172.3 (CO), 171.8 
(CO), 156.0 (ArC), 129.8 (2ArCH), 127.4 (ArC), 114.8 (2ArCH), 54.2 (CH), 51.2 (OCH3), 
36.3 (CH2), 20.8 (CH3); m/z (ESI+, MeCN/H2O) 260 ([M+Na]+, 100%), 238 ([M+H]+, 5). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.168 
Methyl (2S)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoate hydrochloride, 3  
 MeOH (7 mL) was cooled to 0 °C in an ice bath and acetyl chloride 
(0.190 mL, 2.67 mmol) was added dropwise (gas evolved). The 
solution was stirred at 0 °C for 15 min, before portion-wise addition of 
3-nitro-L-tyrosine (0.200 g, 0.884 mmol). The reaction mixture was 
allowed to warm to room temperature, then heated to reflux for 3 h. Solvent was removed in 
vacuo and the resultant solid was recrystallised from MeOH to give the methyl ester 3 as 
yellow needles (0.180 g, 75%). 
Rf (DCM:MeOH, 90:10) = 0.67; mp 191-193 °C, MeOH, lit.169 195-197 °C, MeOH; [α]D = 
+10.0 (c 1.00, MeOH), lit.169 +8.6 (c 0.80, MeOH); IR (neat, cm-1) 3192 (OH), 1740 (C=O), 
1636 (C=C), 1587 (C=C), 1541 (NO); 1H NMR δ (500 MHz, CD3OD) 8.03 (1H, d, J = 2.3 
Hz, ArH), 7.54 (1H, dd, J = 8.6, 2.3 Hz, ArH), 7.20 (1H, d, J = 8.6 Hz, ArH), 4.39 (1H, dd, J 
= 7.3, 6.1 Hz, NH2CH), 3.86 (3H, s, CO2CH3), 3.33-3.28 (1H, m, CHAHB), 3.21 (1H, dd, J = 
14.7, 7.3 Hz, CHAHB); 13C NMR δ (126 MHz, CD3OD) 168.8 (CO), 153.6 (ArC), 137.5 
(ArCH), 134.5 (ArC), 125.9 (ArC), 125.6 (ArCH), 120.4 (ArCH), 55.4 (CH), 52.4 (CH3), 34.6 
(CH2); m/z (ESI+, MeCN/H2O) 241 ([M+H]+, 50%), 181 ([M-CO2CH3]+, 100). 
1H and 13C NMR spectroscopic data are in good agreement with the literature.169 
Methyl (2S)-2-acetamido-3-(4-hydroxy-3-nitrophenyl)propanoate, 4  
The ammonium salt 3 (0.10 g, 0.36 mmol), was dissolved in H2O (1 mL) 
and cooled to 0 °C in an ice bath. NaOAc (0.72 mL, 3.6 mmol; 5 M, aq.) 
was added, before dropwise addition of acetic anhydride (0.05 mL, 0.53 
mmol). The reaction was monitored by TLC until judged to have reached 
completion (~30 min). The aqueous mixture was extracted with DCM (3 × 5 mL), the 
combined organics were dried and solvent was removed in vacuo. Purification was performed 
by column chromatography (dry loaded, EtOAc:Hexane, 67:33) to give the protected amino 
acid derivative 4 as a yellow oil (69 mg, 68%). 
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Rf (EtOAc:Hexane, 67:33) = 0.32; [α]D = +12.4 (c 0.10, DMSO); IR (neat, cm-1) 3285 (OH), 
1742 (C=O), 1634 (C=O), 1535 (NO); 1H NMR δ (500 MHz, CDCl3) 10.50 (1H, s, OH), 7.87 
(1H, d, J = 2.2 Hz, ArH), 7.37 (1H, dd, J = 8.6, 2.2 Hz, ArH), 7.12 (1H, d, J = 8.6 Hz, ArH), 
6.03 (1H, d, J = 7.4 Hz, CONH), 4.89 (1H, dt, J = 7.4, 5.7 Hz, CH), 3.79 (3H, s, CO2CH3), 
3.22 (1H, dd, J = 14.1, 5.8 Hz, CHAHB), 3.09 (1H, dd, J = 14.1, 5.5 Hz, CHAHB), 2.04 (3H, s, 
CH3CO); 13C NMR δ (126 MHz, CDCl3) 171.6 (CO), 169.7 (CO), 154.2 (ArC), 138.6 (ArCH), 
133.4 (ArC), 128.5 (ArC), 125.2 (ArCH), 120.2 (ArCH), 53.1 (CH), 52.7 (OCH3), 36.8 (CH2), 
23.2 (CH3); m/z (ESI+, MeCN/H2O) 283 ([M+H]+, 100%). 
1H and 13C NMR spectroscopic data are in good agreement with the literature.170  
Methyl (2S)-3-(3-amino-4-hydroxyphenyl)-2-acetamidopropanoate, 5  
Method 1: Nitrotyrosine derivative 4 (283 mg, 1.00 mmol) was 
dissolved in EtOH (3.8 mL) and water (0.2 mL). Iron powder (168 mg, 
3.00 mmol) and anhydrous CaCl2 (111 mg, 1.00 mmol) were added and 
the reaction mixture was heated to 60 °C for ~1 h. Iron was removed by 
filtration and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (dry loaded, DCM:MeOH, 95:5) to give the aminotyrosine derivative 5 as a 
brown oil (156 mg, 62%). 
Method 2: Nitrotyrosine derivative 4 (220 mg, 0.779 mmol) was dissolved in DCM (7 mL) 
and 10% Pd/C (8 mg) was added. The reaction was stirred under a H2 atmosphere for 48 h, 
with monitoring by TLC. The reaction mixture was filtered through celite, which was washed 
with EtOAc. The eluate was concentrated in vacuo and the product was purified by column 
chromatography (dry-loaded, DCM:MeOH, 95:5) to give the aminotyrosine derivative 5 as a 
brown oil (51 mg, 23%). 
Method 3: Nitrotyrosine derivative 4 (2.136 g, 7.57 mmol) was dissolved in water (80 mL) 
and Na2S2O4 (18.2 g, 88.9 mmol) was added. The reaction mixture was stirred at rt for 90 min 
and monitored by TLC. The aqueous mixture was lyophilised, then redissolved in MeOH and 
filtered to remove the salt. The eluate was concentrated in vacuo and purified by column 
chromatography (dry-loaded, DCM:MeOH, 95:5) to give the aminotyrosine derivative 5 as a 
brown oil (1.317 g, 69%). 
Rf (DCM:MeOH, 90:10) = 0.46; [α]D = +46.7 (c 0.30, DMSO); IR (neat, cm-1) 3291-3177 
(NH,OH), 1734 (C=O), 1649 (C=O); 1H NMR δ (500 MHz, CD3OD) 6.63 (1H, d, J = 8.0 Hz, 
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ArH), 6.61 (1H, d, J = 2.1 Hz, ArH), 6.43 (1H, dd, J = 8.0, 2.1 Hz, ArH), 4.59 (1H, dd, J = 
8.4, 5.9 Hz, CH), 3.69 (3H, s, CO2CH3), 2.96 (1H, dd, J = 13.9, 5.9 Hz, CHAHB), 2.81 (1H, dd, 
J = 13.9, 8.4 Hz, CHAHB), 1.94 (3H, s, CH3); 13C NMR δ (126 MHz, CD3OD) 172.5 (CO), 
171.8 (CO), 144.1 (ArC), 134.9 (ArC), 128.0 (ArC), 119.2 (ArCH), 116.7 (ArCH), 114.1 
(ArCH), 54.3 (CH), 51.2 (OCH3), 36.6 (CH2), 20.9 (CH3); HRMS (ESI+, MeCN/H2O) 
[M+H]+ found 253.1180, C12H17N2O4 requires 253.1183. 
Ac-Tyr-Gly-Gly-Phe-Leu-NH2, 6  
Ac-Leu-enkephalin-NH2 6 was synthesised 
by solid phase peptide synthesis, according to 
the method described in Section 5.3. The 
lyophilised peptide, was a colourless 
amorphous solid (96% purity by RP-HPLC at 
210 nm, 56% isolated yield). 
Rt (RP-HPLC, H2O:MeCN, Method 1) = 10.04 min; 1H NMR δ (500 MHz, DMSO-d6) 9.14 
(1H, s, Tyr(ArOH)), 8.21 (1H, t, J = 5.7 Hz, Gly(NH)), 8.07-8.01 (2H, m, Tyr(NH), Phe(NH)), 
7.98-7.91 (2H, m, Gly(NH), Leu(NH)), 7.27-7.23 (4H, m, Phe(ArH)), 7.21-7.15 (1H, m, 
Phe(ArH)), 7.07 (1H, s, CONHAHB), 7.02 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 6.95 (1H, s, 
CONHAHB), 6.64 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 4.51 (1H, td, J = 9.3, 4.6 Hz, Phe(α-CH)), 
4.40 (1H, ddd, J = 9.8, 8.0, 4.5 Hz, Tyr(α-CH)), 4.23-4.18 (1H, m, Leu(α-CH)), 3.74-3.70 (2H, 
m, Gly(α-CHAHB), Gly(α-CHAHB)), 3.68-3.60 (2H, m, Gly(α-CHAHB), Gly(α-CHAHB)), 3.04 
(1H, dd, J = 13.8, 4.6 Hz, Phe(CHAHB)), 2.91 (1H, dd, J = 13.9, 4.5 Hz, Tyr(CHAHB)), 2.80 
(1H, dd, J = 13.8, 9.3 Hz, Phe(CHAHB)), 2.64 (1H, dd, J = 13.9, 9.8 Hz, Tyr(CHAHB)), 1.77 
(3H, s, CH3CONH), 1.63-1.52 (1H, m, Leu(γ-CH)), 1.49-1.46 (2H, m, Leu(β-CH2)), 0.89 (3H, 
d, J = 6.6 Hz, Leu(CH3)), 0.84 (3H, d, J = 6.5 Hz, Leu(CH3)); 13C NMR δ (126 MHz, DMSO-
d6) 174.4 (CO), 172.5 (CO), 171.1 (CO), 169.8 (CO), 169.6 (CO), 169.1 (CO), 156.2 (ArC), 
138.2 (ArC), 130.5 (2ArCH), 129.7 (2ArCH), 128.6 (ArC), 128.5 (2ArCH), 126.7 (ArCH), 
115.3 (2ArCH), 55.0 (CH), 54.5 (CH), 51.5 (CH), 42.6 (CH2), 42.4 (CH2), 41.3 (CH2), 37.8 
(CH2), 37.1 (CH2), 24.7 (CH), 23.5 (CH3), 23.0 (CH3), 22.1 (CH3); HRMS (ESI+, MeCN/H20) 
[M+H]+ found 597.3034 C30H41N6O7 requires 597.3031. 
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4-[(E)-2-{5-[(2S)-2-Acetamido-3-methoxy-3-oxopropyl]-2-hydroxyphenyl}diazen-1-
yl]benzoic acid, 7  
4-Aminobenzoic acid (74.0 mg, 0.540 mmol) was 
dissolved in HCl (0.07 mL; conc.) and H2O (1.5 mL) and 
cooled to 0 °C in an ice bath. NaNO2 (61.0 mg, 0.884 mmol) 
in H2O (0.5 mL) was added to the reaction mixture and 
stirred for 20 min whereupon a pale yellow colour developed. Tyrosine derivative 2 (100 mg, 
0.421 mmol), NaOH (15.0 mg, 0.378 mmol) and K2CO3 (76.0 mg, 0.547 mmol) were added 
and the reaction mixture was allowed to warm to room temperature. The reaction was 
monitored by TLC until judged to have reached completion (~1 h). HCl (1 mL; 1 M, aq.) was 
added and the product was removed by filtration. The resultant solids were purified by column 
chromatography (dry loaded, DCM:MeOH:acetic acid, 90:5:5) to give the azobenzene 
derivative 7 as an orange solid (88.0 mg, 42%).  
Rf (DCM:MeOH, 90:10) = 0.28; mp 239‒241 °C; IR (neat, cm-1) 3254 (OH), 1734 (CO), 1684 
(CO), 1653 (CO), 1593 (C=C), 1541 (C=C); 1H NMR δ (500 MHz, CD3OD) 8.23 (2H, d, J = 
8.1 Hz, ArH), 8.03 (2H, d, J = 8.1 Hz, ArH), 7.82 (1H, d, J = 2.3 Hz, ArH), 7.32 (1H, dd, J = 
8.5, 2.3 Hz, ArH), 7.01 (1H, d, J = 8.5 Hz, ArH), 4.77-4.70 (1H, m, CH), 3.74 (3H, s, OCH3), 
3.22 (1H, dd, J = 14.0, 5.7 Hz, CHAHB), 3.03 (1H, dd, J = 14.0, 8.8 Hz, CHAHB), 1.95 (3H, s, 
CH3CONH); 13C NMR δ (126 MHz, CD3OD) 172.1 (CO), 171.8 (CO), 153.8 (CO), 153.8 
(ArC), 153.4 (ArC), 152.3 (ArC), 137.7 (ArC), 134.8 (ArCH), 130.7 (2ArCH), 130.1 (ArCH), 
128.8 (ArC), 121.9 (2ArCH), 117.9 (ArCH), 53.9 (CH), 51.4 (OCH3), 36.0 (CH2), 20.9 (CH3); 
HRMS (ESI+, MeCN/H2O) [M+H]+ found 386.1353, C19H20N3O6 requires 386.1347. 
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4-[(E)-2-(4-Hydroxyphenyl)diazen-1-yl]benzoic acid, 8  
4-Aminobenzoic acid (123 mg, 0.900 mmol) was dissolved in 
HCl (0.12 mL; conc.) and water (2.4 mL) and cooled to 0 °C. 
Sodium nitrite (104 mg, 1.50 mmol) was dissolved in water (0.5 
mL) and added to the reaction mixture. The mixture was stirred 
for 20 min whereupon a pale yellow colour developed. A mixture of phenol (67 mg, 0.720 
mmol), NaOH (26 mg, 0.642 mmol) and K2CO3 (133 mg, 0.960 mmol) in water (2 mL) was 
added dropwise. The reaction mixture was allowed to warm to room temperature and stirred 
for 4 h. The reaction mixture was next acidified with HCl (~2 mL; 1 M, aq.) and the product 
was removed by filtration. The resultant solids were purified by column chromatography (dry 
loaded, DCM:MeOH, 90:10) to give the azobenzene derivative 8 as an orange solid (144 mg, 
83%).  
Rf (DCM:MeOH, 95:5) = 0.25; mp 276-279 °C, lit.66 275-277 °C; IR (neat, cm-1) 3231 (OH), 
1678 (C=O); 1H NMR δ (500 MHz, CD3OD) 8.18 (2H, d, J = 8.6 Hz, ArH), 7.91 (2H, d, J = 
8.6 Hz, ArH), 7.89 (2H, d, J = 8.9 Hz, ArH) 6.96 (2H, d, J = 8.9 Hz, ArH); 13C NMR (126 
MHz, CD3OD) 161.5 (CO), 155.4 (ArC), 146.2 (ArC), 132.9 (ArC), 131.9 (ArC), 130.4 
(2ArCH), 125.0 (2ArCH), 121.8 (2ArCH), 115.5 (2ArCH); m/z (ESI+, MeCN/H2O) 243 
([M+H]+, 100%). 
1H and 13C NMR spectroscopic data are in good agreement with the literature.66 
Methyl (2S)-3-{3-[(E)-2-{4-[(2-{5-[(3aS,4S,6aR)-1-nitroso-2-oxo-hexahydro-1H-thieno[3,4-
d]imidazolidin-4-yl]pentanamido}ethyl)carbamoyl]phenyl}diazen-1-yl]-4-hydroxyphenyl}-
2-acetamidopropanoate, 13 
 Boc-protected aniline 32 
(70.0 mg, 0.138 mmol) was 
dissolved in DCM (2 mL) 
and TFA (0.150 mL, 1.96 
mmol) was added. The 
reaction was stirred at room temperature and monitored by TLC until judged to have reached 
completion (~18 h). Solvent was removed in vacuo, and the residue was redissolved in HCl 
(0.3 mL; 6 N, aq.) and cooled to 0 °C in an ice bath. NaNO2 (24.0 mg, 0.345 mmol) was added 
and the reaction mixture was stirred for 20 min as a pale yellow colour developed. Tyrosine 
derivative 2 (16 mg, 0.067 mmol) was dissolved in NaHCO3 (2 mL; sat. aq.) and cooled to 0 
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°C. The diazonium salt mixture was added dropwise to the tyrosine-containing mixture and 
the reaction mixture was maintained at >pH 7 by addition of solid NaHCO3, with monitoring 
by pH paper. The reaction mixture was allowed to reach room temperature and monitored by 
TLC until judged to have reached completion (~15 min). The reaction mixture was acidified 
with HCl (4 mL; 1 M, aq.) and extracted with EtOAc (3 × 5 mL). The combined organics were 
dried and concentrated in vacuo. Purification was performed by column chromatography (dry-
loaded, DCM:MeOH, 90:10) to give the azobenzene derivative 13 as an orange solid (28 mg, 
64%). 
Rf (DCM:MeOH, 90:10) = 0.34; mp 178-181 °C; [α]D = +115.0 (c 0.20, DMSO); IR (neat, 
cm-1) 3277 (OH), 1744 (CO), 1643 (CO), 1535 (C=C); 1H NMR δ (500 MHz, DMSO-d6) 
10.92 (1H, s, OH), 8.80 (1H, s, Biotin-NH), 8.66 (1H, t, J = 5.5 Hz, NHCO), 8.36 (1H, d, J = 
7.8 Hz, CH3CONH), 8.09-8.01 (4H, m, ArH), 7.96 (1H, t, J = 5.7 Hz, CONH), 7.61 (1H, d, J 
= 2.1 Hz, ArH), 7.32 (1H, dd, J = 8.4, 2.1 Hz, ArH), 7.02 (1H, d,  J = 8.4 Hz, ArH), 4.82 (1H, 
t, J = 6.3 Hz, CHCH2S), 4.47 (1H, td, J = 8.0, 5.7 Hz, CHCO2CH3), 4.25 (1H, dd, J = 6.8, 4.5 
Hz, CHCHS), 3.62 (3H, s, OCH3), 3.37-3.33 (2H, m, CH2), 3.26 (2H, dd, J = 12.4, 6.2 Hz, 
CONHCH2), 3.22-3.15 (1H, m, CHS), 3.02 (1H, dd, J = 13.8, 5.7 Hz, ArCHAHB), 2.95 (1H, 
dd, J = 13.3, 5.8 Hz, CHXHYS), 2.89 (1H, dd, J = 13.8, 9.2, ArCHAHB), 2.67 (1H, d, J = 13.3 
Hz, CHXHYS), 2.10 (2H, t, J = 7.0 Hz, CH2CONH), 1.81 (3H, s, CH3CONH), 1.75-1.64 (1H, 
m, SCHCHMHN), 1.62-1.44 (3H, m, SCHCHMHN, CH2), 1.42-1.21 (2H, m, CH2); 13C NMR δ 
(126 MHz, DMSO-d6) 172.8 (CO), 172.6 (CO), 169.8 (CO), 166.1 (CO), 154.4 (CO), 154.2 
(ArC), 153.5 (ArC), 138.7 (ArC), 136.8 (ArC), 135.5 (ArCH), 129.2 (ArC), 128.9 (2ArCH), 
122.9 (2ArCH), 122.6 (ArCH), 118.7 (ArCH), 60.0 (CH), 59.0 (CH), 54.4 (CH), 54.1 (CH), 
52.3 (OCH3), 39.9 (CH2), 38.7 (CH2), 36.3 (CH2), 35.7 (CH2), 35.0 (CH2), 28.7 (CH2), 28.1 
(CH2), 25.6 (CH2), 22.7 (CH3); HRMS (ESI+, MeCN/H2O) [M+H]+ found 683.2605, 
C31H39N8O8S requires 683.2606.  
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5-[(3aS,4S,6aR)-1-Nitroso-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]-N-[2-({4-
[(E)-2-(4-hydroxyphenyl)diazen-1-yl]phenyl}formamido)ethyl]pentanamide, 14 
Boc-protected aniline 32 (70.0 
mg, 0.138 mmol) was dissolved 
in DCM (2 mL) at room 
temperature. TFA (0.15 mL, 1.96 
mmol) was added and the reaction was monitored by TLC until judged to have reached 
completion (~18 h). Solvent was removed in vacuo before addition of HCl (0.3 mL; 6 N, aq.) 
and the reaction mixture was cooled to 0 °C in an ice bath. NaNO2 (24.0 mg, 0.345 mmol) was 
added and the reaction mixture was stirred for 20 min as a pale yellow colour developed. 
Phenol (6.0 mg, 0.064 mmol) was dissolved in NaHCO3 (2 mL; sat. aq.) and cooled to 0 °C. 
The diazonium salt mixture was added dropwise to the phenol-containing solution and the 
reaction mixture was maintained at >pH 7 by addition of solid NaHCO3, with monitoring by 
pH paper. Once addition was complete, the reaction mixture was allowed to reach room 
temperature and was monitored by TLC until completion (~15 min). The reaction mixture was 
acidified by addition of HCl (4 mL; 1 M, aq.) and extracted with EtOAc (3 × 5 mL). The 
combined organics were dried and concentrated in vacuo. Purification was performed by 
column chromatography (dry-loaded, DCM:MeOH, 95:5) to give the azobenzene derivative 
14 as an orange solid (10.0 mg, 31%). 
Rf (DCM:MeOH, 95:5) = 0.26; mp 174-176 °C; IR (neat, cm-1) 3294 (OH), 1749 (C=O), 1634 
(C=O), 1589 (C=C), 1539 (C=C); 1H NMR δ (500 MHz, DMSO-d6) 10.40 (1H, br s, OH), 
8.80 (1H, s, Biotin-NH), 8.63 (1H, t, J = 5.6 Hz, NHCO), 8.02 (2H, d, J = 8.6 Hz, 2ArH), 7.96 
(1H, t, J = 5.7 Hz, CONH), 7.87 (2H, d, J = 8.6 Hz, 2ArH), 7.84 (2H, d, J = 8.8 Hz, 2ArH), 
6.97 (2H, d, J = 8.8 Hz, 2ArH), 4.82 (1H, ddd, J = 7.1, 5.9, 0.9 Hz, CHCH2S), 4.24 (1H, dd, J 
= 7.1, 4.3 Hz, CHCHS), 3.37-3.31 (2H, m, CH2), 3.26 (2H, dt, J = 6.9, 6.4 Hz, CONHCH2), 
3.20-3.15 (1H, m, CHS), 2.94 (1H, dd, J = 13.3, 5.9 Hz, CHAHBS), 2.67 (1H, d, J = 13.3 Hz, 
CHAHBS), 2.11 (2H, t, J = 7.4 Hz, CH2CO), 1.75-1.64 (1H, m, SCHCHXHY), 1.62-1.45 (3H, 
m, SCHCHXHY, CH2), 1.42-1.12 (2H, m, CH2); 13C NMR δ (126 MHz, DMSO-d6) 172.9 (CO), 
166.2 (CO), 161.9 (CO), 154.2 (ArC), 154.0 (ArC), 145.8 (ArC), 136.2 (ArC), 128.9 (2ArCH), 
125.6 (2ArCH), 122.3 (2ArCH), 116.5 (2ArCH), 60.0 (CH), 59.0 (CH), 54.4 (CH), 39.9 (CH2), 
38.7 (CH2), 35.7 (CH2), 35.0 (CH2), 28.6 (CH2), 28.1 (CH2), 25.6 (CH2); HRMS (ESI+, 
MeCN/H2O) [M+H]+ found 540.2043, C25H30N7O5S requires 540.2029. 
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Methyl (2S)-3-(3-azido-4-hydroxyphenyl)-2-acetamidopropanoate, 15  
3-Aminotyrosine derivative 5 (88 mg, 0.35 mmol) was dissolved in HCl 
(1.2 mL; 0.5 N, aq.) and cooled to 0 °C in an ice bath in the dark. A 
solution of NaNO2 (36 mg, 0.52 mmol) in water (0.4 mL) was added 
dropwise and the mixture was stirred for 10 min. A solution of NaN3 (57 
mg, 0.88 mmol) in water (0.4 mL) was added and the reaction mixture was stirred at 0 °C and 
monitored by TLC until judged to have reached completion (~6 h). The desired product was 
extracted in CHCl3 (3 × 5 mL) and solvent was removed in vacuo. Purification was performed 
by column chromatography (dry-loaded, EtOAc:hexane, 3:1) to give the 3-azidotyrosine 
derivative 15 as a brown oil (56 mg, 67%). 
Rf (DCM:MeOH, 95:5) = 0.26; IR (neat, cm-1) 3265 (OH), 2112 (N3), 1732 (C=O), 1651 
(C=O), 1512 (C=C); 1H NMR δ (500 MHz, CD3OD) 6.84 (1H, dd, J = 8.2, 2.0 Hz, ArH), 6.82 
(1H, d, J = 2.0 Hz, ArH), 6.77 (1H, d, J = 8.2 Hz, ArH), 4.62 (1H, dd, J = 8.7, 5.7 Hz, CH), 
3.71 (3H, s, OCH3), 3.05 (1H, dd, J = 14.0, 5.7 Hz, CHAHB), 2.86 (1H, dd, J = 14.0, 8.7 Hz, 
CHAHB), 1.94 (3H, s, CH3CONH); 13C NMR δ (126 MHz, CD3OD) 172.1 (CO), 171.7 (CO), 
148.7 (ArC), 128.7 (ArC), 126.3 (ArC), 126.2 (ArCH), 120.6 (ArCH), 116.0 (ArCH), 54.0 
(CH), 51.3 (OCH3), 36.1 (CH2), 20.9 (CH3); m/z (ESI+, MeCN/H2O) 301 ([M+Na]+, 3%), 282 
([M-N3+CO2H+H]+, 100), 279 ([M+H]+, 1).  
Methyl 1-{5-[(2S)-2-acetamido-3-methoxy-3-oxopropyl]-2-hydroxyphenyl}-1H-1,2,3-
triazole-4-carboxylate, 16 
Azide 15 (66 mg, 24 μmol) was dissolved in t-amyl alcohol (1.4 
mL) and water (0.7 mL). CuSO4∙5H2O (6.0 mg, 24 μmol) and 
sodium ascorbate (9.5 mg, 48 μmol) were added and the reaction 
mixture was stirred at room temperature for 30 min. Methyl 
propiolate (24 μl, 270 μmol) was added and the reaction was stirred for 16 h. Solvent was 
removed in vacuo and purification was performed by column chromatography (DCM:MeOH, 
95:5) to give the triazole 16 (76 mg, 89%).  
Rf (EtOAc:Hexane, 4:1) = 0.22; IR (neat, cm-1) 3543 (OH), 1734 (C=O), 1719 (C=O), 1638 
(C=O), 1533 (C=C), 1518 (C=C); 1H NMR δ (500 MHz, CDCl3) 9.60 (1H, s, OH), 8.81 (1H, 
s, triazole-CH), 7.57 (1H, d, J = 2.1 Hz, ArH), 7.13 (1H, dd, J = 8.4, 2.1 Hz, ArH), 7.04 (1H, 
d, J = 8.4 Hz, ArH), 6.53 (1H, d, J = 8.3 Hz, CONH), 4.97-4.93 (1H, m, CONHCH), 4.00 (3H, 
s, triazole-CO2CH3), 3.80 (3H, s, CO2CH3), 3.23 (1H, dd, J = 14.1, 5.2 Hz, CHAHB), 3.00 (1H, 
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dd, J = 14.1, 7.7 Hz, CHAHB), 2.03 (3H, s, CH3CONH); 13C NMR δ (500 MHz, CDCl3) 171.9 
(CO), 170.8 (CO), 161.2 (CO), 147.7 (ArC), 139.5 (ArC), 130.9 (ArCH), 128.4 (ArC), 127.8 
(triazole-CH), 123.2 (ArCH), 123.1 (ArC), 118.6 (ArCH), 53.3 (CH), 52.7 (OCH3), 52.4 
(OCH3), 37.4 (CH2), 23.0 (CH3CONH); HRMS (ESI+, MeCN/H2O) [M+H]+ found 363.1305, 
C16H19N4O6 requires 363.1299. 
5-(Dimethylamino)-N-(prop-2-yn-1-yl)naphthalene-1-sulphonamide, 17 
Dansyl chloride (0.10 g, 0.37 mmol) was dissolved in DCM (1 mL) 
and stirred at 0 °C in the dark. NEt3 (52 μl, 1.1 mmol) and 
propargylamine (72 μl, 1.1 mmol) were added and the reaction 
mixture was stirred at 0 °C for 1 h. Solvent was removed in vacuo and purification was 
performed by column chromatography (diethyl ether:hexane, 1:1) to give the alkyne 17 as a 
yellow solid (83 mg, 77%). 
Rf (Et2O:Hexane, 1:1) = 0.39; mp 89-91 °C, lit.171 93-95 °C; IR (neat, cm-1) 3285 (NH), 1670 
(C=C), 1574 (C=C); 1H NMR δ (500 MHz, CDCl3) 8.59 (1H, ddd, J = 8.5, 1.2, 1.0 Hz, ArH), 
8.33-8.25 (2H, m, ArH), 7.61 (1H, dd, J = 8.6, 7.6 Hz, ArH), 7.55 (1H, dd, J = 8.5, 7.3 Hz, 
ArH), 7.22 (1H, dd, J = 7.6, 0.9 Hz, ArH), 4.79 (1H, t, J = 6.0 Hz, SO2NH), 3.80 (2H, dd, J = 
6.1, 2.6 Hz, CH2C≡CH), 2.92 (6H, s, N(CH3)2), 1.94 (1H, t, J = 2.5 Hz, C≡H); 13C NMR δ 
(126 MHz, CDCl3) 152.1 (ArC), 134.2 (ArC), 130.9 (ArCH), 130.0 (ArCH), 129.9 (ArC), 
129.8 (ArC), 128.6 (ArCH), 123.2 (ArCH), 118.5 (ArCH), 115.3 (ArCH), 77.8 (C), 72.7 (CH), 
45.4 (2CH3), 33.1 (CH2); m/z (ESI+, MeCN/H2O) 289 ([M+H]+, 100%). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.171 
Methyl (2S)-3-(3-{4-[5-(dimethylamino)naphthalene-1-sulfonamidomethyl]-1H-1,2,3-
triazol-1-yl}-4-hydroxyphenyl)-2-acetamidopropanoate, 18 
3-Azidotyrosine derivative 15 (50 mg, 0.18 mmol) 
was dissolved in t-amyl alcohol (1.4 mL) and water 
(0.7 mL) and stirred at room temperature in the dark. 
CuSO4∙5H2O (4.5 mg, 0.018 mmol) and sodium 
ascorbate (7.5 mg, 0.038 mmol) were added and the reaction mixture was stirred for 20 min. 
Dansyl alkyne 17 (62 mg, 0.22 mmol) was added and the reaction mixture was stirred at room 
temperature for 18 h. The desired product was extracted in DCM (3 × 5 mL), dried and purified 
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by column chromatography (dry-loaded, DCM:MeOH, 95:5) to give the triazole 18 as a yellow 
oil (85 mg, 83%). 
Rf (DCM:MeOH, 95:5) = 0.38; IR (neat, cm-1) 3071 (OH), 1740 (C=O), 1657 (C=O), 1517 
(C=C); 1H NMR δ (500 MHz, DMSO-d6) 10.36 (1H, s, OH), 8.50 (1H, t, J = 6.0 Hz, NHSO2), 
8.42 (1H, d, J = 8.5 Hz, ArH), 8.35-8.28 (2H, m, CONH, ArH), 8.13 (1H, dd, J = 7.3, 1.2 Hz, 
ArH), 7.97 (1H, s, triazole-CH), 7.60-7.56 (2H, m, ArH), 7.35 (1H, d, J = 2.2 Hz, Tyr(ArH)), 
7.22 (1H, dd, J = 7.6, 0.9 Hz, ArH), 7.16 (1H, dd, J = 8.4, 2.2 Hz, Tyr(ArH)), 6.99 (1H, d, J = 
8.4 Hz, Tyr(ArH)), 4.44 (1H, ddd, J = 9.1, 7.7, 5.6 Hz, Tyr(α-CH)), 4.21 (2H, d, J = 5.8 Hz, 
CH2NHSO2), 3.62 (3H, s, OCH3), 2.99 (1H, dd, J = 13.8, 5.6 Hz, CHAHB), 2.86 (1H, dd, J = 
13.8, 9.1 Hz, CHAHB), 2.77 (6H, s, N(CH3)2), 1.82 (3H, s, CH3CONH); 13C NMR δ (500 MHz, 
CDCl3) 172.6 (CO), 169.8 (CO), 151.8 (ArC), 148.2 (ArC), 143.8 (ArC), 136.5 (ArC), 130.8 
(ArCH), 129.9 (ArCH), 129.5 (ArC), 129.5 (ArC), 128.9 (ArC), 128.8 (ArCH), 128.3 (ArCH), 
125.5 (ArCH), 124.8 (triazole-CH), 124.4 (ArC), 124.0 (ArCH), 119.6 (ArCH), 117.4 (ArCH), 
115.5 (ArCH), 54.2 (CH), 52.3 (CH3), 45.5 (2CH3), 38.3 (CH2), 36.2 (CH2), 22.7 (CH3); 
HRMS (ESI+, MeCN/H2O) [M+H]+ found 567.2025, C27H31N6O6S requires 567.2020. 
2‐hydroxy‐5‐methyl‐4‐[(4‐methylphenyl)imino]cyclohexa‐2,5‐dien‐1‐one, 24 
2-Amino-4-methylphenol (12.4 mg, 0.1 mmol) in MeCN (200 µL) and 
4-methylaniline (10.7 mg, 0.1 mmol) in MeCN (200 µL) were added to 
phosphate buffer (90 mL, 10 mM, pH 6.5). K3FeCN6 (330 mg, 1 mmol) 
was added in H2O (10 mL) and the reaction mixture was stirred at rt for 30 min, with analysis 
by HPLC. The reaction mixture was lyophilised and then redissolved in CHCl3 and filtered to 
remove the Fe species. The product was purified by preparative RP-HPLC (System 4) using 
an isocratic solvent system (H2O + 0.1% TFA: MeCN + 0.1% TFA, 56:44). The collected 
fractions were lyophilised to give the oxidative coupling product 24 as a red/brown amorphous 
solid. 
Rt (HPLC, Method 1): 10.29 min (dimer by-product at 10.02 min); 1H NMR δ (500 MHz, 
DMSO-d6) δ 8.57 (1H, br s, OH), 6.93 – 6.87 (2H, m, 2ArH), 6.57 – 6.56 (2H, m, 2ArH), 6.56 
– 6.52 (2H, m, 2ArH), 2.16 (3H, s, CH3), 1.97 (3H, s, CH3); 13C NMR δ (126 MHz, DMSO-
d6) 145.2 (ArC), 143.7 (ArC), 141.7 (ArC), 132.9 (ArC), 129.7 (2ArCH), 125.9 (ArC), 122.8 
(ArC), 118.1 (ArCH), 114.7 (2ArCH), 111.9 (ArCH), 20.6 (CH3), 17.5 (CH3); HRMS (ESI+, 
MeCN/H2O) [M+H]+ found 228.1017, C14H14NO2 requires 228.1019. 
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5‐({2‐[(2S)‐2‐acetamido‐3‐methoxy‐3‐oxopropyl]‐5‐hydroxy‐4‐oxocyclohexa‐2,5‐dien‐1‐
ylidene}amino)‐2‐(6‐hydroxy‐3‐oxo‐3H‐xanthen‐9‐yl)benzoic acid, 26 
Ac-Tyr(3-NH2)-OMe 5 (100 µL, 100 
mM in DMSO:buffer, 1:1) and 
Fluoresceinamine (100 µL, 1 M in 
DMSO) were added to phosphate 
buffer (10 mL, 10 mM, pH 6.5). 
K3FeCN6 (200 µL, 500 mM in buffer) 
was added and the reaction mixture 
was stirred at rt for 2 h, and monitored 
by HPLC. The reaction mixture was concentrated in vacuo and desalted using a prepacked C18 
silica column (Supelco DSC-18), with elution in MeOH. The product was concentrated in 
vacuo, then suspended in H2O/EtOAc. The aqueous layer was acidified by addition of HCl (1 
M, aq.) and the product was extracted in EtOAc. Finally, the desired product was purified by 
preparative RP-HPLC (System 4) using an isocratic solvent system (H2O + 0.1%: MeCN + 
0.1% TFA, 65:35). The collected fractions were lyophilised to give the oxidative coupling 
product 26 as a red amorphous solid. 
Rt (HPLC, Method 1): 9.80 min (dimer by-product at 8.61 min); 1H NMR δ (500 MHz, 
DMSO-d6) 10.78 (1H, s, ArOH), 10.13 (2H, s, 2ArOH), 8.35 (1H, d, J = 8.4 Hz, NH), 7.39 – 
7.30 (2H, m, 2ArH), 7.25 (1H, dd, J = 8.1, 1.9 Hz, ArH), 6.76 – 6.68 (4H, m, 4ArH), 6.62-
6.56 (3H, m, 3ArH), 6.16 (1H, s, ArH), 4.85 – 4.74 (1H, m, Tyr(α-CH)), 3.64 (3H, s, OCH3), 
(CHAHB obscured by water peak, expected ~3.25 ppm), 2.86 – 2.74 (1H, m, CHAHB), 1.82 
(3H, s, CH3CONH); HRMS (ESI+, MeCN/H2O) [M+H]+ found 597.1499, C32H25N2O10 
requires 597.1504. 
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5.7 Experimental procedures for Chapter 3 
2,5-Dioxopyrrolidin-1-yl 5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-
yl]pentanoate, 27 
D-Biotin (1.50 g, 6.14 mmol) was stirred in hot DMF (45 mL) 
until dissolved. N-hydroxysuccinimide (0.707 g, 6.14 mmol) 
was added to the reaction mixture, followed by DCC (1.90 g, 
9.21 mmol) and DMAP (0.075 g, 0.614 mmol) and the reaction was stirred at room 
temperature for 18 h. The urea by-product was removed by filtration and the filtrate was 
concentrated to dryness in vacuo. The resulting solid was triturated with diethyl ether (4 × 40 
mL), then filtered, washed with propan-2-ol (40 mL) and dried in vacuo to give the NHS-ester, 
27, as a colourless solid (1.92 g, 92%).  
Rf (DCM:MeOH, 80:20) = 0.67; mp 201-203 °C, lit.172 203-204 °C; [α]D = +50.0 (c 1.00, 
DMSO); IR (neat, cm-1) 3223 (NH), 1817 (C=O), 1788 (C=O), 1746 (C=O), 1728 (C=O), 
1697 (C=O); 1H NMR δ (500 MHz, DMSO-d6) 6.40 (1H, s, NH), 6.34 (1H, s, NH), 4.37-4.27 
(1H, m, CHCH2S), 4.16 (1H, ddd, J = 7.7, 4.5, 1.8 Hz, CHCHS), 3.12 (1H, ddd, J = 8.4, 6.4, 
4.5 Hz, CHS), 2.89-2.76 (5H, m, 2COCH2, CHAHBS), 2.68 (2H, t, J = 7.4 Hz, COCH2), 2.59 
(1H, d, J = 12.4 Hz, CHAHBS), 1.72-1.58 (2H, m, CH2), 1.58 – 1.34 (4H, m, CH2); 13C NMR 
(126 MHz, DMSO-d6) δ 170.7 (2CO), 169.4 (CO), 163.1 (CO), 61.5 (CH), 59.6 (CH), 55.7 
(CH), 40.4 (CH2), 30.5 (CH2), 28.3 (CH2), 28.1 (CH2), 25.9 (2CH2), 24.8 (CH2); m/z (ESI+, 
MeCN/H2O) 364 ([M+Na]+, 100%), 342 ([M+H]+, 100), 227 ([M-C4H4NO3]+, 100). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.172 
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tert-Butyl N-(2-aminoethyl)carbamate, 28 
A solution of di-tert-butyl dicarbonate (1.91 g, 8.75 mmol) in DCM (120 
mL) was added dropwise over 4-5 h to a stirred solution of ethane-1,2-
diamine (3.5 mL, 52.4 mmol) in DCM (30 mL). The reaction mixture was stirred at room 
temperature for 18 h. Solvent was removed in vacuo and the remaining oil was partitioned 
between NaHCO3 (50 mL; sat. aq.) and DCM (3 × 50 mL). The combined organics were dried 
and concentrated in vacuo to give the Boc-protected diamine 28 as a colourless oil (1.14 g, 
82%). The crude product was used in a following reaction with no further purification. 
Rf (DCM:MeOH, 80:20) = 0.24; IR (neat, cm-1) 3298 (NH), 1701 (C=O); 1H NMR δ (500 
MHz, CDCl3) 4.94 (1H, br s, NHBoc) 3.22-3.19 (2H, m, CH2NHBoc), 2.83 (2H, t, J = 6.3 Hz, 
NH2CH2), 1.47 (9H, s C(CH3)3); 13C NMR δ (126 MHz, CDCl3) 156.3 (CO), 79.3 (C), 43.2 
(CH2), 41.8 (CH2), 28.4 (3CH3); m/z (ESI+, MeCN/H2O) 183 ([M+Na]+, 100%), 161 ([M+H]+, 
60). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.173 
tert-Butyl N-(2-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-
yl]pentanamido}ethyl) carbamate, 29 
Amine 28 (0.96 g, 5.99 mmol) was dissolved in dry 
DMF (70 mL), before addition of biotin-NHS 27 (2.10 
g, 6.15 mmol) and NEt3 (1.56 mL, 11.2 mmol). The 
reaction mixture was stirred at room temperature for 18 h. Solvent was removed in vacuo and 
the resulting solid was purified by column chromatography (dry-loaded, DCM:MeOH, 90:10) 
to give the Boc-protected amine 29 as a colourless solid (1.87 g, 81%). 
Rf (DCM:MeOH, 90:10) = 0.28; mp 174-176 °C; IR (neat, cm-1) 3325 (NH), 1699 (C=O), 
1684 (C=O), 1626 (C=O); 1H NMR δ (500 MHz, DMSO-d6) 7.76 (1H, t, J = 5.5 Hz, CONH), 
6.75 (1H, t, J = 5.2 Hz, CONH), 6.39 (1H, s, Biotin-NH), 6.34 (1H, s, Biotin-NH), 4.34-4.28 
(1H, m, CHCH2S), 4.16-4.11 (1H, m, CHCHS), 3.14-3.02 (3H, m, NHCH2, CHS), 3.00-2.92 
(2H, m, NHCH2), 2.83 (1H, dd, J = 12.4, 5.1 Hz, CHAHBS), 2.60 (1H, d, J = 12.5 Hz, CHAHBS), 
2.05 (2H, t, J = 7.5 Hz, COCH2), 1.67-1.56 (1H, m, CHXHY), 1.56-1.43 (3H, m, CH2, CHXHY), 
1.38 (9H, s, C(CH3)3), 1.35-1.25 (2H, m, CH2); 13C NMR δ (126MHz, DMSO-d6) 172.6 (CO), 
163.2 (CO), 156.1 (CO), 78.1 (C), 61.5 (CH), 59.7 (CH), 55.9 (CH), 40.3 (CH2), 40.2 (CH2), 
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39.1 (CH2), 35.7 (CH2), 28.7 (3CH3), 28.7 (CH2), 28.5 (CH2), 25.7 (CH2); m/z (ESI+, 
MeCN/H2O) 387 ([M+H]+, 25%), 287 ([M-C5H9O2]+, 100), 270 ([M-C5H10O3]+, 25).  
1H and 13C NMR spectroscopic data is in good agreement with the literature.174 
4-{[(tert-Butoxy)carbonyl]amino}benzoic acid, 30  
4-Aminobenzoic acid (3.43 g, 25.0 mmol) was dissolved in dioxane (50 
mL) and water (25 mL). Triethylamine (7.0 mL, 50.2 mmol) was added 
to the solution, followed by di-tert-butyl dicarbonate (10.9 g, 50.0 
mmol) and the reaction mixture was stirred at room temperature for 18 h. Solvent was removed 
in vacuo, and HCl (15 mL; 3 N, aq.) was added dropwise to the remaining residue. The 
resulting precipitate was filtered, washed with water (2 × 20 mL), hexane (2 × 20 mL), and 
finally dried in vacuo to afford the Boc-protected amine 30 as a colourless solid (5.86 g, 99%). 
Rf (DCM:MeOH, 80:20) = 0.23; mp 187-189 °C, lit. 175 191-192 °C; IR (neat, cm-1) 3368 
(NH), 2980-2497 (OH), 1705 (C=O), 1676 (C=O), 1609 (C=C), 1589 (C=C), 1524 (C=C); 1H 
NMR δ (500 MHz DMSO-d6) 12.60 (1H, br s, CO2H), 9.73 (1 H, s, NH), 7.84 (2H, d, J = 8.4 
Hz, ArH), 7.56 (2H, d, J = 8.4 Hz, ArH), 1.50 (9H, s, C(CH3)3); 13C NMR δ (126 MHz, 
DMSO-d6) 167.5 (CO), 153.0 (CO), 144.2 (ArC), 130.8 (2ArCH), 124.5 (ArC), 117.7 
(2ArCH), 80.1 (C), 28.5 (3CH3); m/z (ESI-, MeCN/H2O) 236 ([M-H]-, 100%). 
1H and 13C NMR spectroscopic data are in good agreement with the literature.175 
2,5-Dioxopyrrolidin-1-yl 4-{[(tert-butoxy)carbonyl]amino}benzoate, 31  
Carboxylic acid 30 (2.85 g, 12.0 mmol) and N-hydroxysuccinimide 
(1.38 g, 12.0 mmol) were dissolved in DCM (50 mL). DCC (2.48 g, 
12.0 mmol) was added to the solution and the reaction mixture was 
stirred at room temperature for 18 h. The urea by-product was removed by filtration and the 
filtrate was concentrated to dryness in vacuo to give the NHS ester 31 as a colourless solid 
(3.13 g, 78%). 
Rf (DCM:MeOH, 90:10) = 0.84; mp 172-174 °C, lit.176 172-173 °C; IR (neat, cm-1) 3290 
(NH), 1767 (C=O), 1728 (C=O), 1697 (C=O); 1H NMR δ (500 MHz, CDCl3) 8.09 (2H, d, J = 
8.9 Hz, ArH), 7.53 (2H, d, J = 8.9 Hz, ArH), 6.80 (1H, s, NH), 2.93 (4H, br s, 2CH2), 1.56 
(9H, s, C(CH3)3); 13C NMR δ (126 MHz, CDCl3) 169.4 (2CO), 161.4 (CO), 151.9 (CO), 144.6 
  Chapter 5: Experimental 
 134 
(ArC), 132.2 (2ArCH), 118.8 (ArC), 117.5 (2ArCH), 81.7 (C), 28.3 (3CH3), 25.7 (2CH2); m/z 
(ESI+, MeCN/H2O) 357 ([M+Na]+, 100%). 
1H and 13C NMR spectroscopic data is in good agreement with the literature.176 
tert-Butyl N-{4-[(2-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-
yl]pentanamido}ethyl) carbamoyl]phenyl}carbamate, 32  
Boc-protected amine 29 (1.87 g, 4.84 mmol) 
was suspended in DCM (50 mL) and TFA 
(5.6 mL, 73.1 mmol) was added. The 
solution was stirred at room temperature for 18 h and then concentrated in vacuo. The residue 
was dissolved in NaHCO3 (65 mL; sat. aq.) and the NHS ester 31 (3.23 g, 9.67 mmol) was 
added in MeCN (60 mL). The reaction was monitored by TLC until judged to have gone to 
completion (~18 h). MeCN was removed in vacuo and the product was extracted in chloroform 
(3 × 60 mL), dried, and concentrated to dryness. Purification was performed by column 
chromatography (dry-loaded, DCM:MeOH, 90:10) to give the Boc-protected aniline 32 as a 
colourless solid (1.67 g, 68%). 
Rf (DCM:MeOH, 90:10) = 0.42; mp 257-260 °C (decomp.); [α]D = +36.0 (c 1.00, DMF); IR 
(neat, cm-1) 3327 (NH), 1692 (C=O), 1649 (C=O), 1632 (C=O), 1612 (C=C); 1H NMR (500 
MHz, DMSO-d6) δ 9.60 (1H, s, NHBoc), 8.31 (1H, t, J = 5.5 Hz, NHCO), 7.90 (1H, t, J = 5.7 
Hz, CONH), 7.75 (2H, d, J = 8.7 Hz, 2ArH), 7.51 (2H, d, J = 8.7 Hz, 2ArH), 6.40 (1H, s, 
Biotin-NH), 6.35 (1H, s, Biotin-NH), 4.30 (1H, dd, J = 7.7, 5.1 Hz, CHCH2S), 4.13-4.06 (1H, 
m, CHCHS), 3.31-3.25 (2H, m, CH2NHCO), 3.24-3.19 (2H, m, CONHCH2), 3.08-2.99 (1H, 
m, CHS), 2.81 (1H, dd, J = 12.4, 5.1 Hz, CHAHBS), 2.59 (1H, d, J = 12.4 Hz, CHAHBS), 2.14-
2.02 (2H, m, CH2CO), 1.64-1.39 (4H, m, 2CH2), 1.49 (9H, s, C(CH3)3), 1.39-1.20 (2H, m, 
CH2); 13C NMR (126 MHz, DMSO-d6) 172.9 (CO), 166.4 (CO), 153.1 (CO), 142.7 (CO), 
128.5 (2ArCH), 128.3 (ArC), 117.5 (2ArCH), 116.4 (ArC), 80.0 (C), 61.5 (CH), 59.7 (CH), 
55.8 (CH), 40.3 (CH2), 39.7 (CH2), 38.8 (CH2), 35.7 (CH2), 28.6 (CH2), 28.6 (3CH3), 28.5 
(CH2), 25.7 (CH2); HRMS (ESI+, MeOH) [M+H]+ found 506.2437, C24H36N5O5S requires 
506.2432. 
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5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-thieno[3,4-d]imidazolidin-4-yl]-N-{2-[(4-
aminophenyl)formamido] ethyl}pentanamide, 33  
Boc-protected aniline 32 (70 mg, 0.14 mmol) 
was suspended in DCM (2 mL). TFA (0.11 mL, 
1.4 mmol) was added and the solution was 
stirred at room temperature for 18 h. The reaction mixture was cooled in an ice bath and excess 
acid was quenched by dropwise addition of Na2CO3 (10 mL; sat. aq.). The product was 
extracted in DCM and dried over MgSO4. The mixture was filtered and solvent was removed 
from the eluate in vacuo to give the amine 33 as a colourless solid (48 mg, 85%).  
Rf (DCM:MeOH, 80:20) = 0.47; mp 230-235 °C (decomp.); [α]D = +30.0 (c 0.20, DMSO); 
IR (neat, cm-1) 3246 (NH), 1628 (C=C); 1H NMR δ (500 MHz, DMSO-d6) 7.99 (1H, t, J = 
5.5 Hz, NHCO), 7.89 (1H, t, J = 5.6 Hz, CONH), 7.55 (2H, d, J = 8.6 Hz, 2ArH), 6.54 (2H, d, 
J = 8.6 Hz, 2ArH), 6.42 (1H, s, Biotin-NH), 6.35 (1H, s, Biotin-NH), 5.59 (2H, s, NH2), 4.33-
4.27 (1H, m, CHCH2S), 4.14-4.07 (1H, m, CHCHS), 3.29-3.22 (2H, m, CH2), 3.22-3.14 (2H, 
m, CH2), 3.09-3.01 (1H, m, CHS), 2.81 (1H, dd, J = 12.4, 5.1 Hz, CHAHBS), 2.58 (1H, m, 
CHAHBS), 2.07 (2H, t, J = 7.4 Hz, CH2CO), 1.67-1.39 (3H, m, CH2, CHXHY ), 1.39-1.18 (3H, 
m, CH2, CHXHY); 13C NMR δ (126 MHz, DMSO-d6) 172.8 (CO), 166.9 (CO), 163.2 (CO), 
152.0 (ArC), 129.1 (2ArCH), 121.6 (ArC), 113.0 (2ArCH), 61.5 (CH), 59.7 (CH), 55.8 (CH), 
40.3 (CH2), 39.6 (CH2), 39.0 (CH2), 35.7 (CH2), 28.6 (CH2), 28.5 (CH2), 25.7 (CH2); HRMS 
(ESI+, MeOH) [M+H]+ found 406.1905, C19H28N5O3S requires 406.1907. 
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5‐[(3aS,4S,6aR)‐1‐nitroso‐2‐oxo‐hexahydro‐1H‐thieno[3,4‐d]imidazol‐4‐yl]pentanoic acid, 
34 
D-Biotin (50 mg, 0.205 mmol) was suspended in water (4 mL) 
and the solution was cooled to 0 °C. TFA (40 µL, 0.520 mmol) 
was added, followed by NaNO2 (25 mg, 0.350 mmol) and the 
reaction mixture was stirred at 0 °C for 2 h, monitored by TLC. 
The product precipitated from solution, and was isolated by filtration and washed with diethyl 
ether. The solid was dried in vacuo to give nitrosobiotin 34 as a pale yellow solid (51 mg, 
91%). 
Rf (DCM:MeOH:AcOH, 98:2:2) = 0.35; IR (neat, cm-1) 3550 (NH), 3410 (NH), 3298 (OH), 
1759 (C=O), 1717 (C=N), 1379 (N=O), 1341 (N=O); 1H NMR δ (500 MHz, DMSO-d6) 11.98 
(1H, s, CO2H), 8.80 (1H, s, NH), 4.83 (1H, ddd, J = 7.0, 5.9, 0.9 Hz, CHCH2S), 4.27 (1H, ddd, 
J = 7.0, 4.3, 1.4 Hz, CHCHS), 3.23 (1H, ddd, J = 8.9, 6.0, 4.3 Hz, CHS), 2.98 (1H, dd, J = 
13.3, 5.9 Hz, CHAHBS), 2.68 (1H, d, J = 13.3 Hz, CHAHB), 2.23 (2H, t, J = 7.4 Hz, CH2CO2H), 
1.77-1.66 (1H, m, SCHCHAHB), 1.58-1.46 (3H, m, SCHCHAHB, CH2CH2CO2H), 1.44-1.28 
(2H, m, CH2CH2CH2CO2H); 13C NMR δ (126 MHz, DMSO-d6) 174.9 (CO), 154.2 (CO), 60.0 
(CHCH2S), 59.0 (CHCHS), 54.4 (CHS), 35.0 (CH2S), 33.9 (CH2), 28.6 (CH2), 28.1 (CH2), 
24.9 (CH2); HRMS (ESI−, MeCN/H2O) [M−H]− found 272.0689, C10H14N3O4S requires 
272.0700. 
Methyl (2S)‐3‐[3‐(2‐{4‐[(2‐{[(tert‐butoxy)carbonyl]amino}ethyl)carbamoyl]phenyl}diazen‐
1‐yl)‐4‐hydroxyphenyl]‐2‐acetamidopropanoate, 35 
Carboxylic acid 7 (50 mg, 0.130 mmol) was 
dissolved in DMF (1 mL), and EDC (35 mg, 
0.183 mmol) and HOBt (10 mg, 0.074 mmol) 
were added. The Boc-protected diamine 28 (52 
mg, 0.324 mmol) was dissolved in DMF (1 mL) and added to the reaction mixture. The 
reaction was monitored by TLC, and the carboxylic acid was consumed after 48 h. Solvent 
was removed in vacuo and the product was purified by preparative RP-HPLC (System 4) using 
an isocratic solvent system (H2O + 0.1%: MeCN + 0.1% TFA, 57:43). The collected fractions 
were lyophilised to give the amide coupling product 35 as an orange amorphous solid (33 mg, 
48%). 
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Rf (DCM:MeOH, 95:5) = 0.54; [α]D = +37.5 (c 0.40, DMSO); IR (neat, cm-1) ; 1H NMR δ 
(500 MHz, CDCl3) 12.65 (1H, s, OH), 7.99 (2H, d, J = 8.3 Hz, 2ArH), 7.89 (2H, d, J = 8.3 Hz, 
2ArH), 7.72 (1H, d, J = 2.3 Hz, ArH), 7.56 (1H, br s, BocNH), 7.14 (1H, dd, J = 8.5, 2.3 Hz, 
ArH), 6.97 (1H, d, J = 8.5 Hz, ArH), 6.19 (1H, d, J = 7.7 Hz, AcNH), 5.17 (1H, t, J = 6.2 Hz, 
NHCOAr), 4.94 (1H, dt, J = 7.7, 5.8 Hz, Tyr(α-CH)), 3.78 (3H, s, OCH3), 3.65 – 3.57 (2H, m, 
BocNHCH2), 3.49 – 3.42 (2H, m, CH2NHCOAr), 3.22 (1H, dd, J = 14.1, 5.8 Hz, Tyr(β-
CHAHB)), 3.15 (1H, dd, J = 14.1, 5.8 Hz, Tyr(β-CHAHB), 2.04 (3H, s, CH3CONH), 1.46 (9H, 
s, Boc(CH3)3); 13C NMR δ (126 MHz, CDCl3) 172.1 (CO), 169.8 (CO), 166.8 (CO), 157.8 
(CO), 152.2 (ArC), 151.9 (ArC), 137.2 (ArC), 136.2 (ArC), 134.8 (ArCH), 133.8 (ArCH), 
128.3 (2ArCH), 127.7 (ArC), 122.3 (2ArCH), 118.5 (ArCH), 80.2 (C), 53.3 (CH), 52.5 (CH), 
42.6 (CH2), 39.9 (CH2), 36.9 (CH2), 28.4 (3CH3), 23.2 (CH3); HRMS (ESI+, MeCN/H2O) 
[M+Na]+ found 550.2275, C26H33N5O7Na requires 550.2272. 
Methyl (2S)‐3‐[3‐(2‐{4‐[(2‐{5‐[(3aS,4S,6aR)‐2‐oxo‐hexahydro‐1H‐thieno[3,4‐d]imidazol‐4‐
yl]pentanamido}ethyl)carbamoyl]phenyl}diazen‐1‐yl)‐4‐hydroxyphenyl]‐2‐
acetamidopropanoate, 36 
Boc-protected azobenzene 35 
(110 mg, 0.290 mmol) was 
dissolved in DCM (6 mL) and 
TFA (0.4 mL, 4.31 mmol) was 
added. The reaction was stirred at rt for 3 h and monitored by TLC with Ninhydrin staining. 
The solvent and TFA were removed under a stream of N2, and the residue was redissolved in 
NaHCO3 (8 mL; sat. aq.). Biotin-NHS 27 (187 mg, 0.55 mmol) was dissolved in DMF (2 mL) 
and added to the reaction mixture. The reaction mixture was stirred at room temperature for 
18 h and monitored by TLC. The reaction mixture was acidified with HCl (1 M, aq.) and the 
product was extracted in EtOAc. Purification was performed by column chromatography (dry-
loaded, DCM:MeOH, 95:5) to give the biotinylated azobenzene 36 as an orange solid (176 
mg, 93%). 
Rf (DCM:MeOH, 90:10) = 0.30; IR (neat, cm-1) 3289 (OH), 1676 (CO), 1643 (CO), 1541 
(C=C); 1H NMR δ (500 MHz, DMSO-d6) 10.92 (1H, s, OH), 8.66 (1H, t, J = 5.6 Hz, 
NHCOAr), 8.36 (1H, d, J = 7.8 Hz, AcNH), 8.09 – 7.99 (4H, m, 4ArH), 7.95 (1H, t, J = 5.8 
Hz, CONHCH2), 7.61 (1H, d, J = 2.3 Hz, ArH), 7.32 (1H, dd, J = 8.5, 2.3 Hz, ArH), 7.02 (1H, 
d, J = 8.5 Hz, ArH), 6.41 (1H, s, Biotin-N(3’)H), 6.34 (1H, s, Biotin-N(1’)H), 4.47 (1H, ddd, 
J = 9.2, 7.8, 5.6 Hz, Tyr(α-CH), 4.29 (1H, dd, J = 7.8, 5.1 Hz, Biotin-CHCH2S), 4.13-4.09 
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(1H, m, Biotin-CHCHS), 3.62 (3H, s, OCH3), 3.39-3.33 (2H, m, CH2NHCO), 3.29-3.22 (2H, 
m, CONHCH2), 3.09-3.02 (1H, m, Biotin-CHS) 3.02 (1H, dd, J = 13.8, 5.6 Hz, Tyr(β-
CHAHB)), 2.89 (1H, dd, J = 13.8, 9.2 Hz, Tyr(β-CHAHB)), 2.80 (1H, dd, J = 12.5, 5.1 Hz, 
Biotin-CHAHBS), 2.57 (1H, d, J = 12.5 Hz, Biotin-CHAHBS), 2.09 (2H, t, J = 7.4 Hz, 
CH2CONH), 1.81 (3H, s, CH3CONH), 1.66-1.57 (1H, m, SCHCHAHB), 1.57-1.41 (3H, m, 
SCHCHAHB, SCHCH2CH2), 1.39-1.20 (2H, m, CH2CH2CONH); 13C NMR δ (126 MHz, 
DMSO-d6) 172.9 (CO), 172.6 (CO), 169.8 (CO), 166.1 (CO), 163.2 (CO), 154.3 (ArC), 153.5 
(ArC), 138.7 (ArC), 136.8 (ArC), 135.4 (ArCH), 129.2 (ArC), 128.9 (2ArCH), 122.9 
(2ArCH), 122.6 (ArCH), 118.7 (ArCH), 61.5 (CH), 59.7 (CH), 55.9 (CH), 54.1 (CH), 52.3 
(CH3), 40.3 (CH2), 39.9 (CH2), 38.6 (CH2), 36.3 (CH2), 35.7 (CH2), 28.6 (CH2), 28.5 (CH2), 
25.7 (CH2), 22.7 (CH3); HRMS (ESI+, MeCN/H2O) [M+Na]+ found 676.2543, 
C31H39N7O7SNa requires 676.2524. 
 
Ac-Tyr(3-NH2)-OMe and Leu-Enk[Tyr(3-NH2)] UHPLC standards 
 
Figure 5-1 UHPLC and MS of the standards used for SAv resin and Affi-Gel catch-and-
release. (a) The 3-aminotyrosine-derived standard 5 gave a retention time of 1.54 min. (b) The 
3-aminotyrosine modified Leu-Enkephalin 37 was obtained from a preformed biotin-Leu-
Enkephalin azobenzene linker, which was incubated with SAv resin and cleaved in Na2S2O4. 
The sample was desalted using a C18 flash cartridge, with elution in MeOH to give a retention 
time of 3.41 min with mass confirmation by ESI-MS. 
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5.8 Experimental procedures for Chapter 4 
5.8.1 Solvent-accessible surface area calculation 
Using PyMOL software, the SASA calculation was performed using the automated SASA 
script. The desired .pdb file was retrieved from the RCSB Protein Data Bank, and saved in the 
same directory as the SASA script ‘get_resn_sasa.py’. The .pdb file was opened in PyMOL 
and the script was called using the command ‘run get_resn_sasa.py’. Upon loading the script, 
the protein backbone is shown as a cartoon, with colour-coded stick representations for Tyr 
(grey), His (purple), Lys (green) and Cys (yellow) residues, as well as the N-terminus (pink). 
The SASA result of the α-NH2 of the N-terminus is displayed automatically in the External 
GUI, and SASA calculation of the Tyr residues can be performed by entering the command 
‘get_tyr_sasa’. Alternatively, ‘get_his_sasa’, ‘get_lys_sasa’ or ‘get_cys_sasa’ can be used to 
calculate the SASA of other residues. The SASA output is displayed in the GUI, and a .txt file 
of the results is also created in the same directory as the script and .pdb file. 
Automated SASA script 
The automated SASA script is given below, with annotation of the ‘get_tyr_sasa’ code in bold. 
'''         #Multi-line string, instead of using hashtag 
 
Authors: 
            Miroslav Kosar, Christopher Allan 
            The University of Edinburgh 
Usage:  
            This script calculates the solvent-accessible surface area of the 
selected atoms. 
            The output results include the SASA value of each selected atom, 
the sum SASA value  
            corresponding to the amino acid in question, and a sum of all 
residues of that type  
            over the whole protein sequence. 
            Five function are defined: 
            get_tyr_sasa    - calculates the SASA at the ortho positions of 
the tyrosine  
                              phenol side chain 
            get_his_sasa    - calculates the SASA at the CE1-position of the 
imidazole  
                              side chain of histidine. 
            get_lys_sasa    - calculates the SASA at the terminal amine of 
the lysine side chain 
            get_cys_sasa    - calculates the SASA at the terminal thiol of 
the cysteine side chain 
            get_nterm_sasa  - calculates the SASA at the N-terminus 
             
''' 
 
#Import Pymol module to pull out Pymol data and functions 
from pymol import cmd 
from pymol import stored 
import time 
start = time.time() 
 
#Visuals  
#'cmd.do' sends command to Pymol 
cmd.do('hide all') 
cmd.do('show cartoon') 
cmd.do('colour gray90, all') 
cmd.do('util.cbaw resn tyr') 
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cmd.do('util.cbab resn his') 
cmd.do('util.cbag resn lys') 
cmd.do('util.cbay resn cys') 
cmd.do('select nterm, resi 1') 
cmd.do('util.cbap nterm') 
cmd.do('select none') 
cmd.do('show sticks, resn tyr') 
cmd.do('show sticks, resn his') 
cmd.do('show sticks, resn lys') 
cmd.do('show sticks, resn cys') 
cmd.do('show sticks, nterm') 
 
#def function get_tyr_sasa(resn="TYR", myname="CE1+CE2"): 
def get_tyr_sasa(resn="TYR", myname="CE1+CE2"): 
    '''(str, str)->Nonetype 
 
    ''' 
    #set 'dot_solvent' to 0 for AREA or 1 for SASA 
    #set 'solvent_radius' to 1.4 to model water 
    #set 'dot_density' to 4 for maximum accuracy, 
    #however this causes long calculation time 
    cmd.set('dot_solvent', 1)  
    cmd.set('solvent_radius', 1.4) 
    cmd.set('dot_density', 2) 
 
    #Open new .txt file in 'write' mode ('w') 
    outfile='tyr_sasa_out.txt' 
    f = open(outfile, 'w') 
    #'target_sel' and 'expression' used to create output, '%s' refers to  
    #item in Tuple (string)  
    target_sel = 'resname %s and name %s' % (resn, myname) 
    #Convert resn (e.g. Tyr) and atomname (e.g. CE1) to all uppercase  
    #characters 
    resn = resn.upper() 
    atomname = myname.upper() 
    #Create empty list called 'stored.infolist' 
    stored.infolist = [] 
    #Add pdb ref. (model), chain, residue number (resv), amino acid (resn),  
    #atom name (name) to list 
    expression = "stored.infolist.append([model,chain,resv,resn,name])" 
    #iterate for each atom, populates list 
    cmd.iterate(target_sel, expression) 
     
    #Store information as a dictionary, '{_' is empty dictionary, populate  
    #with 'keys' and 'values'  
    sasa_per_resi={_ 
    #Create list for keys, fill with strings from 'stored.infolist'  
    #(residue[1] = chain, residue[3] = resn, residue[2] = resv) 
    #'%4s'is a string from a Tuple, formatted to 4 characters (e.g.0001) 
    keys = [] 
    for residue in stored.infolist: 
        key ='Chain-%s-%s-%4s' % (residue [1], residue[3], residue[2]) 
        #Safety artificial values set to keys to check for malfunction and 
        #Zero SASA prediction 
        if key not in sasa_per_resi: 
            sasa_per_resi[key]={_ 
            sasa_per_resi[key]['CE1']=-999.00 
            sasa_per_resi[key]['CE2']=-999.00 
            sasa_per_resi[key]['SUM']=-999.00 
            keys.append(key) 
        #'i' is generic name for variable, residue[2] = resv, 
        #residue[4] = atom name 
        i="resi %s and name %s" % (residue[2], residue[4]) 
        #Overwrite artificial values with actual SASA prediction 
        #'cmd.get_area' is SASA command, '(i)' holds (resi, atom name) 
        value = cmd.get_area(i) 
        #Combine atom ID with SASA value in dictionary 
        sasa_per_resi[key][residue[4]] = value 
     
    #Accessing values and formatting data output 
    for key in keys: 
        #Calculate sum SASA by adding SASA of each ortho position (CE1 + CE2) 
        sasa_sum = sasa_per_resi[key]['CE1'] + sasa_per_resi[key]['CE2'] 
        sasa_per_resi[key]['SUM'] = sasa_sum 
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        #Output format, '%s' = string from Tuple, '%f' = floating point value 
        #from Tuple, '5.2' refers to formatting, 5 characters, 2 of which are 
        #decimal places (e.g.000.01) 
        line = '%s -> CE1: %5.2f   CE2: %5.2f   SUM: %5.2f' % (key, 
sasa_per_resi[key]['CE1'], 
                                                  
sasa_per_resi[key]['CE2'], 
                                                  
sasa_per_resi[key]['SUM']) 
        #Print output ('line') and new line ('\n') 
        print line 
        f.write(line +'\n') 
 
    #Get the total SASA for resn of the protein 
    total_sasa = 0.00 
    for key in sasa_per_resi: 
        for key in keys: 
            total_sasa = total_sasa + sasa_per_resi[key]['CE1'] + 
sasa_per_resi[key]['CE2'] 
        break 
     
    out = 'Total %s SASA: %5.2f' % (resn, total_sasa) 
    print out 
    #Get total number of tyr residues (/2 as Tyr has 2 reactive position, 
    #CE1+CE2, not required for other reactive residues 
    total_tyr = 'Total %s residues: %d' % (resn, len(stored.infolist)/2) 
    print total_tyr 
     
    f.write(out + '\n') 
    f.write(total_tyr + '\n') 
    f.write('total execution time %s seconds'  %(time.time()-start))  
    f.close() 
 
#Bind user-defined function as a command (string name, function) 
cmd.extend('get_tyr_sasa', get_tyr_sasa)     
 
 
def get_his_sasa(resn="HIS", myname="CE1"): 
    '''(str, str)->Nonetype 
 
    ''' 
    cmd.set('dot_solvent', 1)  
    cmd.set('dot_density', 2) 
 
    outfile='his_sasa_out.txt' 
    f = open(outfile, 'w') 
    target_sel = 'resname %s and name %s' % (resn, myname) 
    resn = resn.upper() 
    atomname = myname.upper() 
    stored.infolist = [] 
    expression = "stored.infolist.append([model,chain,resv,resn,name])" 
    cmd.iterate(target_sel, expression) 
     
    sasa_per_resi={_ 
    keys = [] 
    for residue in stored.infolist: 
        key ='Chain-%s-%s-%4s' % (residue[1], residue[3], residue[2]) 
        if key not in sasa_per_resi: 
            sasa_per_resi[key]={_ 
            sasa_per_resi[key]['CE1']=-999.00 
            keys.append(key) 
        i="resi %s and name %s" % (residue[2], residue[4]) 
        value = cmd.get_area(i) 
        sasa_per_resi[key][residue[4]] = value 
 
    for key in keys: 
        line = '%s -> CE1: %5.2f' % (key, sasa_per_resi[key]['CE1']) 
                                             
        print line 
        f.write(line +'\n') 
 
    total_sasa = 0.00 
    for key in sasa_per_resi: 
        for key in keys: 
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            total_sasa = total_sasa + sasa_per_resi[key]['CE1'] 
        break 
     
    out = 'Total %s SASA: %f' % (resn, total_sasa) 
    print out 
    total_his = 'Total %s residues: %d' % (resn, len(stored.infolist)) 
    print total_his 
     
    f.write(total_his + '\n') 
    f.write(out + '\n') 
    f.close() 
 
cmd.extend('get_his_sasa', get_his_sasa) 
 
 
def get_lys_sasa(resn="LYS", myname="NZ"): 
    '''(str, str)->Nonetype 
 
    ''' 
    cmd.set('dot_solvent', 1)  
    cmd.set('dot_density', 2) 
 
    outfile='lys_sasa_out.txt' 
    f = open(outfile, 'w') 
    target_sel = 'resname %s and name %s' % (resn, myname) 
    resn = resn.upper() 
    atomname = myname.upper() 
    stored.infolist = [] 
    expression = "stored.infolist.append([model,chain,resv,resn,name])" 
    cmd.iterate(target_sel, expression) 
     
    sasa_per_resi={_ 
    keys = [] 
    for residue in stored.infolist: 
        key ='Chain-%s-%s-%4s' % (residue[1], residue[3], residue[2]) 
        if key not in sasa_per_resi: 
            sasa_per_resi[key]={_ 
            sasa_per_resi[key]['NZ']=-999.00 
            keys.append(key) 
        i="resi %s and name %s" % (residue[2], residue[4]) 
        value = cmd.get_area(i) 
        sasa_per_resi[key][residue[4]] = value 
 
    for key in keys: 
        line = '%s -> NZ: %5.2f' % (key, sasa_per_resi[key]['NZ']) 
                                             
        print line 
        f.write(line +'\n') 
 
    total_sasa = 0.00 
    for key in sasa_per_resi: 
        for key in keys: 
            total_sasa = total_sasa + sasa_per_resi[key]['NZ'] 
        break 
     
    out = 'Total %s SASA: %f' % (resn, total_sasa) 
    print out 
    total_lys = 'Total %s residues: %d' % (resn, len(stored.infolist)) 
    print total_lys 
     
    f.write(total_lys + '\n') 
    f.write(out + '\n') 
    f.close() 
 
cmd.extend('get_lys_sasa', get_lys_sasa) 
 
 
def get_cys_sasa(resn="CYS", myname="SG"): 
    '''(str, str)->Nonetype 
 
    ''' 
    cmd.set('dot_solvent', 1)  
    cmd.set('dot_density', 2) 
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    outfile='cys_sasa_out.txt' 
    f = open(outfile, 'w') 
    target_sel = 'resname %s and name %s' % (resn, myname) 
    resn = resn.upper() 
    atomname = myname.upper() 
    stored.infolist = [] 
    expression = "stored.infolist.append([model,chain,resv,resn,name])" 
    cmd.iterate(target_sel, expression) 
     
    sasa_per_resi={_ 
    keys = [] 
    for residue in stored.infolist: 
        key ='Chain-%s-%s-%4s' % (residue[1], residue[3], residue[2]) 
        if key not in sasa_per_resi: 
            sasa_per_resi[key]={_ 
            sasa_per_resi[key]['SG']=-999.00 
            keys.append(key) 
        i="resi %s and name %s" % (residue[2], residue[4]) 
        value = cmd.get_area(i) 
        sasa_per_resi[key][residue[4]] = value 
 
    for key in keys: 
        line = '%s -> SG: %5.2f' % (key, sasa_per_resi[key]['SG']) 
                                             
        print line 
        f.write(line +'\n') 
 
    total_sasa = 0.00 
    for key in sasa_per_resi: 
        for key in keys: 
            total_sasa = total_sasa + sasa_per_resi[key]['SG'] 
        break 
     
    out = 'Total %s SASA: %f' % (resn, total_sasa) 
    print out 
    total_cys = 'Total %s residues: %d' % (resn, len(stored.infolist)) 
    print total_cys 
     
    f.write(total_cys + '\n') 
    f.write(out + '\n') 
    f.close() 
 
cmd.extend('get_cys_sasa', get_cys_sasa)         
 
 
def get_nterm_sasa(resi="1", name="N"): 
    '''(str, str)->Nonetype 
 
    ''' 
cmd.set('dot_solvent', 1)  
cmd.set('dot_density', 2) 
 
cmd.select("nterm", "resi 1 and name n") 
nterm_area=cmd.get_area("nterm") 
print 'N-terminus SASA', nterm_area 
     
cmd.extend('get_nterm_sasa', get_nterm_sasa) 
  
  Chapter 5: Experimental 
 144 
Tyr SASA results for protein substrates 
Ribonuclease A (PDB: 4J5Z)   Soybean trypsin inhibitor (PDB: 1BA7) 
Residue SASA (Å2)  Residue SASA (Å2) 
Y025 3.02  Y017 0.00 
Y073 7.76  Y018 7.23 
Y076 29.36  Y062 38.09 
Y092 24.98  Y131 0.00 
Y097 0.96    
Y115 21.68    
 
β-Lactoglobulin A (PDB: 3NPO)  Myoglobin (PDB: 5D5R) 
Residue SASA (Å2)  Residue SASA (Å2) 
Y020 6.11  Y103 8.21 
Y042 0.00  Y146 0.00 
Y099 15.33    
Y102 0.00    
 
Hen egg white lysozyme (PDB: 4YM8) Cytochome C (PDB: 2B4Z) 
Residue SASA (Å2)  Residue SASA (Å2) 
Y020 21.72  Y048 4.59 
Y023 13.44  Y067 11.62 
Y053 13.55  Y074 8.31 
   Y097 9.98 
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5.8.2 TNM modification and reduction of RNase A 
The TNM modification and reduction protocol was adapted from Francis et al.122 TNM (10 
µL, 3.5% v/v in H2O) was added to a solution of RNase A (570 µL, 255 µM RNase A in 100 
mM phosphate buffer, pH 8.8) and the reaction mixture was agitated on a rotator for 24 h at 
rt. Excess TNM was removed by successive concentration and washing using a MWCO spin 
cartridge, phosphate buffer (3 × 400 µL, 100 mM, pH 7.2) and water (2 x 400 µL). The nitrated 
protein was lyophilised and re-dissolved in aqueous Na2S2O4 (300 µL, 100 mM), briefly mixed 
by vortex and agitated on a rotator for 2 h at rt. The sample volume was reduced to ~50 µL on 
a MWCO spin cartridge and desalted by washing with phosphate buffer (5 x 400 µL, 100 mM, 
pH 7.2). 
5.8.3 Top-down fragmentation 
A sample of denatured and reduced catch-and-release modified RNase A was directly infused 
into a Bruker SolariX 12T FT-ICR mass spectrometer using a Triversa Nanomate (Advion 
Biosciences) and an isolated species was fragmented by ECD and CID. 
ECD fragmentation 
The 13+ charge state of the singly modified protein was isolated with ion accumulation time 
of up to 5 sec. 1.7 A was applied to the cathode, the bias voltage was set to 1 V, and the lens 
voltage was 20 V. Dissociation of the isolated species was achieved by applying a pulse for 6 
ms, ECD time was 8 ms. The resulting peptide fragments were calibrated by single point 
calibration to [C131H206N36O39S1]3+: 979.831572 m/z. Using DataAnalysis software (version 
4.1, Bruker Daltronics), a list of monoisotopic masses was generated and this was searched 
against the theoretical masses of all expected peptides using ProSight PTM software (Kelleher 
Lab, Northwestern University)168, 169 with a mass error tolerance of 5 ppm. The identified 
peptide peaks were further scrutinised by comparison with the theoretical isotope distribution 
using DataAnalysis. 
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ECD: Identified peptide ions 
 
 
Peptide ions identified by top-down fragmentation of singly modified RNase A by ECD. 
Peptide 
Ion 
m/z z 
Measured 
Molecular Mass 
(Da) 
Theoretical 
Molecular Mass 
(Da) 
Mass Error 
(ppm) 
c7 717.4263 1+ 716.4193 716.4179 1.98 
c10 575.3224 2+ 1148.6305 1148.6300 0.41 
c23 809.3798 3+ 2425.1179 2425.1290 -4.58 
c49 928.1070 6+ 5562.5986 5562.6069 -1.50 
c69 951.8291 8+ 7606.5747 7606.5899 -2.00 
z6 659.2934 1+ 658.2864 658.2837 4.21 
z24 869.7695 3+ 2606.2847 2606.2816 1.19 
 1304.1474 2+ 2606.2847 2606.2816 1.19 
z27 979.8316 3+ 2936.4731 2936.4719 0.41 
z39 1413.3478 3+ 4237.0218 4237.0113 2.46 
z48 1308.8655 4+ 5231.4332 5231.4326 0.12 
z55 1016.1324 6+ 6090.7481 6090.7496 -0.25 
 1219.1565 5+ 6090.7481 6090.7496 -0.25 
 1523.6951 4+ 6090.7481 6090.7496 -0.25 
z58 1278.9818 5+ 6389.8690 6389.8726 -0.57 
 1598.4726 4+ 6389.8690 6389.8726 -0.57 
z78 1417.6533 6+ 8499.8766 8499.9025 -3.05 
z80 1459.0057 6+ 8747.9910 8748.0186 -3.16 
z81 1267.0153 7+ 8862.0552 8862.0615 -0.71 
z91 1431.9588 7+ 10016.6608 10016.6845 -2.37 
z98 1211.2408 9+ 10892.1019 10892.0951 0.62 
z107 1177.2463 10+ 11762.3990 11762.4129 -1.19 
z114 1255.8772 10+ 12548.6967 12548.7096 -1.03 
z115 1155.9895 11+ 12704.8047 12704.8107 -0.47 
z117 1181.0907 11+ 12980.9114 12980.9217 -0.79 
z118 1192.7363 11+ 13109.0107 13109.0166 -0.45 
z121 1212.1096 11+ 13322.1257 13322.1280 -0.17 
 1333.2197 10+ 13322.1257 13322.1280 -0.17 
z123 1233.0243 11+ 13552.1880 13552.2182 -2.23 
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c7+ 
 
c102+ 
 
c233+ 
 
c496+ 
 
c698+ 
 
z6+ 
 
z243+ 
 
z242+ 
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z273+ 
 
z393+ 
 
z556+ 
 
z555+ 
 
z554+ 
 
z585+ 
 
z584+ 
 
z786+ 
 
  
'1278.98183
5+
1280.58464
1+
modified 24h  reduced  RNASE iso 1056 ECD 6ms_000003.d: +MS2(CASI 1057.00000, ECD)
1279.58346
5+
modified₂₄hreducedRNASEiso₁₀₅₆ECD₆ms₀00003.d:C₂₇₃H₄₁₅N₇₆O₉₂S₅, M+nH, 1278.98198
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z806+ 
 
z817+ 
 
z917+ 
 
z989+ 
 
z10710+ 
 
z11410+ 
 
z11511+ 
 
z11711+ 
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z11811+ 
 
z12111+ 
 
z12110+ 
 
z12311+ 
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ECD: Assessment of potentially reactive sites 
The most complete sequence coverage was observed when the modification was modelled on 
Y115 using Prosite PTM. Sequence coverage was lost when the modification was modelled on 
other Tyr residues. Sequence coverage was also lost when the modification was modelled on 
His residues, which are known to exhibit cross-reactivity with diazonium salts. The single 
exception to this is H105, which could not be distinguished from Y115 under ECD 
fragmentation conditions, however the residues were separable by CID fragmentation. When 
the unmodified protein was modelled, no peptides containing the Y115 residue could be 
identified. 
Y115 
 
Y097 
 
Y092 
 
Y076 
 
Y073 
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Y025 
 
H119 
 
H105 
 
H048 
 
H012 
 
 
Unmodified 
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CID fragmentation 
The 13+ charge state of the singly modified protein was isolated with ion accumulation time 
of up to 3 sec. The collision voltage was 22 V. The resulting peptide fragments were calibrated 
by single point calibration to [C40H59N10O12]+: 871.43084 m/z. Using DataAnalysis software 
(version 4.1, Bruker Daltronics), a list of monoisotopic masses was generated and this was 
searched against the theoretical masses of all expected peptides using ProSight PTM software 
(Kelleher Lab, Northwestern University)168, 169 with a mass error tolerance of 5 ppm. The 
identified peptide peaks were further scrutinised by comparison with the theoretical isotope 
distribution using DataAnalysis. 
CID: Identified peptide ions 
 
Peptide ions identified by top-down fragmentation of singly modified RNase A by CID. 
 
Peptide 
Ion 
m/z z 
Measured 
Molecular Mass 
(Da) 
Theoretical 
Molecular Mass 
(Da) 
Mass Error 
(ppm) 
y8 871.4309 1+ 870.4239 870.4255 -1.86 
y9 970.4992 1+ 969.4922 969.4939 -1.75 
y11 1245.6246 1+ 1244.6180 1244.6200 -1.58 
 
  
  Chapter 5: Experimental 
 154 
y8+ 
 
y9+ 
 
y11+ 
 
 
 
CID: Assessment of potentially reactive sites 
Under CID fragmentation conditions there was poor sequence coverage of the protein, 
presumably due to insufficient reduction of the four disulphides which are native to RNase A 
prior to infusion. However, the identified peptides fell within the key C-terminal region (as 
described by ECD fragmentation), and allowed separation of H105 from Y115. The y11 ion 
contains a –NH2 modification and includes the Y115 residue. The y9 and y8 ions are unmodified 
and do not include Y115. Some unmodified y11 was also identified, and this was thought to 
arise from the CID conditions which are harsher than those used in ECD. 
Y115 
 
Y097 
 
  
871.43086
1+
ca513 iso 1055 CID 22v_000001.d: +MS2(qCID 1053.60239)
871.43084
1+
ca₅₁₃iso₁₀₅₅CID₂₂v₀00001.d:C₄₀H₅₈N₁₀O₁₂, M+nH, 871.43084
0
1
2
7x10
Intens.
0
500
1000
1500
2000
865 870 875 880 m/z
970.49919
1+
ca513 iso 1055 CID 22v_000001.d: +MS2(qCID 1053.60239)
970.49926
1+
ca₅₁₃iso₁₀₅₅CID₂₂v₀00001.d:C₄₅H₆₇N₁₁O₁₃, M+nH, 970.49926
0.00
0.25
0.50
0.75
7x10
Intens.
0
500
1000
1500
2000
960 965 970 975 980 m/z
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Y092 
 
Y076 
 
Y073 
 
Y025 
 
H119 
  
 
H105 
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H048 
 
 
H012 
 
 
Unmodified 
 
 
 
The unmodified y11 ion (1230.61535 m/z) was identified by CID, but not by ECD. The modified 
y11 ion (1245.62625 m/z) was also observed. It is assumed that the NH2 modification was 
removed under the thermal dissociation conditions in CID fragmentation, but was preserved 
under milder ECD fragmentation. 
  
  Chapter 5: Experimental 
 157 
5.8.4 Oxidative coupling of catch-and-release modified proteins 
To a solution of catch-and-release modified protein (62.5 µM) in phosphate buffer (240 µL, 
10 mM, pH 6.5) was added fluoresceinamine (30 µL, 10 mM in DMSO) and K3Fe(CN)6 (30 
µL, 800 mM in buffer). The mixture was briefly mixed by vortex and agitated on a rotator for 
18 h at rt. The sample volume was reduced to ~50 µL on a MWCO spin cartridge and desalted 
by washing with phosphate buffer (5 x 400 µL, 100 mM, pH 7.2). 
5.8.5 FITC-labelling of RNase A 
To a solution of RNase A (290 mM) in bicarbonate buffer (1 mL, 50 mM, pH 9.3) was added 
fluorescein isothiocyanate (100 µL, 44 mM in DMF). The reaction mixture was briefly mixed 
by vortex and agitated on a rotator for 30 min at rt. The sample volume was reduced to ~50 
µL on a MWCO spin cartridge and desalted by washing with phosphate buffer (5 x 400 µL, 
100 mM, pH 7.2). 
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Appendix 1: Peptides 
Peptides synthesised and characterised by project student Christina Burr. 
Ac-Asp-Asp-Ala-Arg-Asn-Thr-Val-Tyr-NH2 
The nanobody-derived 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. The 
lyophilised peptide was a colourless amorphous solid (96% purity by RP-HPLC at 210 nm, 
87% yield). 
Rt (HPLC Method 1) = 7.77 min; 1H NMR δ (500 MHz, DMSO-d6) 9.12 (1H, s, Tyr(ArOH)), 
8.24 (1H, d, J = 7.4 Hz, Asp(NH)), 8.19 (1H, d, J = 7.5 Hz, Asp(NH)), 8.14 (1H, d, J = 7.5 
Hz, Asn(NH)), 7.99 (1H, d, J = 8.0 Hz, NH), 7.75 (1H, d, J = 8.2 Hz, NH), 7.72 (1H, d, J = 
8.2 Hz, NH), 7.71 (1H, d, J = 8.2 Hz, NH), 7.68 (1H, d, J = 7.0 Hz, NH), 7.46 (1H, s, NH), 
7.34 (1H, s, NH), 7.15 (1H, s, NH), 7.02 (1H, s, NH), 7.00 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 
6.63 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 4.98 (1H, s, Thr(OH)), 4.63 (1H, dt, J = 6.8, 6.8 Hz, 
Asn(α-CH), 4.55-4.46 (2H, m, Asp(α-CH), Asp(α-CH)), 4.36-4.22 (4H, m, Ala(α-CH), Arg(α-
CH), Thr(α-CH), Tyr(α-CH)), 4.11-4.00 (2H, m, Thr(β-CH), Val(α-CH)), 3.13-3.03 (2H, m, 
Arg(δ-CH2)), 2.90 (1H, dd, J = 13.9, 5.3, Tyr(β-CHAHB)), 2.76-2.51 (4H, m, Asp(β-CHAHB), 
Asp(β-CHAHB), Asn(β-CHAHB), Tyr(β-CHAHB)), 2.51-2.43 (3H, m, Asp(β-CHAHB), Asp(β-
CHAHB), Asn(β-CHAHB)), 2.03-1.90 (1H, m, Val(β-CH), 1.85 (3H, s, COCH3), 1.74-1.67 (1H, 
m, Arg(β-CHAHB)), 1.58-1.43 (3H, m, Arg(β-CHAHB, γ-CH2)), 1.23 (3H, d, J = 7.0 Hz, Ala(β-
CH3), 1.04 (3H, d, J = 6.3 Hz, Thr(CH3)), 0.74 (3H, d, J = 6.9 Hz, Val(CH3), 0.74 (3H, d, J = 
6.9 Hz, Val(CH3); 13C NMR δ (126 MHz, DMSO-d6) 173.43 (CO), 172.51 (CO), 172.44 (CO), 
172.23 (CO), 172.22 (CO), 171.55 (CO), 171.53 (CO), 171.43 (CO), 170.96 (CO), 170.55 
(CO), 170.50 (CO), 170.25 (CO), 157.03 (ArC), 156.21 (ArC), 130.41 (2ArCH), 128.32 (CN), 
115.35 (2ArCH), 66.88 (CH), 58.90 (CH), 58.52 (CH), 54.74 (CH), 52.34 (CH), 50.23 (CH), 
50.20 (CH), 49.91 (CH), 48.86 (CH), 40.92 (CH2), 37.49 (CH2), 37.12 (CH2), 36.38 (CH2), 
36.17 (CH2), 30.52 (CH), 29.60 (CH2), 25.27 (CH3), 22.98 (CH3), 19.89 (CH3), 19.55 (CH3), 
18.34 (2CH3); m/z (ESI+, MeCN/H2O) 995 ([M+H]+, 15%), 509 ([M+H+Na]2+, 100), 498 
([M+2H]2+, 35); HRMS (ESI+, MeCN/H2O) [M+2H]2+ found 497.7327, [C41H65N13O16]2+ 
requires 497.7331. 
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Ac-Asp-Asp-Phe-Arg-Asn-Thr-Val-Tyr-NH2 
The Phe-substituted 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. 
The lyophilised peptide was a colourless amorphous solid (98% purity by RP-HPLC at 210 
nm, 79% yield). 
Rt (HPLC Method 1) = 8.28 min; 1H NMR δ (500 MHz, DMSO-d6) 9.47 (1H, s, NH), 9.21 
(1H, s, Tyr(ArOH)), 8.64 (1H, d, J = 6.9 Hz, NH), 8.56 (1H, d, J = 6.3 Hz, NH), 8.10 (1H, s, 
NH), 8.09 (1H, s, NH), 7.94 (1H, s, NH), 7.73-7.53 (4H, m, 4 x NH), 7.27-7.20 (4H, m, 
Phe(4ArH)), 7.19-7.13 (1H, m, Phe(ArH)), 7.08-7.02 (2H, m, 2 x NH), 7.01 (2H, d, J = 8.4 
Hz, Tyr(2ArH)), 6.94 (1H, s, 2 x NH), 6.64 (2H, d, J = 8.4 Hz, Tyr(2ArH)), 5.12 (1H, s, 
Thr(OH)), 4.59 (1H, q, J = 7.4 Hz, α-CH), 4.50 (1H, q, J = 7.0 Hz, Asp(α-CH)), 4.44 (1H, td, 
J = 8.8, 3.6 Hz, α-CH), 4.34 (1H, ddd, J = 10.4, 6.8, 3.5 Hz, α-CH), 4.29 (1H, td, J = 8.9, 4.9 
Hz, α-CH), 4.21 (1H, dd, J = 7.8, 4.1 Hz, Thr(α-CH)), 4.10-4.02 (2H, m, Arg(α-CH), Thr(β-
CH)), 4.02-3.97 (1H, m, Val(α-CH)), 3.14 (1H, dd, J = 14.2, 3.5 Hz, β-CHAHB), 3.11-3.06 
(1H, m, Arg(δ-CHAHB)), 3.03-2.95 (2H, m, Arg(δ-CHAHB), β-CHCHD), 2.93 (1H, dd, J = 14.2, 
4.9 Hz, β-CHAHB), 2.71-2.61 (2H, m, β-CHCHD, β-CHEHF), 2.59-2.52 (1H, m, β-CHECHF), 
2.50-2.43 (2H, m, Asp(β-CHACHB), β-CHGCHH), 2.38 (1H, dd, J = 16.0, 7.0 Hz, Asp(β-
CHACHB)), 2.26 (1H, dd, J = 15.5, 3.5 Hz, β-CHGCHH), 1.99-1.89 (1H, m, Val(β-CH)), 1.82 
(3H, s, COCH3), 1.73-1.67 (2H, m, Arg(β-CH2)), 1.61-1.46 (2H, m, Arg(γ-CH2)), 1.06 (3H, d, 
J = 6.3 Hz, Thr(CH3), 0.71 (3H, d, J = 6.8 Hz, Val(CH3)), 0.70 (3H, d, J = 6.8 Hz, Val(CH3)); 
13C NMR δ (126 MHz, DMSO-d6) 173.52 (CO), 173.07 (CO), 173.02 (CO), 172.92 (CO), 
172.45 (CO), 172.24 (CO), 172.05 (CO), 171.81 (CO), 170.90 (CO), 170.84 (CO), 170.76 
(CO), 169.74 (CO), 157.90 (ArC), 156.23 (ArC), 138.65 (ArC), 130.36 (2ArCH), 129.42 
(2ArCH), 128.56 (2ArCH), 128.40 (CN), 126.59 (ArCH), 115.39 (2ArCH), 67.14 (CH), 59.24 
(CH), 59.15 (CH), 55.81 (CH), 54.95 (CH), 54.38 (CH), 50.67 (CH), 50.56 (CH), 50.02 (CH), 
41.10 (CH2), 38.07 (CH2), 37.25 (CH2), 36.91 (CH2), 36.08 (CH2), 30.25 (CH), 28.29 (CH2), 
24.22 (CH2), 22.94 (CH3), 19.91 (CH3), 19.45 (CH3), 18.30 (CH3); m/z (ESI+, MeCN/H2O) 
1071 ([M+H]+, 20%), 555 ([M+H+K]2+, 50), 547 ([M+H+Na]2+, 100), 536 ([M+2H]2+, 40); 
HRMS (ESI+, MeCN/H2O) [M+2H]2+ found 535.7474, [C47H69N13O16]2+ requires 535.7487. 
  Chapter 5: Experimental 
 160 
Ac-Asp-Asp-Trp-Arg-Asn-Thr-Val-Tyr-NH2, 
The Trp-substituted 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. The product 
was purified by 
preparative RP-HPLC (System 4) using an isocratic solvent system (H2O + 0.1%: MeCN + 
0.1% TFA, 94:6). The lyophilised peptide was a colourless amorphous solid (96% purity by 
RP-HPLC at 210 nm, 31% yield). 
Rt (HPLC Method 1) = 8.39 min; 1H NMR δ (500 MHz, DMSO-d6) 12.34 (2H, br s, 2 x 
Asp(CO2H)), 10.72 (1H, d, J = 2.5 Hz, Trp(Indole-NH)), 9.14 (1H, s, Tyr(ArOH)), 8.22 (2H, 
d, J = 7.5 Hz, 2 x Asp(NH)), 8.20-8.13 (1H, m, NH), 8.05 (2H, br s, 2 x NH), 7.76 (1H, d, J = 
8.2 Hz, NH), 7.74-7.68 (2H, m, Thr(NH), Val(NH)), 7.55 (1H, d, J = 7.9 Hz, NH), 7.49 (1H, 
s, NH), 7.32 (1H, d, J = 8.0 Hz, NH), 7.16 (1H, br s, Trp(ArH)), 7.09-6.93 (6H, m, Trp(4ArH), 
Tyr(2ArH)), 6.63 (2H, d, J = 8.5 Hz, Tyr(2ArH), 5.00 (1H, d, J = 5.3 Hz, Thr(OH), 4.67 (1H, 
q, J = 7.0 Hz, α-CH), 4.59-4.40 (3H, m, α-CH, 2 x Asp(α-CH)), 4.32 (1H, td, J = 8.7, 5.3 Hz, 
α-CH), 4.26 (1H, dd, J = 8.1, 3.8 Hz, Thr(α-CH)), 4.09-4.03 (2H, m, Thr(β-CH), Val(α-CH)), 
3.15 (1H, dd, J = 14.9, 4.1 Hz, β-CHAHB), 3.10-2.95 (3H, m, β-CHAHB, Arg(δ-CH2)), 2.90 
(1H, dd, J = 13.9, 5.2 Hz, β-CHCHD), 2.72-2.59 (4H, m, β-CHCHD, β-CHEHF, 2 x Asp(β-
CHAHB)), 2.57-2.39 (3H, m, β-CHEHF, 2 x Asp(β-CHAHB)), 2.03-1.90 (1H, m, Val(β-CH)), 
1.83 (3H, s, COCH3), 1.74-1.62 (1H, m, Arg(β-CHAHB)), 1.60-1.48 (1H, m, Arg(β-CHAHB)), 
1.48-1.32 (2H, m, Arg(γ-CH2)), 1.05 (3H, d, J = 6.3 Hz, Thr(CH3)), 0.74 (3H, d, J = 6.8 Hz, 
Val(CH3)), 0.73 (3H, d, J = 6.8 Hz, Val(CH3)); 13C NMR δ (126 MHz, DMSO-d6) 173.44 
(CO), 172.31 (CO), 172.24 (CO), 171.64 (CO), 171.59 (CO), 170.96 (CO), 170.53 (CO), 
170.27 (CO), 158.32 (ArC), 158.08 (ArC), 157.12 (ArC), 156.21 (CO), 145.12 (ArC), 136.44 
(CO), 130.41 (2ArCH), 128.33 (CO), 127.79 (CO), 124.21 (ArCH), 121.26 (ArCH), 118.81 
(ArCH), 118.69 (ArCH), 116.65 (CN), 115.35 (2ArCH), 111.70 (ArCH), 110.22 (ArC), 66.95 
(CH), 58.94 (CH), 58.58 (CH), 54.76 (CH), 54.24 (CH), 50.24 (CH), 50.23 (CH), 50.16 (CH), 
40.97 (CH2), 37.46 (CH2), 37.11 (2CH2), 36.39 (CH2), 30.50 (CH), 29.53 (CH2), 27.59 (CH2), 
25.00 (CH2), 22.96 (CH3), 19.90 (CH3), 19.54 (CH3), 18.35 (CH3); m/z (ESI+, MeCN/H2O) 
1110 ([M+H]+, 25%), 574 ([M+H+K]2+, 80), 566 ([M+H+Na]2+, 100), 555 ([M+2H]2+, 70); 
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HRMS (ESI, MeCN/H2O) [M+H+K]2+ found 574.2310, [C49H69N14O16K]2+ requires 
574.2321. 
Ac-Asp-Asp-Lys-Arg-Asn-Thr-Val-Tyr-NH2 
The Lys-substituted 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. The 
lyophilised peptide was a 
colourless amorphous solid (96% purity by RP-HPLC at 210 nm). 
Rt (HPLC Method 1) = 7.77 min; 1H NMR δ (500 MHz, DMSO-d6) 11.41 (2H, br s, 2 x 
Asp(CO2H)), 9.15 (1H, s, Tyr(ArOH)), 8.46 (1H, br s, NH), 8.25 (1H, d, J = 7.6 Hz, Asp(NH)), 
8.04 (2H, br s, 2 x NH), 7.75-7.67 (3H, Lys(NH), Arg(NH), NH), 7.69 (1H, d, J = 8.1 Hz, 
Val(NH)), 7.62 (1H, d, J = 8.1 Hz, Thr(NH)), 7.48 (1H, s, (NH), 7.18-6.90 (6H, m, Arg(2NH), 
Tyr(2ArH), 2NH), 6.64 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 4.99 (1H, s, Thr(OH)), 4.62 (1H, q, J 
= 7.2 Hz, α-CH), 4.52 (1H, dd, J = 13.7, 7.7 Hz, Asn(α-CH)), 4.50-4.43 (1H, m, α-CH), 4.31 
(1H, td, J = 8.7, 5.1 Hz, α-CH), 4.24 (1H, dd, J = 8.1, 3.9 Hz, Thr(α-CH)), 4.13 (2H, br s, 
Lys(α-CH), Arg(α-CH)), 4.07-4.01 (2H, m, Val(α-CH), Thr(β-CH)), 3.14-3.08 (1H, m, β-
CHAHB), 3.06-2.99 (1H, m, β-CHAHB), 2.91 (1H, dd, J = 14.0, 5.1, β-CHCHD), 2.81-2.76 (1H, 
m, CHCHD), 2.68-2.61 (4H, m, Asp(β-CHAHB), β-CHEHF, β-CHGHH, β-CHGHH), 2.49-2.41 
(2H, m, Asp(β-CHAHB) β-CHEHF), 1.99-1.90 (1H, m, Val(β-CH)), 1.85 (3H, s, COCH3), 1.80-
1.64 (3H, m, Arg/Lys CH2), 1.65-1.44 (5H, m, Arg/Lys CH2), 1.42-1.29 (2H, m, Lys(CH2)), 
1.05 (3H, d, J = 6.4 Hz, Thr(CH3)), 0.73 (3H, d, J = 7.1 Hz, Val(CH3)), 0.72 (3H, d, J = 7.1 
Hz, Val(CH3)); 13C NMR δ (126 MHz, DMSO-d6) 173.46 (CO), 173.36 (CO), 172.52 (CO), 
172.50 (CO), 172.10 (CO), 172.04 (CO), 171.59 (CO), 170.93 (CO), 170.79 (CO), 170.54 
(CO), 170.25 (CO), 158.34 (ArC), 157.55 (ArC), 156.21 (CO), 130.39 (2ArCH), 128.34 (CN), 
115.36 (2ArCH), 67.02 (CH), 60.22 (CH), 58.98 (CH), 58.70 (CH), 54.80 (CH), 53.58 (CH), 
50.54 (CH), 50.39 (CH), 50.15 (CH), 41.05 (CH2), 38.95 (CH2), 37.39 (CH2), 37.05 (CH2), 
36.76 (CH2), 31.42 (CH2), 30.54 (CH2), 30.43 (CH), 28.77 (CH2), 26.87 (CH2), 24.63 (CH2), 
22.96 (CH3), 22.54 (CH2), 19.87 (CH3), 19.52 (CH3), 18.29 (CH3); m/z (ESI+, MeCN/H2O) 
1052 ([M+H]+, 5%), 526 ([M+2H]2+, 100); HRMS (ESI+, MeCN/H2O) [M+H]+ found 
1051.5184, C44H71N14O16 requires 1051.5167.  
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Ac-Asp-Asp-His-Arg-Asn-Thr-Val-Tyr-NH2 
The Phe-substituted 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. The 
lyophilised peptide was a colourless amorphous solid (96% purity by RP-HPLC at 210 nm). 
Rt (HPLC Method 1) = 7.80 min; 1H NMR δ (500 MHz, DMSO-d6) 8.51 (1H, s, NH), 8.26-
8.20 (1H, m, Arg(NH)), 8.23 (1H, d, J = 7.5 Hz, Asp(NH)), 8.19 (1H, d, J = 7.9 Hz, Asp(NH)), 
7.94 (1H, s, NH), 7.76 (1H, d, J = 8.2 Hz, NH), 7.72 (1H, d, J = 8.2 Hz, Val(NH)), 7.69 (1H, 
d, J = 7.9 Hz, Thr(NH)), 7.51 (1H, s, His(ArNH)), 7.16 (1H, s, NH), 7.10 (1H, s, NH), 7.04 
(1H, s, NH), 7.02-6.97 (4H, m, His(2ArH), Tyr(2ArH)), 6.63 (2H, d, J = 8.5 Hz, Tyr(2ArH)), 
4.66 (1H, q, J = 7.1 Hz, α-CH), 4.59-4.40 (3H, m, 2 x Asp(α-CH), α-CH), 4.32 (1H, td, J = 
8.7, 5.3 Hz, α-CH), 4.25 (1H, dd, J = 8.0, 4.0 Hz, Thr(α-CH)), 4.24-4.20 (1H, m, α-CH), 4.10-
4.00 (2H, m, Thr(β-CH), Val(α-CH)), 3.10-3.04 (3H, m, Arg(δ-CH2), β-CHAHB), 2.97 (1H, 
dd, J = 15.0, 8.1 Hz, CHAHB), 2.90 (1H, dd, J = 14.0, 5.2 Hz, β-CHCHD), 2.71-2.60 (4H, m, 2 
x Asp(CHAHB), β-CHCHD, β-CHEHF), 2.51-2.43 (3H, m, 2 x Asp(β-CHAHB), β-CHEHF), 1.99-
1.90 (1H, m, Val(β-CH)), 1.85 (3H, s, CH3CO), 1.75-1.69 (1H, m, Arg(β-CHAHB)), 1.61-1.55 
(1H, m, Arg(β-CHAHB)), 1.53-1.46 (2H, m, Arg(γ-CH2)), 1.03 (3H, d, J = 6.3 Hz, Thr(CH3)), 
0.73 (3H, d, J = 6.8 Hz, Val(CH3)), 0.72 (3H, d, J = 6.8 Hz, Val(CH3)); 13C NMR δ (126 MHz, 
DMSO-d6) 173.44 (CO), 172.82 (CO), 172.45 (CO), 172.24 (CO), 171.87 (CO), 171.58 (CO), 
171.45 (CO), 171.04 (CO), 170.95 (CO), 170.74 (CO), 170.49 (CO), 170.22 (CO), 158.40 
(ArC), 157.21 (ArC), 156.21 (ArC), 134.68 (ArCH), 130.40 (2ArCH), 128.32 (CN), 117.18 
(ArCH), 115.35 (2ArCH), 66.89 (CH), 60.22 (CH), 58.88 (CH), 58.55 (CH), 54.74 (CH), 
53.06 (CH), 52.88 (CH), 50.33 (CH), 50.20 (CH), 40.96 (CH), 37.40 (CH2), 37.11 (CH2), 
36.68 (CH2), 30.51 (CH2), 29.24 (CH2), 25.00 (CH2), 22.99 (CH2), 22.53 (CH2), 19.87 (CH3), 
19.54 (CH3), 18.33 (CH3), 14.56 (CH3); m/z (ESI+, MeCN/H2O) 531 ([M+2H]2+, 100%); 
HRMS (ESI+, MeCN/H2O) [M+2H]2+ found 530.7457, [C44H67N15O16]2+ requires 530.7440. 
  
  Chapter 5: Experimental 
 163 
Ac-Asp-Asp-Cys-Arg-Asn-Thr-Val-Tyr-NH2 
The Phe-substituted 
peptide was synthesised 
according to the solid-
phase peptide synthesis 
method described in 
Section 5.3. The product 
was purified by preparative RP-HPLC (System 4) using an isocratic solvent system (H2O + 
0.1%: MeCN + 0.1% TFA, 87:13). The lyophilised peptide was a colourless amorphous solid 
(99% purity by RP-HPLC at 210 nm). 
Rt (HPLC Method 1) = 7.84 min; 1H NMR δ (500 MHz, DMSO-d6) 12.35 (2H, br s, 2 x 
Asp(CO2H)), 9.14 (1H, s, Tyr(ArOH)), 8.26 (2H, d, J = 7.2 Hz, 2 x Asp(NH)), 8.17 (1H, s, 
NH), 7.77-7.71 (4H, m, Arg(NH), Thr(NH), Val(NH), NH), 7.47 (1H, s, NH), 7.15 (1H, s, 
NH), 7.03 (1H, s, NH), 7.02-6.97 (3H, m, Tyr(2ArH), NH), 6.63 (2H, d, J = 8.6 Hz, 
Tyr(2ArH)), 4.99 (1H, d, J = 5.2 Hz, Thr(OH)), 4.63 (1H, q, J = 6.9 Hz, α-CH), 4.58-4.47 (2H, 
m, 2 x Asp(α-CH)), 4.38 (1H, q, J = 6.9 Hz, α-CH), 4.31 (1H, td, J = 8.6, 5.3 Hz, Arg(α-CH)), 
4.24 (1H, dd, J = 8.1, 3.8 Hz, Thr(α-CH)), 4.08-4.03 (2H, m, Thr(β-CH), Val(α-CH)), 3.10-
3.05 (2H, m, Arg(δ-CH2)), 2.90 (1H, dd, J = 13.9, 5.2 Hz, β-CHAHB), 2.85-2.73 (1H, m, β-
CHCHD), 2.70-2.58 (4H, m, 2 x Asp(β-CHAHB), CHAHB, CHEHF), 2.58-2.43 (3H, m, 2 x Asp(β-
CHAHB), β-CHEHF), 2.41-2.29 (1H, m, CHCHD), 2.03-1.89 (1H, m, Val(β-CH)), 1.85 (1H, s, 
CH3CO), 1.77-1.65 (1H, m, (Arg(β-CHAHB)), 1.64-1.42 (3H, m, Arg(β-CHAHB), Arg(γ-CH2)), 
1.04 (3H, d, J = 6.3 Hz, Thr(CH3)), 0.74 (3H, d, J = 6.9 Hz, Val(CH3)), 0.73 (3H, d, J = 6.9 
Hz, Val(CH3)); 13C NMR δ (126 MHz, DMSO-d6) 173.45 (CO), 173.43 (CO), 172.29 (CO), 
172.26 (CO), 172.18 (CO), 171.64 (CO), 171.54 (CO), 171.18 (CO), 170.96 (CO), 170.52 
(CO), 170.36 (CO), 157.16 (ArC), 156.45 (ArC), 156.21 (CO), 130.41 (2ArCH), 128.33 (CN), 
115.35 (2ArCH), 66.88 (CH), 58.93 (CH), 58.54 (CH), 55.77 (CH), 54.75 (CH), 52.79 (CH), 
50.30 (CH), 50.28 (CH), 50.25 (CH), 40.95 (CH2), 37.50 (CH2), 37.11 (CH2), 36.40 (CH2), 
30.50 (CH), 29.41 (CH2), 26.48 (CH2), 25.24 (2CH2), 22.99 (CH3), 19.89 (CH3), 19.54 (CH3), 
18.36 (CH3); m/z (ESI+, MeCN/H2O) 1048 ([M+Na]+, 25%), 1026 ([M+H]+, 100), 525 
([M+2H]2+, 15); HRMS (ESI+, MeCN/H2O) [M+Na]+ found 1048.4099, C41H63N13O16SNa 
requires 1048.4129. 
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Appendix 2: Peptide HPLC data 
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Appendix 3: SASA data 
SASA evaluation of the PDB deposits used in Figure 4-10. 
SASA evaluation of X-ray crystal structures of native sequence RNase A 
PDB ID 
Resolution 
(Å) 
Y025 
(Å2) 
Y073 
(Å2) 
Y076 
(Å2) 
Y092 
(Å2) 
Y097 
(Å2) 
Y115 
(Å2) 
Total 
(Å2) 
4J5Z 1.80 3.72 8.09 27.58 23.71 0.59 20.64 84.33 
1AFU 2.00 3.07 8.96 31.54 24.54 1.55 23.73 93.39 
1BEL 1.60 2.35 7.45 36.54 22.40 2.28 23.20 94.22 
1BZQ 2.80 5.85 6.07 37.11 22.36 0.80 21.43 93.62 
1DFJ 2.50 3.66 8.89 31.69 20.81 1.52 13.23 79.80 
1EOS 2.00 3.07 8.96 33.77 25.34 1.55 22.29 94.98 
1EOW 2.00 3.75 8.34 32.81 22.19 1.55 21.89 90.53 
1FS3 1.40 1.48 8.09 28.50 21.47 1.31 20.64 81.49 
1JN4 1.80 3.91 8.17 30.74 26.64 0.76 21.57 91.79 
1JVT 2.05 2.28 7.41 31.57 23.84 1.55 20.81 87.46 
1JVU 1.78 3.07 8.96 30.02 23.86 1.55 20.89 88.35 
1KF5 1.15 3.00 7.37 30.81 23.86 0.80 19.58 85.42 
1KF7 1.15 3.00 6.58 31.40 22.99 0.80 19.58 84.35 
1O0F 1.50 5.35 8.96 30.78 23.86 0.00 20.81 89.76 
1O0H 1.20 3.79 8.96 29.22 23.94 0.76 21.61 88.28 
1O0M 1.50 6.14 8.96 27.71 23.88 0.76 21.61 89.06 
1O0N 1.50 5.35 8.96 29.98 24.58 1.48 21.61 91.96 
1O0O 1.20 2.28 8.96 29.94 26.02 0.76 21.61 89.57 
1RBX 1.69 3.00 8.38 28.62 22.31 0.80 21.09 84.20 
1RCA 1.90 4.30 5.99 28.54 23.75 0.80 20.30 83.68 
1RHA 1.80 2.28 6.58 35.25 26.78 0.80 21.68 93.37 
1RHB 1.50 3.00 5.99 34.95 23.03 0.80 23.33 91.10 
1RNC 1.50 2.24 6.79 35.12 21.55 0.80 21.09 87.59 
1RND 1.50 3.00 5.99 32.98 21.47 0.80 20.30 84.54 
1RNM 2.00 3.54 9.61 32.40 21.47 0.59 21.61 89.22 
1RNN 1.80 5.86 7.33 28.71 22.99 1.31 20.81 87.01 
1RNO 1.90 3.64 7.33 29.47 23.03 0.59 22.19 86.25 
1RNQ 2.00 3.54 6.61 33.05 22.48 1.31 22.91 89.90 
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1RNW 1.80 3.72 7.33 31.57 24.54 0.59 20.77 88.52 
1RNX 1.90 2.92 7.33 30.19 20.89 0.59 24.54 86.46 
1RNY 2.00 2.92 6.54 28.67 22.99 0.59 21.47 83.18 
1RNZ 1.90 2.96 7.33 30.19 20.81 0.59 22.19 84.07 
1ROB 1.60 3.00 9.14 32.09 20.75 0.80 21.89 87.67 
1RPF 2.20 3.00 9.76 32.56 21.00 0.76 22.61 89.69 
1RPG 1.40 5.06 8.38 33.64 23.78 0.80 21.09 92.75 
1RPH 2.20 3.72 7.33 32.16 20.05 0.00 22.15 85.41 
1RUV 1.25 2.24 9.14 28.33 21.43 0.80 20.30 82.24 
1U1B 2.00 5.89 10.37 32.67 22.55 1.52 20.73 93.73 
1W4O 1.60 3.15 8.17 31.50 24.66 0.76 21.61 89.85 
1W4P 1.69 2.28 8.96 30.02 23.86 0.76 20.81 86.69 
1W4Q 1.68 4.59 8.96 30.02 26.06 0.76 22.33 92.72 
1WBU 1.90 4.59 8.96 29.98 22.36 0.76 20.09 86.74 
1XPS 1.80 3.79 8.38 24.64 23.16 1.52 22.87 84.36 
1XPT 1.90 4.51 7.66 34.15 25.43 0.80 20.56 93.11 
1Z6D 1.54 4.59 8.96 29.98 22.34 0.76 20.89 87.52 
1Z6S 1.50 3.79 9.68 31.54 23.82 0.00 21.53 90.36 
2BLP 1.40 2.31 6.90 30.68 21.99 0.76 21.19 83.83 
2E3W 1.05 3.15 7.62 30.68 23.56 1.55 21.19 87.75 
2G8Q 1.50 3.79 8.96 31.50 23.86 0.00 21.61 89.72 
2G8R 1.70 6.07 8.20 32.22 21.76 0.00 20.81 89.06 
2QCA 1.33 3.75 6.69 35.55 23.27 1.52 24.28 95.06 
2RNS 1.60 7.70 8.46 33.24 25.83 2.20 21.93 99.36 
2W5G 1.70 2.28 8.20 29.98 26.86 0.76 22.25 90.33 
2W5K 1.70 3.07 8.17 31.57 26.86 1.48 22.33 93.48 
2W5L 1.70 2.28 7.41 30.78 24.51 0.76 22.33 88.07 
2W5M 1.80 3.87 8.96 30.78 24.58 0.76 23.05 92.00 
3D6O 1.58 5.31 8.96 31.50 23.86 0.76 21.61 92.00 
3D6P 1.60 2.28 8.96 30.78 23.86 0.76 21.61 88.25 
3D6Q 1.60 3.79 7.41 32.98 25.34 0.00 20.81 90.33 
3D7B 1.60 3.79 8.17 32.29 24.58 0.00 22.33 91.16 
3D8Y 1.72 3.79 7.41 31.46 25.34 0.00 20.85 88.85 
3D8Z 1.98 4.59 8.17 30.82 23.06 0.76 20.85 88.25 
3DH5 1.60 2.20 7.33 31.19 21.61 1.31 19.16 82.80 
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3DXG 1.39 3.03 7.41 31.57 24.58 0.00 23.81 90.40 
3DXH 1.40 4.55 7.41 30.78 23.14 0.00 23.09 88.97 
3MZQ 1.50 2.90 6.69 32.39 24.58 2.28 20.96 89.80 
3MZR 1.50 2.31 6.69 32.52 25.38 3.07 21.68 91.65 
4G8V 1.70 4.59 7.41 31.57 23.14 0.00 20.81 87.52 
4G8Y 1.80 3.79 8.13 31.50 23.86 0.00 20.81 88.09 
4G90 1.90 3.79 8.13 31.54 24.58 0.00 20.81 88.85 
4L55 1.65 2.28 7.41 30.78 23.86 0.76 20.09 85.18 
4MXF 2.25 0.00 8.17 29.26 24.68 0.76 22.36 85.23 
5RSA 2.00 4.34 9.72 26.30 23.78 0.80 22.61 87.55 
7RSA 1.26 3.58 9.14 30.65 23.78 0.80 21.85 89.80 
9RSA 1.80 3.54 8.96 32.85 23.92 0.72 20.52 90.51 
Average 1.70 3.59 8.03 31.26 23.54 0.86 21.44 88.72 
Std Dev. 0.31 1.23 1.02 2.16 1.57 0.61 1.43 3.61 
 
SASA evaluation of an NMR structure of RNase A (PDB ID: 2AAS, 32 conformers) 
Conformer 
Y025 
(Å2) 
Y073 
(Å2) 
Y076 
(Å2) 
Y092 
(Å2) 
Y097 
(Å2) 
Y115 
(Å2) 
Total 
(Å2) 
1 8.30 11.24 33.46 31.22 0.00 21.43 105.65 
2 10.44 9.65 33.75 30.67 0.00 24.35 108.86 
3 8.85 10.37 35.91 18.10 0.00 25.28 98.51 
4 9.65 7.34 33.01 25.98 0.00 22.72 98.70 
5 5.35 7.34 33.72 28.77 0.00 23.35 98.53 
6 9.61 9.65 32.88 26.12 0.00 23.35 101.61 
7 9.02 8.13 34.95 26.91 0.80 26.38 106.19 
8 7.51 8.85 34.98 22.91 0.00 24.83 99.08 
9 8.93 6.58 14.86 26.67 0.00 19.77 76.81 
10 6.58 7.33 14.90 29.02 0.00 22.56 80.39 
11 8.13 6.58 12.83 30.95 0.00 20.36 78.85 
12 9.65 8.89 25.58 28.98 0.00 24.15 97.25 
13 9.65 7.34 12.11 27.16 0.00 19.05 75.31 
14 9.65 12.72 16.79 27.25 0.00 16.85 83.26 
15 8.85 10.44 30.72 27.50 0.00 21.43 98.94 
16 8.85 12.72 34.36 27.46 0.00 26.08 109.47 
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17 8.30 11.16 34.23 31.37 0.00 22.02 107.08 
18 9.71 7.34 35.88 31.94 0.00 22.08 106.95 
19 8.85 7.34 26.86 18.06 0.00 17.10 78.21 
20 9.78 7.34 35.16 26.99 0.00 20.56 99.83 
21 5.35 8.93 32.95 26.19 0.00 21.15 94.57 
22 11.88 10.37 37.47 25.15 0.00 17.06 101.93 
23 10.92 9.68 35.67 27.42 0.80 20.81 105.30 
24 8.99 8.85 34.91 26.82 0.00 20.70 100.27 
25 9.65 7.37 14.29 29.06 0.00 26.59 86.96 
26 8.89 8.89 12.55 30.40 0.00 26.49 87.22 
27 8.85 8.89 14.97 27.29 0.00 24.15 84.15 
28 11.09 12.72 15.24 28.26 0.00 26.49 93.80 
29 8.93 7.34 12.70 30.42 0.00 22.12 81.51 
30 5.10 12.72 14.40 28.43 0.00 17.57 78.22 
31 11.09 11.16 35.27 26.67 0.00 20.60 104.79 
32 8.85 12.72 34.36 27.46 0.00 26.08 109.47 
Average 8.91 9.31 26.93 27.43 0.05 22.30 94.93 
Std. Dev. 1.59 2.01 9.70 3.16 0.20 2.94 11.19 
 
SASA evaluation of a neutron diffraction structure of RNase A 
PDB ref. 
Resolution 
(Å) 
Y025 
(Å2) 
Y073 
(Å2) 
Y076 
(Å2) 
Y092 
(Å2) 
Y097 
(Å2) 
Y115 
(Å2) 
Total 
(Å2) 
3A1R 1.70 2.28 6.79 32.29 23.03 0.80 20.37 85.56 
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Appendix 4: Permissions 
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Appendix 5: Abbreviations 
Amino acid 3-letter and 1-letter codes: 
Alanine  Ala A  Arginine Arg R 
Asparagine Asn N  Aspartic acid Asp D 
Cysteine Cys C  Glutamic acid Glu E 
Glutamine Gln Q  Glycine  Gly G 
Histidine His H  Isoleucine Ile I 
Leucine Leu L  Lysine  Lys K 
Methionine Met M  Phenylalanine Phe F 
Proline  Pro P  Serine  Ser S 
Threonine Thr T  Tryptophan Trp W 
Tyrosine Tyr Y  Valine  Val V 
 
ADC   Antibody-drug conjugate 
aq.   Aqueous 
Av   Avidin 
BSA   Bovine serum albumin 
CH   Constant domain (heavy chain)  
CID   Collision-induced dissociation 
CL   Constant domain (light chain) 
COSY   Correlated Spectroscopy 
CuAAC  Copper-catalysed azide-alkyne cycloaddition 
CV   Column volume 
Cyt. C   Cytochrome C 
Da   Daltons 
DCC   Dicyclohexylcarbodiimide 
DCM   Dichloromethane 
dd   dot density 
DIC   Diisopropylcarbodiimide 
DIPEA   Diisopropylethylamine 
DMAP   4-Dimethylaminopyridine 
DMF   Dimethylformamide 
ECD   Electron-capture dissociation 
EDC   1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EPR   Electron paramagnetic resonance 
EWG   Electron-withdrawing group 
FDA   Federal Drug Administration  
FITC   Flourescein isothiocyanate 
FT-ICR   Fourier-transform ion cyclotron resonance 
GFP   Green fluorescent protein 
GUI   Graphical user interface 
h   Hours 
HEWL   Lysozyme C 
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HOBt   1-Hydroxybenzotriazole 
HPLC   High performance liquid chromatography 
HRMS   High resolution mass spectrometry 
Hz   Hertz 
IUPAC   International union of pure and applied chemistry 
MaxEnt  Maximum entropy deconvolution 
Mb   Myoglobin 
MeCN   Acetonitrile 
MeOH   Methanol 
min   Minutes 
MS   Mass spectrometry 
MW   Molecular weight 
MWCO  Molecular weight cut-off 
m/z   Mass to charge ratio 
NCL   Native chemical ligation 
NHS   N-Hydroxysuccinimide 
nm   Nanometres 
NMR   Nuclear magnetic resonance 
OC   Oxidative coupling 
PABA   para-Aminobenzoic acid 
PBD ID  Protein data bank identification code 
PEG   Polyethylene glycol 
ppm   Parts per million 
PTAD   4-Phenyl-3H-1,2,4-triazoline-3,5(4H)-dione 
PTM   Post-translational modification 
RNase A  Ribonuclease A 
rt   Room temperature 
RuACC  Ru-catalysed azide-alkyne cycloaddition 
s   Seconds 
SASA   Solvent-accessible surface area 
sat.   Saturated 
SAv   Streptavidin  
SBTI   Soybean trypsin inhibitor 
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC   Size-exclusion chromatography 
SPAAC  Strain-promoted azide-alkyne cycloaddition 
SPPS   Solid-phase peptide synthesis 
SPR   Surface plasmon resonance 
TCEP   Tris(2-carboxyethyl)phosphine 
TFA   Trifluoroacetic acid 
TIS   Triisopropylsilane 
TLC   thin layer chromatography 
TNBS   2,4,6,-Trinitrobenzenesulfonic acid 
TNM   Tetranitromethane 
UAA   Unnatural amino acid 
UHPLC  Ultra high performance liquid chromatography 
UV   Ultraviolet 
VdW   Van der Waals 
VH   Variable domain (heavy chain) 
VL   Variable domain (light chain) 
β- Lac   β-Lactoglobulin A 
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